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The complexity of life can be appreciated when looking at the structural diversity of 
biopolymers involved in biological processes. A wide variety of carbohydrates, peptides and 
nucleic acids plays crucial roles in an even wider range of important biochemical events. To 
gain insight in these biological processes the need for synthetically obtained fragments of 
biopolymers and derivatives thereof has risen in the last half of the twentieth century. Synthetic 
protocols towards oligonucleic acids and peptides have been developed allowing access to well-
defined material for research in medicinal chemistry, chemical biology and structural biology. 
An enormous leap forward in gaining accessibility to such materials was the introduction of 
insoluble polymeric supports for the synthesis of peptides and oligonucleic acids.1-3 The limits 
of solution phase assembly, such as insolubility and difficulties in purification after each 
sequential step, are greatly reduced by using solid support chemistry.2 Automated synthesis 
based on this approach has proven to be a useful tool to obtain protein fragments and 
oligonucleotides. Hybrid structures between different classes of biopolymers, such as 
glycoproteins, glycolipids and nucleoproteins4,5 however are not always easily accessible using 
the currently used solid phase based approaches. Conditions that are used in the synthesis of one 
biopolymer fragment might not be compatible with the stability of the second biopolymer 
fragment.  
The aim of the work described in this thesis is to develop synthetic methods that give access 
to hybrid molecules containing both a peptide part and a nucleic acid part. These methods 
should be applicable on solid support and ultimately open the way to the synthesis of more 










An overview of naturally occurring hybrid molecules, consisting of a peptide and a nucleic acid 
and synthetic efforts to obtain fragments and derivates of these interesting molecules is 
presented in this chapter.  
 
1.0 Post-translational modifications 
Investigation of post-translational modifications of proteins is a major research topic since these 
modifications are key players in regulation of eukaryotic cellular processes.6 Such 
modifications range from the introduction of a simple acetyl7 or phosphate8 group to attachment 
of small proteins such as ubiquitin.9 Some post-translational modifications even cause alteration 
of the amino acid sequence of the target protein such as for instance deamidation of asparagine 
to aspartic acid residues.10 Introduction of nucleic acid monomers are also found amongst the 




Adenosine diphosphate ribosylation (ADP-ribosylation) is effected by two classes of enzymes 
called poly-ADP-ribosyl polymerases (PARPs) or mono-ADP-ribosyl transferases (MARTs).11 
These enzymes transfer ADP-ribose from β-NAD+ to nucleophilic functional groups in the side 
chain of amino acid residues of the target protein, a process that is accompanied by the release 
of nicotinamide (see Figure 1).12  
Figure 1 
 
ADP-ribosylation has an influence on a variety of processes ranging from the triggering of 
DNA repair mechanisms to regulation of immune responses.13,14  
Schramm and co-workers have done extensive research on identifying the transition state of the 
ADP-ribosylation process effected by the bacterial pertussis toxin.15-18 For this work they treat a 
synthetic peptide fragment with pertussis toxin and NAD+ analogues to obtain ADP-ribosyl 































































modified peptides that can be conjugated to ADP-ribose.19 These prepared conjugates carrying a 
non-natural linkage to ADP-ribose are recognized by poly-ADP-ribosylating enzymes in 
enzymatic essays. Although several other reports on modified NAD+ analogues have been 
published20-24, no fully chemical synthesis of ADP-ribosyl containing peptides is known to date.  
 
1.2 Adenylylation 
Adenylylation is another post translational modification process in which adenosine 
monophosphate (AMP) is transferred from adenosine triphosphate (ATP) to a nucleophilic 
residue in the protein backbone under the influence of adenylyl transferring enzymes (see 
Figure 2).25 If this nucleophilic residue is a hydroxyl (in the case of serine, threonine or 
tyrosine) a stable phosphodiester bond is formed between adenosine and the protein. 
Adenylylation reactions involving the introduction of such a stable adenylyl adduct usually 
plays a role in the regulation of protein activity.26 When carboxylate or amine side chains are 
adenylylated unstable mixed anhydrides or phosphoramidates are formed. The function of 
adenylylation in this type of reactions is the introduction of a good leaving group. In this 
transient process the energy stored in the α,β- phosphoric anhydride bond in ATP is released. 
This overall process facilitates thermodynamically unfavorable reactions to take place. 
Examples of adenylyl transferases are bacterial enzymes that adenylylate GTPases.27-29 
Figure 2 
 
A synthetic route towards adenylylated peptides was published using a H-phosphonate 
approach.30 Unprotected serine or threonine containing resin-bound peptides were transformed 
to their corresponding H-phosphonates and subsequently coupled to 2’,3’-isopropyl adenosine 
and oxidized. Cleavage from the solid support and protective group removal using 95% 
trifluoroacetic acid yielded the target peptides. The yields, however, were very low, which 
might be due to depurination of the nucleotidyl peptides in acidic environment. Although small 
quantities of adenylyl serine or threonine peptides were obtained, this method might not be 
widely applicable since the adenylyl peptides seem to be unstable under the conditions used in 
this approach. Furthermore, a similar H-phosphonate approach was reported to be inefficient for 
the synthesis of tyrosine containing nucleotidyl peptides, thereby limiting the scope of such a 
H-phosphonate method to obtain adenylyl peptides.31 Another approach towards adenylylated 
peptides is based on the assembly of pre-adenylylated Fmoc protected amino acids.32,33 In this 
approach 2’, 3’-O-isopropylidene protection is installed on the ribosyl part of adenosine and the 












































protected nucleoside is coupled to suitably protected serine, threonine and tyrosine. After 
oxidation and protective group manipulations these adenylyl amino acids are incorporated in 
peptides using an on-line solid phase peptide synthesis method. Acidic removal of the 
protective groups and simultaneous cleavage from the resin gives access to the adenylylated 
peptides accompanied by trace amounts of depurinated analogues. 
 
2.0 Antibiotics 
Some bacterial species are found to produce antibiotics, containing a peptide and nucleotide 
part, to defend themselves. Escherichia coli for instance produces the antibiotic Microcin C7 
(see Figure 3).34 The peptidyl part of this phosphoramidate mediates the transport of the 
antibiotic into the target bacterial cell, where processing leads to cleavage of the peptide bond 
between alanine and aspartic acid releasing the aspartic acid adenyl phosphoramidate which 
acts as an inhibitor of protein synthesis in the targeted bacterium.35,36 A similar defense 
mechanism is employed by the eggs of the Japanese fish Stichaeus grigorjewi, that produce the 
Dinogunelin toxin (see Figure 3, R is either a proton or a unsaturated lipid residue).37 Another 
example is Phosmidosine (see Figure 3), where 8-oxo-adenosine is attached to proline via a 
similar phosphoramidate linkage.38 This antifungal antibiotic originating from Streptomyces 
durhmeusie is also found to possess anti-cancer activity. Phosmidosine and some analogues 
thereof have been prepared by coupling the methoxy-phosphoramidite of 8-oxo-adenosine to a 























































Nucleoproteins are a class of hybrid biomolecules in which a protein is covalently linked to a 
nucleic acid chain via a phosphodiester bond between the 3’- or 5’-end of the DNA or RNA and 
the hydroxyl function of a serine, threonine or tyrosine residue in the protein backbone (See 




Such nucleoproteins play important roles in the replication of RNA-viruses, DNA-viruses and 
bacteriophages: 
RNA-viruses. In the case of poliovirus, a well investigated example of a RNA-virus, the small 
protein VPg (Viral Protein genome-linked), consisting of only 22 amino acids is attached via 
the tyrosine hydroxyl moiety to the 5’-end uridylic acid residue of the viral genome.40 This 
protein acts as a cap-structure at the 5’-end of the viral RNA. Besides protecting the viral 
genome from exonuclease degradation VPg is believed to be a primer in progeny strand 
synthesis either as the free peptide or as its uridylylated form VPgpU or VPgpUpU.41 
DNA-viruses. In adenovirus, an example of a DNA-virus, both 5’-ends of the double stranded 
viral genome are linked to a 55kD protein called TP (Terminal Protein) via a phosphodiester 
bond between serine residue 580 in the protein backbone and the 5’-deoxycytidylic acid of the 
genome. This nucleoprotein is believed to act as primer in DNA-replication.42-44 
Bacteriophages. In a similar fashion bacteriophage Ф29 DNA is covalently attached via the 5’-
end deoxyadenosine to a serine residue in the 27kD protein called P3.45,46 This nucleoprotein is 
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gene A protein, which is believed to cleave the double stranded DNA of the phage by the 
formation of a phosphodiester bond between a tyrosine residue and the 5’-end adenylic acid 
residue at the cleavage site, thereby creating a starting point for replication.47  
Topoisomerases. Nucleoproteins also occur as intermediates in unwinding and rewinding of 
supercoiled DNA in higher organisms. Topoisomerase type I and type II enzymes cleave the 
DNA backbone, reduce tension on the intertwined DNA to facilitate access for replication 
enzymes and then reconnect the cleaved DNA.48 Topoisomerase type I enzymes induce single 
strand breaks via the formation of an intermediate in which a tyrosine residue in the protein’s 
backbone is connected covalently to the 3’-phosphate of the broken DNA. Topoisomerase type 
II enzymes induce double strand breaks forming phosphodiester bond between a tyrosine or 
serine and the 5’-ends of both broken DNA strands.49 Several drugs inhibiting topoisomerases 
are used in antibacterial and anticancer therapies. These drugs prevent the topoisomerase to 
reconnect the broken DNA, resulting in a permanent protein-bound DNA lesion, which 
eventually leads to apoptosis.50  
P53-protein. Another protein that is found to be covalently linked to RNA is tumor 
suppressor protein P53. This protein is involved in DNA repair and cell cycle regulation and the 
inability to express this protein leads to tumor formation.51 It is proposed that P53 is linked to 
the 5’-end of the RNA via Ser-389.52 
The synthesis of nucleoproteins or fragments thereof named nucleopeptides, is far more 
demanding than the synthesis of the individual nucleic acid and peptide fragments. When 
synthesizing such hybrid biopolymers, the inherent acid lability of the oligonucleotides 
prohibits the use of strong acid, which is commonly used in deprotection protocols in peptide 
chemistry. Likewise the strong basic conditions required for the removal of acyl protective 
groups at the exocyclic amines of nucleobases may be accompanied by unwanted β-elimination 
of phosphorylated serine and threonine residues.53 In this process the proton on the α-position of 
serine or threonine is abstracted resulting in formation of dehydroalanine and the 
oligonucleotide 5’-phosphate. On top of this a complex protective group strategy is needed, 
requiring orthogonality of the permanent and temporary protective groups in the peptide and 
nucleic acid part of the projected nucleopeptide. One has to take all these properties of 
nucleopeptides and the desired protection scheme into account when devising a suitable 












3.1 Synthesis of nucleopeptides in solution 
Initial efforts to synthesize nucleopeptides take advantage of a balanced combination of solution 
approaches known from nucleic acid and peptide chemistry. A summary of different methods to 
install the crucial phosphodiester linkage between the peptide part and the nucleic acid part of 
nucleopeptides is described below, focusing on the phosphorus chemistry involved and the 
protective groups used in these strategies.  
 
3.1.1 Phosphotriester approach 
Van Boom and coworkers reported the first synthetically made ribonucleopeptide 5 (see Figure 
5), which is prepared using a modified phosphotriester approach.54 In this example bi-functional 
phosphorylating agent 3 equipped with two leaving groups (1-benzotriazolyl) and one 
permanent protective group (2-chlorophenyl) is first coupled to the hydroxyl functionality of 
dipeptide 1, followed by coupling to dinucleotide 2 using N-methyl imidazole as activator. The 
protective groups used in this sequence of reactions are 2-nitrophenylsulfenyl (NPS) on the 
peptide N-terminus, 2-chlorophenyl on the phosphodiester, tetrahydropyranyl (THP) on the 2’-
hydroxyl functions of the uridylic acid residues, acetyl on the 3’-hydroxyl of the terminal 
uridylic acid residue, while the C-terminal carboxylate of the peptide is capped as carboxamide. 
After construction of the protected phosphodiester linkage between the peptide part and the 
nucleotide part, removal of the protective groups was accomplished in a three step procedure. 
First oximate-reagent55 was used to cleave the 2-chlorophenyl. Secondly a triethylamine-
methanol-water treatment cleaved the acetyl group and a final acidic hydrolysis of the NPS and 
THP by treating with methanolic HCl (pH 2.5) for 3 hours followed by aqueous HCl (pH 2) for 
14 hours. The order of removing protective groups in this sequence of reactions is carefully 


















































4 R1 = 2-chlorophenyl, R2 = THP, R3 = Ac, R4 = NPS
5 R1 = , R2 = R3 = R4 = H
NO2
S O O





The same phosphotriester methodology was applied in the preparation of deoxynucleopeptides 
6 and 7, having a phosphodiester between tyrosine or threonine residues and tetra-
deoxynucleotide [5’-pATAT-3’], respectively (see Figure 6).57 The exocyclic amine of adenine 
was protected using the NPS group, whereas the terminal thymidylic acid 3’-OH function was 
protected with the levulinoyl (Lev) group. Both protective groups could be removed without 
problems using tri-n-butylphosphine and hydrazine respectively, avoiding strong acidic 
conditions. In the case of 7 two issues deserve attention. First, the C-terminal allyl ester 
introduced to give access to the free acid, could not be removed using Pd(0) based procedures, 
rendering a partially protected nucleopeptide fragment. Second, the choice of protective groups 
in the preparation of 7 avoids the use of strong base as it was reported in a preliminary study 
that harsh alkaline conditions led to β-elimination at the amino acid side chain in syntheses of 
H-Ala-Ser[5’-pTT-3’]-NH2 and H-Ala-Thr[5’-pTT-3’]-NH2.53 The phosphotriester approach 
was also employed to give nucleopeptides containing the dideoxynucleotide [5’-pGC-3’] (see 
Figure 6, compound 8 and 9).58 The protecting group used on the guanidine base was di-n-
butylformamidine (DNB), which is removable using hydrazinolysis, and NPS on cytidine. The 
2-chlorophenyl groups, used as protection on the phosphodiester bonds, were removed using 
TBAF. The peptide C-terminal acid of 9 was protected as 2-(hydroxymethyl-9,10-















































































































3.1.2 Phosphorothioate triesters 
An alternative for the 2-chlorophenyl as phosphate protecting groups is a (substituted) 
phenylsulfenyl group.53, 59-62 Advantage of sulfenyl groups are the relatively mild deprotection 
procedures such as silver acetate, iodine in pyridine followed by water or (n-Bu3Sn)2O followed 
by TMSCl. These procedures avoid strong base, which is deleterious for serine and threonine 
containing nucleopeptides. Fully protected nucleopeptides 14 and 15 were prepared by reaction 
of phosphorylating agent 13 with dinucleotide 10 and subsequent condensation of the mono-
hydroxybenzotriazole intermediate with dipeptides 11 or 12 (see Figure 7).53,59 The sulphenyl 
group in nucleopeptides 14 and 15 could be easily removed using silver acetate in pyridine-
water, after which further deprotection gave access to 16 and 17.  
Figure 7 
 
Another phosphorothioate approach makes use of phosphorothioate peptides, assembled from 
phosphorothioate amino acids61, that are activated and subsequently coupled to 
diribonucleotides to give diribonucleotide dipeptide Ala-Tyr[5’-pUU-3’] and 
dideoxyribonucleotide tripeptide Ala-Ser[5’-pTT-3’]-Phe 21, of which the synthesis is depicted 




























14 R1 = OClC6H4 , R2 = THP, R3 = H, R4 = NPS, R5 = OMPS
15 R1 = OClC6H4 , R2 = THP, R3 = Me, R4 = NPS, R5 = OMPS
16 R2 = R3 = R4 = H, R1 = R5 = O





















20 R1 = S-Aryl, R2 = TcBoc









































Deprotection of the phosphorothioates triesters using (n-Bu3Sn)2O resulted in formation of the 
unprotected phosphodiester bonds. The (2,2,2-trichloro-tert-butoxycarbonyl) (TcBoc) and 
phenacyl (Pac) ester groups could be removed using Zn/acetylacetone in pyridine under mild 
conditions. 
3.1.3 H-phosphonate approach 
The observation that oximate based procedures to remove 2-chlorophenyl protection on the 
phosphotriester moiety led to β-elimination in serine nucleopeptides, encouraged the 
investigation of the so-called H-phosphonate approach in nucleopeptide synthesis.31 In this 
approach the H-phosphonates of protected threonine and serine tripeptides (22 and 23, see 
Figure 9) were formed by reacting the peptide with salicylchlorophosphine to give an 
intermediate phosphite triester that was hydrolyzed to give H-phosphonates 24 and 25, 
respectively. Subsequent reaction of H-phosphonate 24 or 25 with the free 5’-hydroxyl of 3’-O-
acetyl thymidine under the agency of pivaloylchloride, followed by oxidation with iodine and 
immediate hydrolysis using water gave protected nucleopeptides 26 and 27. Although the 
formation of the phosphodiester bond between thymidylic acid and peptides containing 
threonine or serine proved to be fruitful a similar coupling with tyrosine was not efficient, 

















22, 24, 26 R1 = H, R2 = CH(CH3)C2H5






























































3.1.4 Phosphoramidite approach 
The phosphoramidite approach reported by Beaucage and Caruthers63, based on the phosphite 
triester method first reported by Letsinger and Ogilvie64, became the most used method in solid 
support based oligonucleotide synthesis. Therefore this method was also applied in 
nucleopeptide synthesis. Phosphitylation of peptide 28 using phosphordiamidite 29 gave rise to 
phosphoramidite 30 (see Figure 10).57 The crude amidite was condensed under influence of 
tetrazole with separately prepared tetradeoxynucleotide 31, followed by oxidation using 
peroxide to give protected nucleopeptide 32. Using the phosphoramidite approach a higher 
yield (90%) is reported for the synthesis of 32 when compared to the phosphotriester method 
(64%).57 Fully protected 32 was treated with TBAF in pyridine/water to cleave the phosphate 
protection 2-chlorophenyl and allyl groups, tri-n-butylphosphine in dioxane/water to cleave the 
NPS groups and hydrazine hydrate in pyridine/acetic acid to remove the Lev group, resulting in 
nucleopeptide 33. No conditions however were found to cleave the C-terminal allyl ester.  
Figure 10 
 
Waldmann and co-workers have used a similar phosphoramidite approach to obtain 
nucleopeptides in which deoxycytidylic acid 36 is linked to a serine containing tripeptidyl 
phosphoramidite 35 (see Figure 11) to give fully protected nucleopeptide 37.65 The goal of this 
work was to extend the protective group repertoire used in nucleopeptide synthesis by the 
introduction of the phenylacetoxy benzyloxycarbonyl (PhAcOZ) group. This N-terminal 
PhAcOZ protective group in 37 can be removed by the enzyme penicillin G acylase under mild 
conditions (pH 6.8) to give 38. No attempts were made however to remove all other protective 





































































32 R1 = NPS, R2 = Lev, R3 = ClC4H6, R4 = All


















3.2 Syntheses of nucleopeptides on solid support 
The (automated) solid phase synthesis of oligonucleotides and peptides eventually proved to be 
the best approach to obtain these biomolecules. The methodologies used in oligonucleotide and 
peptide chemistry were therefore adapted for the synthesis of nucleopeptides. 
 
3.2.1 Synthesis of nucleopeptides starting from resin-bound oligonucleotides 
Applying the phosphoramidite methodology on a solid support was found to be most efficient in 
the preparation of oligonucleotides. In this method the first dimethoxytrityl (DMT) protected 
nucleotide is attached to the solid support (A) (see Figure 12) via a linker that is stable en route 
to the immobilized oligonucleotide (E), but can be cleaved in the final stage of the synthesis. 
The repetitive cycle in oligonucleotide synthesis starts with liberation of the primary hydroxyl 
function to give alcohol (B). Coupling with a 3’-phosphoramidite reagent (C) under agency of 
an activator gives phosphite triester intermediate (D), which is subsequently oxidized to give 
phosphotriester (E). Removal of the 5’- protecting group on the just attached nucleotide 
elongates the oligonucleotide with one nucleic acid residue. Repeating this cycle will elongate 
the resin-bound oligonucleotide chain from the 3’-end in the direction of the 5’-end, until final 

























































































Nucleopeptides 39 - 41 were prepared via this method (exemplified for 39, see Figure 13).66-68 
First oligonucleotide 42 was prepared on solid support. Next, peptidylphosphoramidite 43 was 
coupled and subsequently oxidized to give fully protected 44. Deprotection and release from the 
solid support gave access to nucleopeptide fragment 39. The main feature in the protective 
group strategy used in the construction of 39 - 41 is the use of fluoride labile 2-(tert-
butyldiphenylsilyloxymethyl)-benzoyl (SiOMB)69 groups on the exocyclic amines of the 
nucleobases. Cyanoethyl protection, and the oxalylester anchor were cleaved simultaneously 
with the SiOMB groups using fluoride ions in water-pyridine, proving this method to be 
compatible with the integrity of the nucleopeptide fragments. The 3’-hydroxyl functions of 
ribonucleopeptide 41 were protected with TBDMS groups, which were also cleaved by the 
fluoride treatment. The N-termini of 39 and 41 were masked with the NPS group, which was 


















































In the case of nucleopeptide 40 the peptide N-terminal amine as well as the acid functions were 
masked as nitro-benzyl carbamate/ester, which were removed under reductive conditions using 
sodium dithionite and sodium bicarbonate. Although the mild deblocking conditions needed for 
nitro-benzyl group removal prevented β-elimination, the deprotection was incomplete, 
complicating purification.  
Peptidyl phosphoramidites allow access to larger nucleopeptide fragments than the solution 
based approaches, but there are also limitations to this technique. Low solubility of fully 
protected peptide fragments and the ensuing problems in preparation of peptidyl 
phosphoramidites70, as well as decreased reactivity of such amidites are main disadvantages of 




















































































































3.2.2 Synthesis of nucleopeptides starting from resin-bound peptides 
Reversing the order of nucleopeptide assembly by first preparing a resin bound peptide 
followed by repetitive coupling cycles of the appropriate nucleotide phosphoramidite to a 
hydroxyl function in the peptide backbone, might avoid the solubility and reactivity issues 
mentioned above. Extensive work by Grandas and co-workers has resulted in a wide repertoire 
of deoxynucleopeptides.70-78 An example of this approach is represented by the synthesis of 50 
(see Figure 14).71 Leucyl amino methyl polystyrene resin 45 was coupled to α-(4-
nitrophenyl)ethyl ester of Boc protected C-terminal aspartic acid β-fluorenemethyl ester 46.  
Figure 14 
 
Subsequent sequential elongation of the peptide using Boc-based chemistry and final capping 
resulted in peptide 48. DNA assembly on the free hydroxyl of serine was effected by repetitive 
coupling cycles with the appropriate 5’-phosphoramidite, capping, oxidation and liberation of 
the 3’-hydroxyl. In standard DNA synthesis 3’-phosphoramidites are used and the growing 
DNA chain is elongated from the 3’-end towards the 5’-end. In this particular case, 5’-
phosphoramidites were prepared and used to elongate the growing oligonucleotide from the 5’-
end towards the 3’-end. This non-standard approach proceeded without problems and final 
cleavage from the support by TBAF and removal of all nucleobase protective groups using 
ammonia in dioxane resulted in formation of the target nucleopeptide 50. 
Most of the results of the group of Grandas show examples of peptides linked to the 3’-end of 
DNA (in contrast to the example given in Figure 14, which is linked to the 5’-end). Such 3’-
linked deoxyribonucleopeptides are for instance formed by topoisomerase I enzymes. Standard 
















































nucleopeptides. Side chain protection in all naturally occurring amino acids used in this strategy 
are generally base-labile protective groups, of which an overview is described below.  
 
The hydroxyl containing amino acid residues in nucleopeptide sequences, beside the linkage 
site for the oligonucleotide (see for instance 51, Figure 15), were found to be efficiently 




Incorporation of a histidine residue (see for instance 52, Figure 15) was reported to proceed 
best by using the tosyl-protection group in peptides synthesis and removing this protection with 
HOBt prior to assembly of the nucleic acid part.72 It is not an option to use unprotected histidine 
during peptide synthesis since this causes epimerization at the α-carbon. 
Lysine containing nucleopeptides (see for instance 53, Figure 15) were reported to be best 
protected using either the fluorenemethyloxycarbonyl (Fmoc) or trifluoroacetyl (TFAc) group 
on the ε-amine function.76 However, the alkaline conditions needed to cleave the TFAc group 
limit its use. 
Arginine containing nucleopeptides (see for instance 54, Figure 15) were obtained by 
protecting the arginine side chain using Fmoc groups.75 Due to the difficulties in the preparation 
of Fmoc-Arg(Fmoc)2-OH it was decided in the synthesis of 59, (see Figure 15) not to use 
protection on arginine. Ornithine side products were found indicating cleavage of the guanidine 
moiety in the arginine side chain. Other side reactions found at the guanidine group, when using 
unprotected arginine are acylation by amino acids in subsequent peptide coupling steps or 
nucleotide incorporation.78 
Tryptophane containing nucleopeptides (see for instance 55, Figure 15) were obtained by 
protecting the indole ring with the formyl group, which could be efficiently removed by an 
ammonia treatment.76  
For cysteine containing peptides the standard protection of cysteine residues using the tert-
butyl sulfenyl group is reported to give β-elimination in the final aqueous ammonia treatment.79 
The resulting dehydroalanine can be converted to serine or 2,3-diaminopropionic acid residues 




































complete conversion of cysteine to serine.78 After cleavage of the S-tBu group the free thiol is 
prone do disulfide formation or to alkylation by the acrylonitrile generated by cleavage of the 
cyanoethyl phosphate protective group. To avoid above mentioned problems the best method 
found so far is cleaving the S-tBu using NH3/ 1M DTT in dioxane for 8 hours at room 
temperature. 
The synthesis of methionine containing nucleopeptides (see 57, Figure 15) can be 
accompanied by alkylation as a side reaction. Furthermore, aqueous iodine conditions used to 
oxidize phosphites to phosphotriesters might cause iodination and subsequent oxidation of the 
methionine residues. In peptide chemistry a well known method is to use methionine sulfoxide 
analogues, that are reduced after chain assembly, with for instance N-
methylmercaptoacetamide. This strategy proved efficient for the synthesis of nucleopeptide 
57.80  
Asparagine and glutamine containing nucleopeptides were synthesized using unprotected Asn 
or Gln building blocks.76,78 Although primary carboxamides are reported to react with 
phosphoramidites81 no significant amount of branched products were detected in the synthesis 
of an asparagine containing nucleopeptide (see 58, Figure 15). In the synthesis of 60 the 
aqueous ammonia treatment to remove acyl protection groups resulted in the formation of 
several side products.78 Attack of the side chain carboxamide on the α-carbon of asparagine can 














































































On the other hand, attack of the NH in the amide bond between tyrosine and asparagine can 
result in the formation of an aspartimide (pathway B, Figure 16). Hydrolytic opening of this 
aspartimide can give rise to the aspartic acid containing peptide (pathway C) and to the β-
peptide (pathway C’). Deamidation of the nucleopeptide can give rise to the aspartic acid 
containing peptide as well (pathway E). Opening of the aspartimide ring by ammonia can give 
rise to the β-peptide isomer (pathway D). Extensive characterization of the formed products 
however is difficult due to their size and complexity. The only performed analysis on the 
formed products is MALDI-TOF analysis which cannot cast a light on the identity of the 
isolated product and the side-reaction(s) that have occurred in the synthesis of 60. 
In studies on the incorporation of histidine, lysine, arginine and tryptophan in the 
nucleopeptides described above, it was opted to use an artificial linkage site between the 
peptide and deoxyoligonucleotide in order to circumvent problems such as β-elimination, 
associated with the labile nature of serine and threonine.72 The use of homoserine (Hs) instead 
of serine not only improved the stability under basic conditions74 but also improves the stability 
of nucleopeptides against 3’-exonuclease activity in biological systems.75  
Although the above described solid phase based methodology is a powerful tool to create 
nucleopeptides, still the synthesis of each specific nucleopeptide is a challenge. Potential side 
reactions in both the peptide and nucleic acid parts and base lability are recurring problems, the 






















3.2.3 Use of pre-uridylylated building blocks 
Uridylylated VPg’s are proposed to act as primers in viral replication and for this reason are 
interesting targets for nucleopeptide synthesis. The mono-uridylylated VPg (VPgpU) of polio 




In this strategy pre-uridylylated tyrosine building 63 is of crucial importance. Coupling of 
protected tyrosine 61 and phosphoramidite 62, followed by oxidation and protective group 
manipulations renders 63. Pentameric peptide 64 was assembled on very acid-labile HMPB 
resin using pre-uridylylated tyrosine 65 via a Fmoc-based peptide synthesis protocol (in contrast 
to the Boc-based synthesis of nucleopeptides described in section 1.2.2). After release from the 
solid support and removal of all protective groups except the N-terminal Alloc, nucleopeptide 
64 was coupled to partially protected heptadecamer 65. This protected peptide was prepared 
separately on Rink amide MBHA resin. Condensation of 64 and 65 using the coupling mixture 
BOP/HOBt resulted in protected uridylylated VPgpU 66, which was deprotected using Pd(0)-
catalyzed hydrostannolysis of the Alloc groups and allyl ester to give the unprotected 
nucleoprotein 67. The use of pre-uridylylated building blocks was also examined in the fully 
sequential solid support based synthesis of the VPgpU’s of polio virus (68), coxsackie virus 
(69) and cowpea mosaic virus (70, see Figure 18).83 Starting from Rink Amide MBHA resin the 
















































tyrosine 63 or uridylylated serine 71 (see Figure 18). Protective groups on the amino acid side 
chain functionalities used in this protocol were all acid labile. Acidic cleavage of protective 
groups on the peptide side chains and liberation of the peptides from the solid support followed 
by ammonia treatment to remove the acyl protection on the nucleoside as well as the N-terminal 
Fmoc gave tyrosine nucleopeptides 68 and 69 without problems. In the synthesis of serine 
nucleopeptide 70, the phosphodiester moiety was protected using the 2-chlorophenyl protective 
group instead of the cyanoethyl, since the 2-chlorophenyl can be removed using fluoride ions in 
aqueous solvent (water/pyridine) to avoid strong base.  
Figure 18 
 
The advantage of this stepwise approach versus the block coupling method described earlier to 
obtain mono-uridylylated nucleoproteins is the ease of sequential synthesis and the use of 
protective groups that are cleaved using a simpler less complicated deprotection protocol. 
However this method does not allow the introduction of oligonucleic acid fragments since 
strong acid (95% trifluoroacetic acid) is used during the deprotection. 
 
3.2.4 Solid phase convergent synthesis 
Using a similar block coupling approach the double uridylylated nucleoproteins of coxsackie 
virus and polio virus type 1 (VPgpUpU’s) were synthesized (as exemplified for polio virus 
VPgpUpU 76, see Figure 19).84 Pentapeptide 74 was prepared by reacting phosphoramidite 73 
with resin bound 72, followed by oxidation and cleavage of acyl protective groups and 
concomitant release from the solid support. Coupling of double uridylylated pentapeptide 74 to 
the appropriate, protected C-terminal heptadecamers of coxsackie virus or polio virus 
respectively followed by deprotection gives access to the respective VPgpUpU’s. In a 
previously reported block coupling approach towards VPgpU nucleoproteins, the arginine 




































During solid phase peptide synthesis however, the δ-Alloc group on arginine was found to be 
partially cleaved causing side reactions to occur and thereby complicating the purification 
process.84 For this reason the arginine residue in the heptadecamer fragment en route to 75 was 
protected with the acid labile Pbf protective group which was removed prior to the block 










































Outline of this thesis 
Chapter 2 of this thesis describes the properties of a phosphoramidite equipped with two p-
methoxybenzyl groups. Arbuzov like reactions allow the preparation of phosphates, 
phosphoramidates, phosphorothioates, pyrophosphates and phosphofluoridates in a one-pot 
procedure. 
Chapter 3 describes the synthesis of pre-ribosylated glutamine and asparagine building blocks 
and their incorporation in peptides, that are natural sites of ADP-ribosylation. The methodology 
described in Chapter 2 to create phosphates and pyrophosphates is applied in the synthesis of 
mono-ADP-ribosylated peptides both in solution and solid support based approaches.  
Chapter 4 deals with the ribosylation of adenosine at the 2’-OH in an α-selective fashion. This 
glycosylated nucleoside is the repetitive unit of poly-ADP-ribose. The introduction of an 
orthogonal protective group pattern is described that would allow the use of this building block 
in stepwise poly-ADP-ribosylated peptide synthesis.  
In Chapter 5 a general method to obtain five picornavirus VPgpU’s is reported using a pre-
uridylylated tyrosine building block. 
In Chapter 6 the method from Chapter 5 is extended to generate the other three canonical pre-
nucleotidylated tyrosine building blocks. These are then used to generate the corresponding 
nucleotidylated polio virus VPg proteins. 
Chapter 7 describes a linear solid support based synthesis of the nucleopeptide derived from 
the N-terminal region of picornaviral VPg. This approach demonstrates RNA synthesis using 
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Phosphorus containing functional groups are not only essential elements of nucleic acids but are 
also present in other naturally occurring compounds such as proteins2, carbohydrates3 and 
lipids.4 Among these biomolecules phosphomono- and diesters2,3, pyro- and triphosphates5,6, 
phosphoramidates7 and C-phosphonates8 can be discerned. The pivotal role that these 
phosphoric acid derivatives play in a broad palette of biological processes has stimulated 
research into the synthesis of these classes of compounds.9,10 In addition, the pharmacological 
potential of phosphate ester analogues11-13 led to the development of artificial phosphate 
derivatives such as phosphorothioates14 and phosphofluoridates.15 Initially developed to meet 
the needs of automated nucleic acid synthesis, the phosphoramidite approach is one of the most 
applied synthetic methodologies towards phosphate ester containing molecules.16-18 Introduction 
of phosphate esters is generally attained with the aid of amidites provided with protecting 
groups, which are often base-labile.19,20 Upon activation with a weakly acidic azole the amidite 
reagent reacts with an alcohol to give a phosphite triester. Subsequent oxidation to the 
phosphotriester and deprotection using alkaline conditions furnishes the target phosphodi- or 
monoester.21  
As part of ongoing efforts22-24 aiming at the synthesis of naturally occurring phosphates and 
derivatives thereof via the phosphoramidite approach the phosphitylation properties of 
methoxybenzyl-N,N-diisopropylphosphoramidites 1 and 2 (Figure 1) were explored. One of the 
interesting envisioned properties of these substituted benzyl groups is their stability towards 
mild alkaline conditions and their lability towards mild acidic conditions. These reagents 
provide attractive entries to phosphomonoesters, since phosphitylation of the alcohol of choice 




mild acidic removal of both p-methoxybenzyl groups would readily provide the corresponding 
phosphomonoester. Reagent 2 (Figure 1) equipped with o,p-dimethoxybenzyl groups would 
conceivably lead to a phosphotriester moiety convertible to a phosphomonoester under even 
milder conditions. An additional useful feature of reagents 1 and 2 is the potential of 
methoxybenzyl substituents to engage in Arbuzov-type reactions.25 This would open the way to 
the synthesis of modified phosphates.  
Figure 1 
 
Methoxybenzyl phosphoramidites 1 and 2 
 
Results and Discussion 
 
Phosphoramidites 1 and 2 were synthesized in good yields via a procedure reported for a related 
compound26, comprising treatment of p-methoxybenzylalcohol and 2,4-
dimethoxybenzylalcohol, respectively, with N,N-diisopropylaminodichlorophosphine in the 
presence of triethylamine. Reaction of reagent 1 (1.2 eq.) with thymidine 3 (1.0 eq.) using 
dicyanoimidazole (DCI) (1.2 eq.) as activator (Scheme 1) gave, as monitored by 31P-NMR 
spectroscopy (δ: 141.8 ppm), formation of phosphite triester 4 as the major product together 
with some minor phosphonates (δ: 14.1, 9.1 ppm), caused by the hydrolysis of excess reagent 1. 
In the subsequent steps 4 was used without isolation, since silica gel column chromatography 
yielded only 29% of 4, presumably due to its instability. Addition of anhydrous tBuO2H to 
oxidize phosphite 4, followed by p-methoxybenzyl deprotection using 3% TFA in DCM and 
chromatographic purification yielded phosphate 5 (31P-NMR, δ: 1.6 ppm) in 78% yield. In 
contrast, phosphitylation of 3 using agent 2 under identical conditions failed to yield the 
intended phosphite triester but instead produced unidentified C- and H-phosphonates in a 1:1 
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Scheme 1. Synthesis of phosphate 5 and phoshorothioate 6 
 
Reagents and conditions; i. 1, DCI, MeCN, 0 oC, 20 min, ii. 5.5 M tBuO2H, 2 h, r.t., iii. 3% TFA in DCM, 5 min, r.t., 
78% (over two steps), iv. (PhS)2, MeCN, 16 h, r.t., 79%. 
Having demonstrated the effectiveness of phosphitylating agent 1 to introduce phosphate 
monoesters under mild acidic (deprotection) conditions the susceptibility of di-(p-
methoxybenzyl) protected phosphite triester 4 to undergo an Arbuzov-type reaction was 
explored. Thymidine 3 was converted into phosphite triester 4 as described above, but now the 
reaction mixture was treated with diphenyldisulfide at the time the transformation of 3 to 4 was 
complete (as revealed by NMR) leading to phosphorothioate diester 6 in 79% yield (Scheme 1). 
Surprisingly complete in situ cleavage of both p-methoxybenzyl protecting groups was 
observed when the reaction was monitored by 31P-NMR spectroscopy, while it was expected to 
observe the corresponding triester still carrying one p-methoxybenzyl group. This one-pot 
procedure thus allows an immediate access to S-phenyl phosphorothioates, known precursors27 
in the synthesis of pyrophosphates. The question arose whether these results could be extended 
to other Arbuzov-type reactions using this one-pot procedure. The use of iodine as the oxidation 
reagent for 4 would allow introduction of a range of nucleophilic atoms at the phosphorus 
center via the putative phosphoryliodide.28  
An interesting class of compounds are the phosphoromorpholidates, the most well-known 
intermediates en route to pyrophosphates.29 The solution phase synthesis of thymidine 
phosphoromorpholidate derivative 8 (Scheme 2) was undertaken by adaptation of an iodine 
mediated procedure to create phosphoromorpholidates on a solid support.30 Thymidine 7 was 
phosphitylated with 1 in presence of DCI under the same conditions as described above and the 
obtained di-(p-methoxybenzyl) phosphite triester was oxidized with iodine in pyridine and 
subsequently treated with morpholine for 1 hour. After silica gel column chromatography 
morpholidate 8 was isolated in 86% yield.31 Following an analogous procedure using iso-



































To broaden the scope of the one-pot procedure the use of non-nitrogen nucleophiles was 
investigated. Addition of DAST as fluoride source to the reaction mixture after iodine-mediated 
oxidation resulted in the formation of phosphofluoridate 10 (80%). Similarly, addition of the 
sodium salt of p-nitrophenol to the oxidized reaction mixture resulted in formation of the 
corresponding phosphodiester 11 (44%). Surprisingly, addition of water did not result in the 
formation of the expected phosphate monoester but furnished symmetric pyrophosphate 12 
(78%).  
Scheme 2. Synthesis of phosphate monoesters 8 – 11 and symmetric pyrophosphate 12 
 
Reagents ands conditions: i. 1, DCI, MeCN, 0 oC, 20 min, ii. I2, pyridine, 30 min, r.t., iii. morpholine, 1 h, r.t. (86% over 
three steps), iv. iso-butylamine,1 h, r.t. (79% over three steps), v. DAST,16 h, r.t. (80% over three steps), vi. p-
nitrophenolate sodium salt, 16 h, r.t. (44% over three steps), vii. H2O,16 h, r.t. (78% over three steps). 
 
This unexpected formation of the pyrophosphate 12 upon addition of water as well as the fact 
that no special treatment is needed to remove the second p-methoxybenzyl group in the 
remaining reactions (Scheme 2) put forward the question on the identity of the reactive 
intermediates involved in the reaction sequence of this one-pot procedure. On the basis of the 
data that resulted from the analysis of selected reactions by 31P NMR spectroscopy the 
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Scheme 3. Proposed reaction mechanism 
 
 
Activation of amidite 1 (31P-NMR, δ: 147.5) with DCI and subsequent coupling with alcohol 3 
gave the phosphite triester 4 (31P-NMR, δ: 141.8, see Scheme 1). Treatment of the phosphite 
triester 4 with iodine in pyridine (Scheme 3) would lead to phosponium species A and the 
subsequent phosphoryliodide B, having a resonance around δ: -44, as described.28 However, 
this resonance could not be detected, but instead a signal at δ: -11.2 was observed. This 
indicated that the putative phosphoryliodide B was transformed immediately into another 
intermediate with concomitant cleavage of the second p-methoxybenzyl group (PMB). This loss 
of the protective group can be explained by nucleophilic attack of iodide generated in step C on 
the benzylic position of the PMB group. On the basis of literature data that comparable 
phosphorazolides have 31P-NMR resonances at δ: -12.2 and -11.24 the resonance at δ: -11.2 was 
tentatively assigned to the dicyanoimidazolide species D.29,32 Subsequent addition of a 
nucleophile would lead to displacement of dicyanoimidazole to give the corresponding 
phosphate derivative. The proposed dicyanoimidazolide D as the reactive intermediate would 
explain not only the removal of both p-methoxybenzyl groups but also the formation of 
pyrophosphate 12. Addition of water will partly and slowly hydrolyze dicyanoimidazolide D to 
give the corresponding monophosphate that, in turn, reacts faster than water with D to give 
pyrophosphate (for example 12, Scheme 2). 
To further establish the applicability of this one pot procedure in the preparation of various 
phosphite derivatives, the syntheses of asymmetric pyrophosphate33 14 and phosphoramidon 
precursor34 16 (Scheme 4) were undertaken. Crude pyrophosphate 14 was obtained by 
phosphitylation of protected adenosine 13 with 1 under the influence of DCI, subsequent 
iodine/pyridine oxidation and, finally, addition of thymidine phosphate 5. RP-HPLC and gel 
filtration yielded homogeneous pyrophosphate 14 in moderate yield (27%). Similarly 
phosphoramidon precursor 16 was synthesized in a moderate yield (19%) by phosphitylating β-
rhamnose-triacetate 15 with 1, iodine oxidation and addition of leucyltryptophane ethyl ester. 
Such modest yields, compared to synthesis of compounds 8 - 12 are probably caused by the 
















































Scheme 4. Synthesis of asymmetric pyrophosphate 14 and phosphoramidon precursor 16 
 
Reagents and conditions: i. 1, DCI, MeCN, 0 oC, 20 min, ii. I2, pyridine, 1 h, r.t., iii. 5 (Scheme 1),16 h, r.t., 27% (over 
three steps), iv. H-Leu-Trp-OEt, 16 h, r.t. 19% (over three steps). 
In conclusion, an efficient one-pot procedure to phosphoramidates, phosphorothioates, 
pyrophosphates and phosphofluoridates has been presented that comprises a sequence of 
reactions starting with phosphitylation of an alcohol with di-(p-methoxybenzyl)-N,N-
diisopropylphosphoramidite 1, followed by oxidation with iodine and treatment with a 
nucleophile of choice. The favourable properties of the p-methoxybenzyl groups allowed the 
use of reagent 1 to introduce phosphate monoesters under relatively mild acidic conditions. This 
feature as well as the potential to form asymmetric pyrophosphates will be further explored in 


























































General: All chemicals were used as received. Petroleum Ether with a boiling range of 40 ‐ 60°C was 
used. THF and Et2O were distilled over LiAlH4 prior to use. DCM was distilled over CaH2 prior to use. 
All other solvents used under anhydrous conditions were stored over molecular sieves (4Å) except for 
methanol which was stored over 3Å molecular sieves. Solvents used for workup and column 
chromatography were of technical grade and distilled before use. Unless stated otherwise, solvents were 
removed by rotary evaporation under reduced pressure at 40°C. Reactions were monitored by 
TLC‐analysis using Merck 25 DC plastikfolien 60 F254 with detection by spraying with 20% H2SO4 in 
EtOH, (NH4)6Mo7O24·4H2O (25 g/L) and (NH4)4Ce(SO4)4·2H2O (10 g/L) in 10% sulfuric acid or by 
spraying with a solution of ninhydrin (3 g/L) in EtOH / AcOH (20/1 v/v), followed by charring at approx. 
150°C. Column chromatography was performed using silica gel (0.04 – 0.063 mm, 60 Å, Screening 
Devices). For LC-MS analysis a JASCO HPLC‐system (detection simultaneously at 214 and 254 nm) 
equipped with an analytical C18 column (4.6 mmD × 50 mmL, 3μ particle size) in combination with 
eluents A: H2O, B: MeCN and C: 0.5% aq. TFA was used and coupled to a PE/SCIEX API 165 single 
quadruple mass spectrometer (Perkin-Elmer). Alternatively a Thermo Finnigan LCQ Advantage MAX 
ion-trap mass spectrometer with an electrospray ion source coupled to Surveyor HPLC system (Thermo 
Finnegan) was used with the same analytical column. For reversed‐phase HPLC purification of final 
compounds, an automated HPLC system supplied with a C18 column (10.0 mmD × 250 mmL, 5μ particle 
size) was used. High resolution mass spectra were recorded by direct injection (2 μL of a 2 μM solution in 
water/acetonitrile; 50/50; v/v and 0.1% formic acid) on a mass spectrometer (Thermo Finnigan LTQ 
Orbitrap) equipped with an electrospray ion source in positive mode (source voltage 3.5 kV, sheath gas 
flow 10, capillary temperature 250 °C) with resolution R = 60000 at m/z 400 (mass range m/z = 150‐2000) 
and dioctylpthalate (m/z = 391.2842) as a “lock mass”. The high resolution mass spectrometer was 
calibrated prior to measurements with a calibration mixture (Thermo Finnigan). 1H‐ and 13C‐NMR spectra 
were measured on a Brüker AV‐400 (400 MHz), a Brüker AV‐500 (500 MHz) or a Brüker DMX‐600 (600 
MHz). Chemical shifts are given in ppm (δ) relative to TMS (0 ppm) and coupling constants are given in 
Hz. Phosphitylation reactions were monitored using 31P-NMR, by placing 400 µL of the crude reaction 
mixture in a NMR-tube. An acetone-cappilary filled with acetone-d6 was used as external lock. Chemical 
shifts are given in ppm (δ) relative to 85% aq. H3PO4 (0 ppm). IR spectra of the neat compounds were 
recorded on a Shimadzu FTIR-8300 and are reported in cm-1. Optical rotations are measured in CHCl3 at a 
concentration of 10 mg/mL at 25 0C on a Propol automatic polarimeter (Sodium D-line, λ = 589 nm). 
 
Di-(p-methoxybenzyl)-N, N-diisopropylphosphoramidite (1)  
 
To a cooled (0 oC) solution of N, N-diisopropylphosphorodichloridite (2.4 g, 12.0 mmol) in Et2O (50 mL) 
was added dropwise a solution of p-methoxybenzyl alcohol (3.8 mL, 30 mmol) and TEA (5.6 mL, 40 
mmol) in Et2O (50 mL). After 1 hour, the suspension was filtered and washed with sat. aq. NaHCO3. The 
filtrate was dried using MgSO4, concentrated and purified using silica gel column chromatography 
PE:TEA (99:1  23:2, v/v) as eluent to afford 1 as a colourless oil (3.98 g, 82%). 1H-NMR (400 MHz, 
CDCl3), δ: 7.26 (d, J = 8.6 Hz, 4H, Arom. PMB), 6.85 (d, J = 8.7 Hz, 4H, Arom. PMB), 4.71 - 4.59 (m, 
4H, CH2 PMB), 3.78 (s, 6H, CH3 PMB), 3.72 - 3.63 (m, 2H, CH iPr), 1.20, 1.19 (2x s, 12H, CH3 iPr).13C-

















PMB), 55.2 (CH3 PMB), 43.0, 42.9 (CH iPr), 24.6, 24.5 (CH3 iPr). 31P-NMR (162 MHz, CDCl3), δ: 
147.52. IR: 2965, 1612, 1512, 1244, 1172, 1027, 967, 818, 729, 514. HRMS [C22H32NO4P + H]+: calc. 
406.2141, fnd. 406.2099. 
 






To a cooled (0 oC) solution of N, N-diisopropylphosphorodichloridite (0.5 g, 2.5 mmol) in Et2O (10 mL) 
was added dropwise a solution of 2,4-dimethoxybenzylalcohol (0.9 g, 5.2 mmol) and TEA (1.2 mL, 8.3 
mmol) in Et2O (10 mL). The reaction was slowly warmed to room temperature and after 1 hour, the 
suspension was diluted in 40 mL pentane and filtered. The filtrate was concentrated and purified using 
silica gel column chromatography using Et2O: PE:TEA as eluent (0:95:5  10:85:5, v/v) to afford 2 as a 
colourless oil (0.43 g, 0.9 mmol, 36%). 1H-NMR (400 MHz, MeCN-d3), δ: 7.25 (d, J = 8.3 Hz, 2H, Arom. 
DMB), 6.51 (d, J = 10.5, 2H, Arom. DMB),6.48 (s, 2H, Arom. DMB), 4.73 - 4.54 (m, 4H, CH2 DMB), 
4.04 - 3.54 (2x s, 12H CH3 DMB), 3.74 - 3.56 (m, 2H, CH iPr), 1.20, 1.19 (2x s, 12H, CH3 iPr).13C-NMR 
(100 MHz, MeCN-d3), δ: 161.6, 159.1 (Cq Arom.), 130.6 (Arom.), 121.0 (Cq Arom.), 105.2, 99.1 
(Arom.), 61.2, 61.0 (CH2 DMB), 56.1, 56.0 (CH3 DMB), 43.9, 43.8 (CH iPr), 25.1, 25.0 (CH3 iPr). 31P-






To a solution of 5’-(4’,4-dimethoxytrityl)thymidine (5.45 g, 10 mmol) in DCM (50 mL) was added TEA 
(4.2 mL, 30 mmol), DMAP (0.24 g, 2 mmol) and benzoylchloride (3.0 mL, 26 mmol) after which the 
reaction mixture was stirred for 16 hours. The reaction mixture was concentrated and taken up in EtOAc 
followed by washing with sat. aq. NaHCO3. The organic layer was dried (MgSO4) and concentrated. The 
residue was dissolved in DCM (60 mL) and dichloroacetic acid (2.5 mL, 30 mmol) was added. After 15 
min triethylsilane (16.1 mL, 100 mmol) was added and the reaction mixture was stirred at r.t. for 30 min. 
After washing with sat. aq. NaHCO3, drying using MgSO4 and concentration the residue was purified 
using silica gel column chromatography (0:100 10:90 MeOH/DCM v/v) to yield the title compound as a 
white foam (4.38 g, 9.7 mmol, 97%). 1H-NMR (400 MHz, CDCl3), δ: 8.03 (d, J = 1.1 Hz, 2H, Arom. Bz), 
7.94 (d, J = 1.1 Hz, 2H, Arom. Bz), 7.81 (d, J = 1.1 Hz, 1H, H6), 7.74 - 7.54 (2x m, 2H, Arom. Bz), 7.46 
(2x t, J = 10.8, 4.9 Hz, 4H, Arom. Bz), 6.40 (dd, J = 8.3, 6.0 Hz, 1H, H1’), 5.58 (dt, J = 5.9, 2.0 Hz, 1H, 
H3’), 4.24 (q, J = 2.3 Hz, 1H, H4’), 3.99 - 3.93 (m, 2H, H5’), 2.84 (bs, 1H, OH), 2.63 - 2.44 (m, 2H, H2’), 
1.96 (d, J = 1.0 Hz, 3H, CH3 T).13C-NMR (100 MHz, CDCl3), δ: 168.9 (CO Bz), 166.1, 162.8 (C4, C2), 
149.4 (CO Bz), 136.1 (C6), 135.1, 133.6 (Arom. Bz), 131.4 (Cq Bz), 130.4, 129.6, 129.1, 128.5 (Arom. 
Bz), 111.3 (C5), 85.7 (C1’), 85.3 (C4’), 75.3 (C3’), 65.2 (C5’), 37.6 (C2’), 12.6 (CH3T). IR: 3417, 1756, 
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To a cooled (0 oC) solution of thymidine 3 (200 mg, 0.45 mmol) and 1 (0.20 mL, 0.50 mmol) in MeCN (3 
mL) was slowly added a solution of DCI (60 mg, 0.5 mmol) in MeCN (1 mL). After 20 min. 31P-NMR 
showed complete disappearance of 1 (148.5) and formation of triester 4 (31P-NMR; 141.8). The solution 
thus obtained was used directly in the subsequent transformations. An analytical sample of 4 was 
concentrated and purified by column chromatography using a gradient of EA:PE:TEA 20:80:0.1 (v/v/v) to 
yield the title compound as a colourless oil (95 mg, 0.13 mmol, 29%). 1H-NMR (400 MHz, CD3CN), δ: 
8.14 - 8.03 (m, 2H, Arom.), 8.03 - 7.94 (m, 2H, Arom.), 7.75 (s, 1H, H6), 7.67 – 7.64 (m, 1H, Arom.), 
7.55 (2x t, J = 7.8 Hz, 4H, Arom.), 7.37 - 7.20 (m, 4H, Arom.), 6.91 (dd, J = 8.5, 1.2 Hz, 4H, Arom.), 6.36 
(dd, J = 8.2, 6.0 Hz, 1H, H1’), 5.49 - 5.48 (m, 1H, H3’), 4.88 (d, J = 8.2 Hz, 4H, CH2 PMB), 4.37 (q, J = 
3.0 Hz, 1H, H4’), 4.23 - 4.03 (m, 2H, H5’), 3.86 - 3.71 (m, 6H, OMe PMB), 2.69 - 2.34 (m, 2H, H2’), 1.86 
(s, 3H, CH3 T).13C-NMR (100 MHz, MeCN-d3), δ: 170.7 (CO Bz), 166.7, 163.8 (C4, C2), 150.5 (CO Bz), 
137.1 (C6), 136.3, 134.4 (Arom. Bz), 132.6, 131.2 (Cq Bz), 130.8 (Cq PMB), 130.5, 130.40, 130.37, 129.6 
(Arom. Bz), 114.8 (Arom. PMB), 111.8 (C5), 86.2 (C1’), 84.8, 84.7 (C4’), 76.2 (C3’), 65.6, 65.4, 65.1, 
65.0 (CH2 PMB) , 63.3, 63.2 (C5’), 55.9 (CH3 OMe), 38.2 (C2’), 12.7 (CH3 T). 31P-NMR (162 MHz, 
MeCN-d3), δ: 141.87. IR: 2933, 1748, 170, 1659, 1612, 1515, 1449, 1246, 1175, 1096, 1026, 975, 713. 
HRMS [C40H39N2O11P+ H]+: calc. 755.2364, fnd. 755.2361. 
 






To a cooled (0 oC) solution of phosphite triester 4 (1.8 mmol) in MeCN (5 mL) was added tBuO2H (1.0 
mL, 5.5 M in nonane) and the reaction mixture was stirred for 2 hours. The reaction mixture was 
concentrated and coevaporated three times with toluene. The residue was taken up in anhydrous DCM (20 
mL) and TFA (0.6 mL) was added. After 5 min, toluene (5 mL) was added and the mixture was 
concentrated. The crude product was purified by silica gel column chromatography using DCM:MeOH as 
eluent (1:0  17:3 v/v) and treated with Amberlite Na+-resin to yield 5 as a sodium salt (0.91 g, 78 %). 
1H-NMR (400 MHz, MeOD-d4), δ: 8.04 (s, 1H, H6), 8.03 (d, J = 7.5 Hz, 2H, Arom. Bz), 7.96 (d, J = 7.4 
Hz, 2H, Arom. Bz), 7.81 - 7.37 (m, 6H, Arom. Bz), 6.56 - 6.31 (m, 1H, H1’), 5.68 (d, J = 5.2 Hz, 1H, 
H3’), 4.40 (s, 1H, H4’), 4.31 - 4.12 (m, 2H, H5’), 2.76 - 2.41 (m, 2H, H2’), 2.03 (s, 3H, CH3 T). 13C-NMR 
(100 MHz, MeOD-d4), δ: 170.3 (CO Bz), 167.3, 164.9 (C2,C4), 151.1 (CO Bz), 138.4 (C6), 136.3, 134.6 
(Arom. Bz), 133.0 (Cq, Bz), 131.5 (Arom. Bz), 130.6 (Cq Bz), 130.4,129.7, 129.1 (Arom. Bz), 112.5 (C-5), 
86.6 (C1’), 85.9 (C4’), 78.1 (C3’), 66.3 (C5’), 38.5 (C2’), 12.6 (CH3 T). 31P-NMR (162 MHz, 
CDCl3/MeOD-d4), δ: 1.60. IR: 3390, 1747, 1699, 1661, 1635, 1600, 1450, 1318, 1270, 1178, 1099, 1061, 




























i. 5.5 M tBuO2H
















To a cooled (0 oC) solution of phosphite triester 4 (0.42 mmol) in MeCN (4 mL) was added 
diphenyldisulfide (0.22 g, 1.0 mmol) and the reaction mixture was stirred for an additional 16 hours. The 
reaction mixture was concentrated and the crude product was purified by silica gel column 
chromatography using DCM:MeOH as eluent (1:0  23:2 v/v) and treated with Amberlite Na+-resin to 
yield 6 (0.24 g, 79 %). 1H-NMR (400 MHz, MeOD-d4), δ: 8.12 (s, 1H, H6), 8.04 (d, J = 7.8 Hz, 2H, 
Arom. Bz), 7.96 (d, J = 7.9 Hz, 2H, Arom. Bz), 7.79 - 7.24 (m, 6H, Arom. Bz), 7.20 - 7.12 (m, 5H, Arom. 
Ph), 6.44 (t, J = 7.6 Hz, 1H, H1’), 5.62 (d, J = 5.4 Hz, 1H, H3’), 4.30 (s, 1H, H4’), 4.03 - 3.88 (m, 2H, 
H5’), 2.73 - 2.44 (m, 2H, H2’), 2.00 (s, 3H, CH3 T).13C-NMR (100 MHz, MeOD-d4), δ: 170.6 (CO 
Bz),167.4, 166.2 (C4, C2), 151.0 (CO Bz), 138.3 (C6), 136.3, 134.6 (CH Bz), 133.0 (Cq Bz), 131.5, 130.7, 
130.4, 129.7 (Arom. Bz), 111.9 (C5), 87.1 (C1’), 86.8 (C4’), 77.0 (C3’), 63.0 (C5’), 38.7 (C2’), 12.5 (CH3, 
T). 31P-NMR (81 MHz, CDCl3/MeOD-d4), δ: 12.1. IR: 3406, 2925, 1760, 1700, 1661, 1644, 1447, 1267, 






To a solution of 5’-(4’,4-dimethoxytrityl)thymidine (8.17 g, 15 mmol) in pyridine (75 mL) was added a 
catalytic amount of DMAP and benzoylchloride (2.3 mL, 20 mmol) followed by stirring for 2 hours at 
room temperature. After concentration the residue was taken up in EtOAc and washed with an aqueous 
CuSO4 solution and the organic phase was dried (MgSO4) and concentrated. The crude residue was 
dissolved in dry DMF (50 mL) and K2CO3 (10.3 g, 75 mmol) and pivaloyloxymethylchloride (5.5 mL, 
37.5 mmol) were added and the mixture was stirred for 16 hours at room temperature. After concentration 
the residue was dissolved in DCM (50 mL) and TFA (1.5 mL) was added. The reaction mixture was 
quenched by the addition of MeOH (5 mL) and neutralized using TEA (2.8 mL, 20 mmol) after 1 hour. 
The reaction mixture was washed with water and sat. aq. NaCl, dried and concentrated. The crude residue 
was purified using silica gel column chromatography using a gradient of PE:EtOAc (80:20  40:60 v/v) 
to yield the title compound as a white foam (5.11 g, 11.1 mmol, 86%). 1H-NMR (400 MHz, CDCl3), δ: 
7.95 (d, J = 8.0 Hz, 2H, Arom. Bz), 7.80 (s, 1H, H6), 7.60 (t, J = 7.4 Hz, 1H, Arom. Bz), 7.46 (t, J = 7.7 
Hz, 2H, Arom. Bz), 6.47 (dd, J = 8.4, 5.9 Hz, 1H, H1’), 6.08 - 5.84 (m, 2H, CH2 POM), 5.69 - 5.57 (m, 
1H, H3’), 4.30 (d, J = 2.0 Hz, 1H, H4’), 4.19 - 3.95 (m, 2H, H5’), 3.31 (bs, 1H, OH), 2.98 - 2.33 (m, 2H, 
H2’), 1.97 (s, 3H CH3 T), 1.19 (s, 9H, tBu). 13C-NMR (100 MHz, CDCl3), δ: 177.6 (CO POM), 166.0, 
162.5 (C4,C2), 150.3 (CO Bz), 135.2 (C6), 133.7, 133.4 (Arom. Bz), 129.5 (Cq Bz), 129.8, 127.9 (Arom. 
Bz), 110.3 (C5), 86.0 (C1’), 85.1 (C4’), 75.4 (C3’), 64.9 (CH2 POM), 62.4 (C5’), 38.7 (Cq tBu), 37.5 
(C2’), 26.8 (tBu), 13.0 (CH3 T). IR: 3489, 2976, 1714, 1652, 1465, 1267, 1096, 711. HRMS [C23H28N2O8 
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To a cooled (0 oC) solution of 7 (0.46 g, 1.0 mmol) and 1 (0.63 g, 1.3 mmol) in MeCN (15 mL) was 
slowly added a solution of DCI (0.15 g, 1.25 mmol) in MeCN (5 mL). After 20 min, a solution of iodine in 
pyridine (2 mL, 0.5 M) was added to the reaction mixture until the solution kept its brown colour. After 30 
min of additional stirring, morpholine (0.26 mL, 3.0 mmol) was added and the mixture was stirred for an 
hour and then concentrated. The crude product was pre-purified by silica gel column chromatography 
using DCM:MeOH:TEA as eluent (98:0:2  8:2:0, v/v/v) to yield the slightly impure title compound 
(0.52 g, 86%). A part of this crude product was further purified using HPLC and treated with Amberlite 
Na+-resin to afford the sodium salt. 1H-NMR (500 MHz, MeOD-d4), δ : 8.07 (d, J = 7.4 Hz, 2H, Arom. 
Bz), 7.98 (s, 1H, H6), 7.64 - 7.44 (m, 3H, Arom. Bz), 6.47 (dd, J = 8.6, 5.9 Hz, 1H, H1’), 5.94 - 5.92 (m, 
2H, CH2 POM), 5.65 (d, J = 5.4 Hz, 1H, H3’), 4.38 (s, 1H, H4’), 4.22 - 3.99 (m, 2H, H5’), 3.71 - 3.58 (m, 
4H, CH2 Morph.), 3.13 (dd, J = 9.0, 4.6 Hz, 4H, CH2 Morph.), 2.70 - 2.47 (m, 2H, H2’), 2.01 (s, 3H, CH3 
T), 1.17 (s, 9H, tBu POM).13C-NMR (125 MHz, MeOD-d4), δ: 179.0 (CO POM), 167.3, 164.5 (C4, C2), 
152.0 (CO Bz), 137.3 (C6), 134.6 (Arom. Bz), 131.0 (Cq Bz), 130.6, 129.6 (Arom. Bz), 111.4 (C5), 87.1 
(C1’), 85.7 (C4’), 77.8 (C3’), 68.6 (CH2N morpholine), 66.3 (CH2 POM), 65.8 (C5), 46.7 (CH2O, 
morpholine), 39.8 (Cq POM), 38.4 (C2’), 27.4 (CH3 POM), 13.2 (CH3 T). 31P-NMR (162 MHz, MeOD-
d4), δ: 6.42. IR: 1717, 1663, 1452, 1269, 1258, 1099, 712. HRMS [C27H36N3O11P +H]+: calc. 610.2160, 
fnd. 610.2157. 
 





To a cooled (0 oC) solution of 7 (0.46 g, 1.0 mmol) and 1 (0.63 g, 1.3 mmol) in MeCN (15 mL) was 
slowly added a solution of DCI (0.15 g, 1.25 mmol) in MeCN (5 mL). After 20 min, a solution of iodine in 
pyridine (2.0 mL, 0.5 M) was added to the reaction mixture until the solution kept its brown colour. After 
30 min of additional stirring, isobutylamine (0.3 mL, 3.0 mmol) was added and stirred for an hour. The 
reaction mixture was concentrated and the crude product was pre-purified by silica gel column 
chromatography using DCM:MeOH:TEA as eluent (98:0:2  8:3:0, v/v/v) to yield slightly impure 9 (0.24 
g, 79 %). A part of this crude product was further purified using HPLC and treated with Amberlite Na+-
resin to afford the sodium salt. 13C-NMR (125 MHz, MeOD-d4), δ: 179.12 (CO POM), 167.4, 164.5 (C2, 
C4), 152.10 (CO Bz), 137.51 (C6), 134.58 (Arom. Bz), 130.93 (Cq, Bz), 130.64, 129.66 (Arom. Bz), 
111.54 (C5), 87.08 (C1’), 85.73, 85.66 (C4’, JCP = 9.2 Hz), 77.74 (C3’), 66.25 (C5’), 65.50 (CH2 POM), 
49.52 (CH2 isobutyl), 38.31 (C2’), 31.34 (CH isobutyl), 27.34 (CH3 POM), 20.58, 19.37 (CH3 isobutyl), 
13.28 (CH3 T). 31P-NMR (80.7 MHz, MeOD-d4), δ: 7.42. MS: 596.2 [M + H]+. IR: 1716, 1666, 1469, 












































To a cooled (0 oC) solution of 3 (0.45 mmol) and 1 (0.59 mmol) in MeCN (4 mL) was slowly added a 
solution of DCI (0.59 mmol) in MeCN (1 mL). After 20 min, a solution of iodine in pyridine was added to 
the reaction mixture until the solution kept its brown colour. After 30 min of additional stirring, DAST 
(0.07 mL, 1.17 mmol) was added followed by 16 hours of stirring. The reaction mixture was concentrated 
and the crude product was purified by silica gel column chromatography using DCM:MeOH as eluent (1:0 
 98:2 v/v) and treatment with Amberlite Na+-resin to yield 10 (0.19 g, 80 %). 1H-NMR (400 MHz, 
MeOD-d4), δ : 8.08 - 7.87 (m, 5H, Arom. Bz/ H6), 7.70 (t, J = 7.5 Hz, 1H, Arom. Bz), 7.56 - 7.44 (m, 3H, 
Arom. Bz), 7.25 - 6.99 (m, 2H, Arom. Bz), 6.43 (t, J = 7.3 Hz, 1H, H1’), 5.62 (s, 1H, H3’), 4.39 (s, 2H, 
H4’), 4.37 - 4.17 (m, 2H, H5’), 2.57 (dd, J = 6.9, 3.4 Hz, 2H, H2’), 2.00 (s, 3H, CH3 T).13C-NMR (100 
MHz, MeOD-d4), δ: 170.3 (CO Bz), 167.3,164.8 (C2, C4), 151.0 (CO Bz), 137.8 (C6), 136.3, 134.6 
(Arom. Bz), 132.9 (Cq, Bz), 131.5 (Arom. Bz), 130.8 (Cq Bz), 130.4, 129.9, 129.7, 129.2 (CH, Bz), 112.4 
(C5), 86.6 (C1’), 85.4 (C4’), 77.4 (C3’), 67.6 (C5’), 38.4 (C2’), 12.5 (CH3 T). 31P-NMR (162, MeOD-d4), 
δ: -2.27, -8.01 (d, JPF = 930 Hz). IR: 3391, 1747, 1698, 1652, 1656, 1599, 1449,1250, 1100, 1061, 823, 
714, 489. HRMS [C24H22FN2O9P +H]+ : calc. 533.1119, fnd. 533.1118. 
 





To a cooled (0 oC) solution of 3 (0.25 mmol) and 1 (0.33 mmol) in MeCN (2.5 mL) was slowly added a 
solution of DCI (0.33 mmol) in MeCN (1 mL). After 20 min, a solution of iodine in pyridine was added to 
the reaction mixture until the solution kept its brown colour. After 30 min of additional stirring, p-
nitrophenol sodium salt (0.05 g, 0.33 mmol) was added followed by 16 hours of stirring. The reaction 
mixture was concentrated and the crude product was purified by silica gel column chromatography using 
DCM:MeOH as eluent (1:0  97:3 v/v) and treated with Amberlite Na+-resin to yield 11 (73 mg, 44%). 
1H-NMR (400 MHz, MeCN-d3), δ: 8.14 - 7.31 (m, 16H, Arom. NO2Ph/Arom. Bz/H6), 6.42 (bs, 1H, H1’), 
5.54 (bs, 1H, H3’), 4.38 (bs, 1H, H4’), 4.27 (bs, 2H, H5’), 2.46 (bs, 2H, H2’), 1.89 (bs, 3H CH3 T). 13C-
NMR (100 MHz MeCN-d3), δ: 170.7 (CO Bz), 166.7, 163.8 (C4, C2), 158.0 (Cq NO2Ph), 150.4 (CO Bz), 
143.8 (Cq NO2Ph), 137.3 (C6), 136.3, 134.4 (Arom. Bz), 132.0 (Cq, Bz), 131.2, 130.5, 130.4, 129.5 
(Arom. Bz), 126.2, 121.4 (Arom. NO2Ph), 111.9 (C5), 85.9 (C1’), 84.4 (C4’), 76.6 (C3’), 65.0 (C5’), 37.9 
(C2’), 12.9 (CH3 T). 31P-NMR (160 MHz, MeCN-d3), δ: -6.32. IR: 1748, 1700, 1658, 1652, 1344, 1248, 
















































To a cooled (0 oC) solution of 3 (0.55 mmol) and 1 (0.71 mmol) in MeCN (5 mL) was slowly added a 
solution of DCI (0.71 mmol) in MeCN (1 mL). After 20 min, a solution of iodine in pyridine was added to 
the reaction mixture until the solution kept its brown colour. After 30 min of additional stirring, H2O (70 
µL, 3.5 mmol) was added followed by 16 hours of stirring. The reaction mixture was concentrated and the 
crude product was purified by silica gel column chromatography using DCM:MeOH:H2O as eluent (1:0:0 
 6:3:1 v/v/v) followed by Amberlite Na+ -resin treatment to yield 12 (0.45 g, 78 %). 1H-NMR (400 
MHz, MeOD-d4), δ: 8.10 - 7.86 (m, 10H, Arom. Bz), 7.77 - 7.32 (m, 12H, Arom. Bz/H6), 6.54 - 6.37 (m, 
2H, H1’), 5.74 (d, J = 4.4 Hz, 2H, H3’), 4.49 - 4.38 (m, 6H, H4’, H5’), 2.86 - 2.46 (m, 4H, H2’), 2.05 (s, 
6H, CH3 T). 13C-NMR (100 MHz, MeOD-d4), δ: 169.9 (CO Bz), 167.1, 164.2 (C2, C4), 150.5 (CO Bz), 
137.5 (C6), 136.0, 134.4 (Arom. Bz), 132.2 (Cq Bz), 130.3, 129.9, 129.3, 129.2 (Arom. Bz), 112.2 (C5), 
86.1 (C1’), 84.9 (C4’), 76.9 (C3’), 66.5 (C5’), 37.7 (C2’), 12.6 (CH3 T). 31P-NMR (162 MHz, 
CDCl3/MeOD-d4), δ: -8.44. IR: 3384, 1748, 1699, 1661, 1645, 1635, 1448, 1249, 1108, 1066, 931, 712. 
HRMS [C48H44N4O19P2 + H]+: calc. 1043.2147, fnd. 1043.2157. 
 




N6-Benzoyladenosine35 (1.8 g, 4.8 mmol) was dissolved in pyridine (25 mL) after coevaporation with 
pyridine. TBDMS-Cl ( 10 mmol, 1.5 g) was added and the reaction mixture was stirred for 1 hour at room 
temperature. After this iso-butyric anhydride (20 mmol, 3.7 mL) was added and the reaction mixture was 
stirred for 48 hours. The reaction mixture was concentrated and taken up in DCM. After washing with 5% 
citric acid and H2O the organic phase was dried (MgSO4) and concentrated. The residue was taken up in 
MeCN/ H2O (50 mL, 4:1, v/v) and p-TsOH (5 mmol, 0.8 g) was added after which the reaction mixture 
was stirred at room temperature for 2 hours. The reaction mixture was concentrated and purified using 
silica gel column chromatography EA/PE (0:100  45:55 v/v) to afford the title compound as a white 
foam (1.9 g, 3.9 mmol, 78%). 1H-NMR (400 MHz, CDCl3); δ 9.26 (s, 1H, NH), 8.76 (s, 1H, H2), 8.14 (s, 
1H, H8), 8.07 - 7.96 (m, 2H, Arom. Bz), 7.71 - 7.56 (m, 1H, Arom. Bz), 7.51 (dd, J = 10.4, 4.7 Hz, 2H, 
Arom. Bz), 6.13 (d, J = 7.5 Hz, 1H, H1’), 6.01 (dd, J = 7.5, 5.4 Hz, 1H, H2’), 5.88 (bs, 1H, OH), 5.71 (dd, 
J = 5.4, 1.3 Hz, 1H, H3’), 4.35 (d, J = 1.4 Hz, 1H, H4’), 4.10 (dd, J = 12.8, 1.6 Hz, 1H, H5A’), 3.88 (d, J = 
12.8 Hz, 1H, H5B’), 2.65 (hept., J = 7.0 Hz, 1H, CH iBu), 2.50 (hept., J = 7.0 Hz, 1H, CH iBu), 1.24 (dd, J 
= 7.0, 2.2 Hz, 6H, CH3 iBu), 1.09 (dd, J = 14.0, 7.0 Hz, 6H, CH3 iBu).13C-NMR (400 MHz, CDCl3); δ 
175.7, 175.1 (CO iBu), 164.6 (CO Bz), 152.3 (C2), 150.9 (C6), 150.2 (C4), 142.2 (C8), 133.3 (Cq Bz), 
132.8, 128.8, 127.9 (Bz), 124.4 (C5), 88.4 (C1’), 86.3 (C4’), 72.8 (C2’), 72.2 (C3’), 62.4 (C5’), 33.8, 33.5 











































To a cooled solution of adenosine 13 (0.18 mmol, 0.92 mg) in MeCN (5 mL) and 1 (0.25 mmol, 97 uL) 
was added DCI (0.22 mmol, 26 mg). After 20 min a solution of iodine in pyridine (0.5 M) was added to 
the reaction mixture and stirred for 1 hour. Then, phosphate 5 (0.25 mmol) in 2.5 mL MeCN was added 
and stirred at room temperature for 16 hours. RP-HPLC purification followed by gel filtration using a 
HW40 column (50 mM triethylammonium acetate in H2O as eluent) afforded the title compound as a 
white solid (62 mg, 27 %). 1H-NMR (400 MHz, MeOD-d4), δ: 8.70 (s, 1H, H8-A), 8.50 (s, 1H, H2-A), 
7.90 (d, J = 7.6 Hz, 2H, Arom. Bz), 7.76 (m, 3H, Arom. Bz/ H6-T), 7.68 (d, J = 7.2 Hz, 3H, Arom. Bz), 
7.47 (dd, J = 13.4, 6.4 Hz, 4H, Arom. Bz), 7.38 (t, J = 7.5 Hz, 2H, Arom. Bz), 7.27 (d, J = 6.9 Hz, 2H, 
Arom. Bz), 6.29 (d, J = 5.8 Hz, 1H, H1’-A), 5.99 (d, J = 7.2 Hz, 1H, H1’-T.), 5.73 (d, J = 5.5 Hz, 1H, 
H2’-A), 5.63 (s, 1H, H3’-A), 5.40 (s, 1H, H3’-T), 4.49 (s, 1H, H4’-A), 4.26 (s, 1H, H4’-T), 4.19 (s, 4H, 
H5’-A, H5’-T), 2.72 - 2.56 (m, 1H, CH iBu), 2.50 - 2.40 (m, 1H, CH iBu), 2.36 (s, 2H, H2’-T), 1.87 (s, 
3H, CH3-T), 1.11 (dd, J = 9.2, 7.3 Hz, 6H, CH3 iBu), 0.91 (dd, J = 16.6, 6.9 Hz, 6H, CH3 iBu). 31P-NMR 
(162 MHz, MeOD-d4), δ: -10.69, -10.80, -10.96, -11.07 (dd, J = 18.3, 42.7 Hz). IR: 3358, 2927, 1746, 
1699, 1661, 1652, 1455, 1247,1099. HRMS [C49H51N7O19P2 +H]+: calc. 1104.2787, fnd. 1104.2796. 
 





To a cooled solution of 2,3,4-tri-O-acetyl-β-L-rhamnopyranose34 (0.5 mmol, 0.145 mg) in MeCN (4.5 mL) 
and 1 (0.6 mmol, 235 uL) was added DCI (0.55 mmol, 65 mg). After 20 min a solution of iodine in 
pyridine (0.5 M) was added and the reaction mixture was stirred for 20 min. Then, H-Leu-Trp-OEt34 (0.50 
mmol) in 1.0 mL MeCN was added and stirred at room temperature for 48 hours. RP-HPLC purification 
followed by gel filtration using a HW40 column (50 mM triethylammonium acetate in H2O as eluent) 
afforded the title compound as a white solid (74 mg, 19 %). 1H-NMR (400 MHz, MeOD-d4), δ: 9.07 (bs, 
1H, Trp-indole NH), 7.52 (d, J = 7.8 Hz, 1H, Trp-NH), 7.45 (d, J = 7.6 Hz, 1H, Trp ArH), 7.34 (d, J = 8.1 
Hz, 1H, Trp ArH), 7.23 (s, 1H, Trp CH indole), 7.13 (t, J = 7.4 Hz, 1H, Trp ArH), 7.05 (t, J = 7.4 Hz, 1H, 
Trp ArH), 5.44 (d, J = 7.5 Hz, 1H, Rha-H1’), 5.37 - 5.25 (m, 2H, Rha-H2’, Rha-H3’), 5.06 (t, J = 10.0 Hz, 
1H, Rha-H4’), 4.79 (dd, J = 13.2, 5.7 Hz, 1H, Trp-CH), 4.25 - 3.99 (m, 3H, Rha-H5’, Trp-OCH2CH), 3.78 
- 3.69 (m, 1H, Leu-CH), 3.31 (dd, J = 5.2, 2.6 Hz, 2H, Trp-CH2), 2.96 - 2.93 (m, 1H, Leu-NH), 2.12 (s, 
3H, OAc), 2.02 (s, 3H, OAc), 1.97 (s, 3H, OAc), 1.83 - 1.68 (m, 2H, Leu-CH(CH3)2, Leu-CH2), 1.63 (s, 
1H, Leu-CH2), 1.25 - 1.12 (m, 6H, Trp-OCH2CH3, Rha-CH3), 0.88 (dd, J = 6.4, 2.5 Hz, 6H, Leu-
















































A Versatile One-Pot Procedure to Phosphate Monoesters and Pyrophosphates 
49 
 
References and Notes 
 
1  Van der Heden van Noort, G. J.; Verhagen, C. P.; Van der Horst, M. G.; Overkleeft, H. S.; Van der 
Marel, G. A.; Filippov, D. V.; Org. Lett., 2008, 10, 4461 - 4464. 
2 McMurray, J. S.; Coleman, D. R.; Wang, W.; Campbell, M. L.; Biopolymers, 2001, 60, 3 - 31.  
3 Nikolaev, A. V.; Botvinko, I. V.; Ross, A. J.; Carbohydr. Res., 2007, 342, 297 - 344. 
4 Beaucage, S. L.; Iyer, R. P.; Tetrahedron, 1993, 49, 10441 - 10488. 
5 Burgess, K.; Cook, D.; Chem. Rev., 2000, 100, 2047 - 2059. 
6 Hindsgaul, O. F., M.; Molecular Glycobiology; Oxford University Press: New York, 1994. 
7 Umezawa, S.; Tatsuta, K.; Izawa, O.; Tsuchiya, T.; Tetrahedron Lett., 1972, 13, 97 - 100. 
8 Fields, S. C.; Tetrahedron, 1999, 55, 12237 - 12272. 
9 Kraszewski, A.; Stawinski, J.; Pure Appl. Chem., 2007, 79, 2217 - 2227. 
10 Michalski, J.; Dabkowski, W.; Top. Curr. Chem., 2004, 232, 93 - 144. 
11 Moriguchi, T.; Asai, N.; Okada, K.; Seio, K.; Sasaki, T.; Sekine, M.; J. Org. Chem., 2002, 67, 3290 - 
3300. 
12  Burkart, M. D.; Vincent, S. P.; Duffels, A.; Murray, B. W.; Ley, S. V.; Wong, C. H.; Bioorg. Med. 
Chem., 2000, 8, 1937 - 1946. 
13 Klinman, D. M.; Yi, A. K.; Beaucage, S. L.; Conover, J.; Krieg, A. M.; Proc. Natl. Acad. Sci. U.S.A. 
1996, 93, 2879-2883. 
14 Stein, C. A.; Subasinghe, C.; Shinozuka, K.; Cohen, J. S.; Nucleic Acids Res., 1988, 16, 3209 -3221. 
15 Bollmark, M.; Stawinski, J.; Nucleosides Nucleotides Nucleic Acids, 1998, 17, 663 - 680. 
16 Nifantiev, E. E.; Grachev, M. K.; Burmistrov, S. Y.; Chem. Rev., 2000, 100, 3755 - 3799. 
17 Beaucage, S. L.; Iyer, R. P.; Tetrahedron, 1993, 49, 6123 - 6194. 
18 Beaucage, S. L.; Iyer, R. P.; Tetrahedron, 1992, 48, 2223 - 2311. 
19 Ausin, C.; Grajkowski, A.; Cieslak, J.; Beaucage, S. L.; Org. Lett., 2005, 7, 4201 - 4204. 
20 Lartia, R.; Asseline, U.; Tetrahedron. Lett., 2004, 45, 5949 - 5952. 
21 Nurminen, E.; Lonnberg, H.; J. Phys. Org. Chem., 2004, 17, 1 - 17. 
22 Ghisaidoobe, A. B. T.; de Koning, M. C.; Duynstee, H. I.; Ten Kortenaar, P. B. W.; Overkleeft, H. S.; 
Filippov, D. V.; van der Marel, G. A.; Terahedron Lett., 2008, 49, 3129 - 3132. 
23 Kriek, N.; Meeuwenoord, N. J.; van den Elst, H.; Heus, H. A.; van der Marel, G. A.; Filippov, D. V.; 




24 Filippov, D.; Timmers, C. M.; Roerdink, A. R.; van der Marel, G. A.; van Boom, J. H.; Terahedron 
Lett., 1998, 39, 4891 - 4894.  
25 Meyer, A.; Morvan, F.; Vasseur, J. J.; Tetrahedron Lett., 2004, 45, 3745 - 3748. 
26 Dreef, C. E.; Tuinman, R. J.; Lefeber, A. W. M.; Elle, C. J. J.; van der Marel, G. A.; van Boom, J. H.; 
Tetrahedron, 1991, 47, 4709 - 4722. 
27 Shuto, S.; Shirato, M.; Sumita, Y.; Ueno, Y.; Matsuda, A.; Terahedron Lett., 1998, 39, 7341 -7344. 
28 Nielsen, J.; Caruthers, M. H.; J. Am. Chem. Soc., 1988, 110, 6275 - 6276. 
29 Wittmann, V.; Wong, C. H.; J. Org. Chem., 1997, 62, 2144 - 2147. 
30 Cooke, L. A.; Frauendorf, C.; Gilea, M. A.; Holmes, S. C.; Vyle, J. S.; Terahedron Lett., 2006, 47, 719 
- 722. 
31 It became apparent that under the influence of morpholine or iso-butylamine the benzoyl protecting 
group on the nucleobase was removed. This problem was non-existent when the more stable POM 
group was used for protection of the thymine base. 
32 Chandrasegaran, S.; Murakami, A.; Kan, L. S.; J. Org. Chem., 1984, 49, 4951 - 4957. 
33 Ohkubo, A.; Aoki, K.; Seio, K.; Sekine, M.; Terahedron Lett., 2004, 45, 979 - 982. 
34 Donahue, M. G.; Johnston, J. N.; Bioorg. Med. Chem. Lett., 2006, 16, 5602 - 5604. 







Synthesis of Mono-ADP-Ribosylated Oligopeptides Using 








Adenosine diphosphate ribosylation (ADP-ribosylation) is a posttranslational modification of 
proteins that is effected by poly-ADP-ribosyl polymerases (PARPs) or mono-ADP-ribosyl 
transferases (MARTs).2,3 These enzymes transfer ADP-ribose from β-NAD+ to nucleophilic 
functional groups in the side chain of amino acid residues of the target protein, such as Asn, 
































































PARP’s interact with cellular proteins that play a role in DNA-repair mechanisms, transcription 
regulation, immune response and cell metabolism. For instance, poly-ADP-ribose synthesis 
mediated by PARP-1/2 on the N- or C-terminal part of histone H1- and H2B-proteins after 
single-strand DNA breaks, facilitates access to the DNA lesion by relaxation of the chromatin 
and induces recruitment of repair enzymes.4 In the absence of DNA breaks, however, poly-
ADP-ribose polymer (PAR) mediated chromatin loosening is also observed, allowing 
transcriptional activation.5 PARP-1 is also reported to interact with and to stimulate the 
production of transcriptional factor NF-κB, that regulates immune and inflammatory responses; 
PARP-1 deficient mice or mice treated with PARP inhibitors showed increased resistance 
against inflammatory stimuli.6,7 PAR and PARP’s are important in the regulation of 
chromosomal segregation and possibly play a role in the regulation of cell devision.8 
Interestingly it was recently proposed that inhibiting ADP-ribosylation might be a novel 
approach to cancer therapy.9 Tumor cells of tumor-suppressor protein BRCA1 or BRCA2 
mutation carriers have a specific DNA-repair defect and can be selectively killed in the absence 
of an exogenous DNA-damaging agent using PARP inhibitor olaparib. This treatment has little 
adverse effects when compared to conventional radio- or chemotherapy. 
In contrast to poly-ADP-ribosylation, which is mostly effected by mammalian enzymes, the 
best studied mono-ADP-ribosylation events are of bacterial origin. The diphtheria toxin from 
Corynebacterium diphtheria, for instance, inhibits translation of eukaryotic elongation factor 2 
(eEF2) blocking its functioning on the ribosome and thus intervening with protein synthesis, 
ultimately killing the cell.10 Toxins originating from Bacillus cereus, Staphylococcus aureus, 
and Clostridium botulinum also possess ADP-ribosyl transferase activity and target a part of the 
invaded hosts Rho-enzyme family, thereby inducing breakdown of the cytoskeleton.11  
Although ADP-ribosylating enzymes have been identified in many prokaryotic and 
eukaryotic species as well as in viruses, most biological processes in which they partake and 
their exact mode of action in these processes have not been clarified completely.3 The 
elucidation of the role and mechanisms of ADP-ribosylation events would benefit greatly from 
the availability of well-defined ADP-ribosylated peptides and analogues thereof. The main 
issues addressed in this chapter towards the construction of mono-ADP-ribosylated peptides 
entail the synthesis of protected ribosylated amino acids that are compatible with peptide 
synthesis, development of a protective group strategy for the solid phase peptide synthesis that 
is compatible with the integrity of the ribosyl adenosine diphosphate moiety and an appropriate 
procedure for pyrophosphate formation.  
Results and Discussion 
Known ADP-ribosylation sites in naturally occurring proteins include Asn-41 of the 
mammalian Rho protein, the target of mono-ADP-ribosylation catalyzed by a toxin from 
Clostridium botulinum and Glu-3 of the human H2B histone, which is a substrate for PARP 
enzymes.12-14 In the later case, the ADP-ribose moiety is linked to the glutamic acid residue via 
an ester bond, which is known to be unstable under mild basic conditions.2,13 Therefore an 
amide bond, linking glutamine to the ADP-ribose moiety, comparable to the naturally occurring 
amide bond linking the asparagine residue in Rho proteins to the ADP-ribose moiety, was 
envisioned to be a better choice as synthetic target for histone H2B derived peptides. This 
amide linked glutamine ADP-ribose is isosteric to the natural glutamic acid ADP-ribosyl ester.  
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The key N-ribosylated Asn and Gln building blocks 7 and 8 (Scheme 1) were provided with the 
mutually orthogonal TBDPS and Fmoc protecting groups, allowing the introduction of a 
pyrophosphate moiety and elongation of the peptide chain in a sequential manner. The route of 
synthesis started with the silylation of the primary alcohol of known β-D-ribofuranosyl azide 
115 and subsequent acylation of the secondary 2’ and 3’ hydroxyls in 2 to give fully protected 
azide 3 in a near quantitative yield. Reduction of β-azide 3 at 10oC using PtO2/H216 resulted in 
the formation of hemi-aminal ether 4, as a mixture of epimers at C-1. Others have prepared a 
similar ribosylamine in poor yield (6%), due to its instability.17 For this reason the hemi-aminal 
ether mixture was used immediately as a crude and EDC mediated coupling with either Cbz-
Glu-OBn or Cbz-Asp-OBn gave the ribosylated amino acids 5 and 6 respectively, as anomeric 
mixtures. In addition a minor side reaction was detected in both cases, originating from 
migration of the acetyl group from the 2’O to the 1’NH in 4 followed by coupling of the amino 
acid to the 2’O position to form an ester linkage. 
Scheme 1. Ribosylated Asn and Gln Fmoc amino acids 
 
Reagents and conditions; i. TBDPSCl, pyridine, r.t., 16 h, quantitative, ii. Ac2O, pyridine, r.t., 16 h, 98%, iii. PtO2, H2, 
EtOAc, 10 oC, 2 h, iv. Z-Asp-OBn or Z-Glu-OBn, EDC.HCl, DCM, 16 h, r.t., 47% or 61%, respectively (over two 
steps), v. 10% Pd/C, H2, MeOH, r.t., vi. FmocOSu, NaHCO3, water/acetone, 2 h, r.t., 84% or 97%, respectively (over 
two steps). 
The anomeric mixture could be separated using silica gel column chromatography, but unlike in 
pyranoses, the coupling constants obtained from 1H-NMR spectroscopy of the separated 
isomers could not be used to determine the anomeric configuration of 5a/5b and 6a/6b 
respectively, due to their small difference.18 In the case of ribosyl-asparagine mixture 5a/5b, the 
J1’,2’ values found for the higher running product (TLC; Rf = 0.5) were 5.8 Hz in MeOD-d4 and 
5.2 Hz in CDCl3 and the J1’,2’ values found for the lower running product (TLC; Rf = 0.4) were 
4.9 Hz in MeOD-d4 and 5.6 Hz in CDCl3. This small difference in the J1’,2’ values of ca 1 Hz 
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The H-1’ was empirically found to resonate at lower field for 1,2-cis derivatives as compared 
to 1,2-trans compounds.18 In the case of 5a/5b, the H-1’ of the higher running product (TLC; Rf 
= 0.5) resonated at 5.61 ppm in MeOD-d4 and 5.76 ppm in CDCl3. The H-1’ of the lower 
running product (TLC; Rf = 0.4) resonated at 4.87 ppm in MeOD-d4 and 5.56 ppm in CDCl3. 
This indicated that the higher running spot would be the β-anomer and the lower running spot 
the α-anomer.  
These identities could be further confirmed by means of NOE NMR spectroscopy 
experiments. Presence of a cross-peak between H1’and H3’ of ribose indicated the cis 
configuration 5a, whereas for the corresponding trans epimer 5b a cross-peak between H1’and 
H4’ was observed in the NOESY spectra (see Figure 2). Similar results were obtained for 
ribosyl-glutamine 6. Hydrogenation of the α-anomers 5a and 6a to cleave the benzyl ester and 
Cbz protective groups, and subsequent introduction of the Fmoc group under Schotten-




With suitably protected ribosylated Gln and Asn building blocks in hand the synthesis of 
mono-ADP-ribosylated dipeptide 19 in solution was undertaken (see Scheme 2). Peptide 
fragment 19 is derived from the bovine Rho protein, that is ADP-ribosylated by the Clostridium 
botulinum C3 toxin at the Asn-41 residue.12 The partially protected precursor 18 of target 
dipeptide 19 was provided with base labile protecting groups (Fm, Fmoc, Ac and Cbz 
carbonate) to permit a straightforward basic deprotection procedure in the final stage of the 
synthesis, since it was envisaged that both the glycosidic linkage and the pyrophosphate moiety 
in the target molecule 19 would be stable under such conditions. The route of synthesis started 
with the preparation of suitably protected tyrosine derivative 11 (Scheme 2) by conversion of 
commercially available Boc-Tyr(OBn)-OH into Fm ester 9, followed by hydrogenolysis of the 
benzyl ether and subsequent installation of the Cbz group at the released phenolic hydroxyl 
function. Acidic removal of the Boc group in 11 and EDC assisted coupling to ribosylated Asn 
building block 7 resulted in the formation of dipeptide 12. After unmasking the 5’-OH with 
HF/pyridine, the phosphate and the pyrophosphate functionality were introduced sequentially 
by adaptation of the procedure described in Chapter 2.19 Phosphate monoester 15 was obtained 
by phosphitylation of ribosylated dipeptide 13 with di(p-methoxybenzyl)-N,N-
diisopropylphosphoramidite 14 and activator dicyanoimidazole (DCI), followed by oxidation of 
the intermediate phosphite triester with anhydrous t-BuO2H and finally p-methoxybenzyl 
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iodine afforded the putative intermediate 17, an activated phosphorimidazolidate suitable for 
pyrophosphate formation. Addition of crude 15 to in situ formed 17 resulted in the partially 
protected m-ADP-ribosylated dipeptide 18, which was purified using RP-HPLC. Removal of 
Fm and Fmoc groups using DBU, followed by cleavage of the remaining acyl functions using 
aqueous ammonia and gel filtration resulted in 4.1 mg (4.9 µmol) of the homogeneous target 
compound 19. 
Scheme 2 Synthesis of mono-ADP-ribosylated dipeptide 19 
 
Reagents and conditions: i. Pd/C, H2, n-PrOH/EtOAc, r.t., 1 h, 73%, ii. CbzCl, DiPEA, DCM, r.t., 2 h, 84%, iii. 3M HCl 
EtOAc, 30 min, r.t., iv. 7, EDC.HCl, DiPEA, DCM, 1.5 h, r.t., (84% over three steps), v. HF/pyridine, r.t., 1 h, 85%, vi. 
14, DCI, MeCN/DCM, 0 oC, 1 h, vii. 5.5 M tBuO2H, 2 h, r.t., viii. 3% TFA, DCM, 5 min, r.t, ix. I2, pyr., 0 oC, 30 min, x. 
r.t., 16 h, (15%), xi. DBU, 30 min., r.t., xii. NH3 aq., dioxane, 16 h, r.t., (58%). 
The successful synthesis of the m-ADP-ribosylated dipeptide 19 prompted to investigate an 
approach towards elongated m-ADP-ribosyl peptide fragments. Having established an efficient 
solution phase method for the incorporation of ribosylated amino acid 7 as well as application 
of the method to prepare phosphate and pyrophosphate moieties with the aid of phosphitylating 
agent 14 described in Chapter 2, the question arose whether these methods would also be 
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to introduce the pyrophosphate function by reacting a phosphate monoester with an activated 
phosphorimidazolidate. The phosphorimidazolidate of an immobilized ribosylated peptide can 
be reacted with the phosphate monoester of a nucleotide or conversely a peptide-resin equipped 
with a phosphate monoester can be reacted with the nucleotide phosphorimidazolidate. m-ADP-
ribosylated peptides, 25 and 32 (see Scheme 3 and Scheme 4) were constructed each using one 
of these procedures. 
The first procedure to introduce the pyrophosphate on resin involves introduction of the 
reactive phosphorimidazolidate at the 5’ hydroxyl of immobilized ribosylated peptide and 
addition of the phosphate monoester. Hydroxymethylbenzoic acid (HMBA) was selected as a 
suitable linker for the on-resin synthesis of hexapeptide 25 (see Scheme 3) containing an ADP-
ribosylated Asn residue. The HMBA-linker would allow the removal of the base labile 
protective groups on the peptide as well as the release of the ADP-ribosylated peptide from the 
resin in a single step. Furthermore HMBA is reported to be a good choice to afford thioesters, 
which will be convenient in the future for the synthesis of larger m-ADP-ribosylated peptides or 
proteins using native chemical ligation.  
Hexapeptide 20 was assembled on commercially available Tentagel resin equipped with the 
HMBA linker using a BOP/HOBt Fmoc-based SPPS protocol.20 En route to immobilized 20 the 
incorporation of ribosylated Asn building block 7 and ensuing repetition of the amino acid 
coupling cycle proceeded uneventfully as was determined by LC-MS analysis of the crude 
ribosyl peptide, obtained after cleavage of an analytical sample from the solid support and 
removal of the protecting groups in 20. Unmasking of the 5’-hydroxyl on ribose 20 with 
TEA/HF in pyridine preceded the introduction of the ADP moiety. The activated 
phosphorimidazolidate was installed at the 5’ hydroxyl of the immobilized peptide 21 using 
DCI assisted phosphitylation with reagent 14 and subsequent oxidation using iodine in pyridine. 
Addition of known N6-benzoyl-2’,3’-di-O-iso-butyryladenylyl-5’-monophosphate19 23 led to 
formation of the immobilized and protected ADP-ribosylated peptide 24. The Dmab group on 
the glutamic acid residue side chain was removed by a two step procedure21 and subsequent 
removal of the remaining protecting groups and concomitant cleavage from the resin was 
effected by treatment with methanolic ammonia to give C-terminal methyl ester 25. LC-MS 
analysis of the crude reaction mixture showed besides the main product 25 the presence of a 
few side products, of which the C-terminal carboxamide, the terminal phosphate and the 
corresponding H-phosphonate could be identified.22 The formation of H-phosphonate was 
explained by invoking a partial degradation of the phosphite triester on the resin prior to iodine 
oxidation, the presence of the phosphate monoester was attributed to hydrolysis of the 
phosphorimidazolidate due to incomplete coupling with the incoming phosphate monoester. 
Nevertheless, 0.8 mg (0.6 µmol) of the pure m-ADP-ribosylated hexapeptide 25 could be 
obtained after two RP-HPLC cycles and the identity of the product was ascertained by 31P-







Synthesis of Mono-ADP-Ribosylated Oligopeptides Using Ribosylated Amino Acid Building Blocks 
57 
 
Scheme 3. mono-ADP-ribosylated peptides 25  
 
Reagents and conditions: i. HF/pyridine, r.t., 75 min, ii. 14 (Scheme 2), DCI, MeCN/DCM, 0 oC, 1 h, iii. I2, pyr., 0 oC, 
30 min, iv. 23, v. 2% hydrazine, DMF, 3x 5 min, r.t., vi. 5 mM NaOH, MeOH, 3 h, r.t., vii. 7N NH3/MeOH, 16 h, r.t., 
viii. RP-HPLC purification,  
The second procedure to form the pyrophosphate linkage involved the introduction of the 
phosphate monoester at the 5’ hydroxyl residue of immobilized ribosylated peptide 29 to give 
30 while phosphorimidazolidate 17 prepared in solution, was added to this solid support to 
obtain 31 (see Scheme 4). Such a procedure has the potential to be more effective as unwanted 
hydrolysis of the intermediate phosphorimidazolidate can be counterbalanced by the addition of 
an excess of 17. The target ADP-ribosylated heptapeptide 32 is an isosteric fragment of the 
naturally occurring N-terminus of human histone H2B ADP-ribosylated at E-3 (Scheme 4).13,14 
Precursor heptapeptide 26 was prepared using Tentagel resin equipped with the HMBA linker 
and a BOP/HOBt Fmoc-based SPPS protocol.20 Removal of trityl protective groups on the 
serine residues followed by acetylation of the thus freed hydroxyls allows final basic 
deprotection conditions to remove all protective groups in a single step. Next ribosylated Gln 
building block 8 and Fmoc-Pro-OH were incorporated and LC-MS analysis of the crude 
ribosylated peptide 28, obtained after cleavage of an analytical sample from the solid support 
and removal of the protecting groups, revealed that all previous steps had proceeded efficiently. 
Ensuing fluoride treatment of 28 released the 5’ hydroxyl of ribose to give suitably protected 
ribosyl peptide 29. On resin phosphate monoester formation was attained by phosphitylation 
with 14, oxidation of the intermediate phosphite triester with tBuO2H and p-methoxybenzyl 
removal using 3% TFA to obtain intermediate 30. This phosphate equipped resin was treated 
20 R = TBDPS

























































24 R1 = HMBA- , R2 = Acyl, R3=Dmab














with an excess of phosphorimidazolidate 17 to give the immobilized protected m-ADP-
ribosylated 31. Complete deprotection and cleavage from the solid support was effected by 
treatment with methanolic ammonia. Purification of the mixture by RP-HPLC followed by gel 
filtration afforded 1.3 mg (1.0 µmol) homogeneous m-ADP-ribosylated heptapeptide 32.  
 
Scheme 4. mono-ADP-ribosylated peptides 32  
 
Reagents and conditions: i. 5% TFA, DCM, 3x 5 min, r.t, ii. Ac2O, DMAP, NMP, 25 min, r.t., iii. HF/pyridine, r.t., 75 
min, iv. 14 (Scheme 2), DCI, MeCN, 0 oC, 1 h, v.5.5M tBuO2H, 1 h, r.t., vi. 3% TFA, DCM, 3x 5 min, r.t., vii. 17 
(Scheme 2), MeCN, r.t., 16 h, viii. 7N NH3/MeOH, ix. RP-HPLC purification. 
Analysis of the crude mixture by LC-MS showed besides the main product 32, again the 
terminal phosphate monoester and the corresponding H-phosphonate as side products. The 
formation of the peptide H-phosphonate in course of the phosphitylation reaction proved to be a 
significant hindrance en route to the target ADP-ribosylated peptides and, in order to suppress 
this unwanted transformation, we reinvestigated the phosphitylation reaction of 14 on the 
immobilized ribosylated peptide. Unfortunately it proved to be impossible to suppress the 
formation of the H-phosphonate by variation of the excess of 14, the temperature or the reaction 
time. Attempts to use an alternative phosphorylation method involving the treatment of the 
26 R' = Trt
































28 R' = Ac, R = TBDPS
































31 R1= HMBA- , R2=Acyl
32 R1= NH2, R2= H
vii.
viii., ix.
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immobilized peptide with POCl3 in presence of pyridine did not result in an improved formation 
of the targeted phosphate monoester on resin.23  
A number of applications can be envisaged for the peptides accessible by the methodology 
described here. One line of research would be the attachment of ADP-ribosylated peptides, such 
as the ones prepared in this study, to a carrier protein as well-defined haptens to generate 
antibodies against the ADP-ribose modification. Such tools might prove invaluable for the 
identification of mono-ADP-ribosylated cellular proteins, an intriguing but little understood 
post-translational modification.24 In this fashion peptide 32 may find use in the discovery of the 
hitherto unknown ribosylation on the Gln side chain. In an alternative line of research, ADP- 
ribosylated peptides 19, 25, and 32 or closely related analogues represent well-defined 
substrates for elongation by enzymes of the PARP family. As certain small peptides are 
reported to be accepted as substrates for PARP-1 (nonapeptide) and ADP-ribose protein lyase 
(pentapeptide, PE(ADP-ribosyl)PAK), a better insight into the mechanism of the action of 
PARP enzymes can be attained by using synthetic mono-ADP-ribosylated peptides as substrates 
in elongation assays.25 When combined with established chemical ligation tactics to extend the 
polypeptide chain26, mono-ADP-ribosylated peptides containing ADP-ribosylated glutamine 
(prepared using Fmoc amino acid 8) allow preparation of poly-ADP-ribosylated proteins 
containing a stabilized ribose-protein linkage, if they would indeed be accepted by PARPs as 
substrates. Such constructs are unattainable by current biochemical techniques. 
 
Conclusion 
In conclusion a convenient method for the synthesis of protected ribosylated asparagine (7) and 
glutamine (8) building blocks is presented, based on the reduction of a protected furanose 
bearing an anomeric azide and the in situ coupling of the formed hemi-aminal ether to either 
aspartic or glutamic acid derivatives. After protective group manipulations these ribosylated 
amino acid building blocks are used in the synthesis of milligram amounts of well-defined 












General: All chemicals were used as received. EtOAc, pyridine, n-PrOH and MeCN were stored over 
activated 4Å molecular sieves and MeOH was stored over 3Å molecular sieves for at least 24 hours prior 
to use. DCM was distilled over CaH2 and dioxane over LiAlH4 prior to use. Solvents were removed by 
rotary evaporation under reduced pressure at a temperature not exceeding 40°C. Optical rotations are 
measured in CHCl3 or MeOH at a concentration of 10 mg/mL at 25 0C. TLC analysis, silica gel column 
chromatography, NMR, LCMS, HPLC and HRMS techniques used are described in Chapter 2.  
Procedure for solid phase peptide synthesis – Peptides 19 and 26 were synthesized on Tentagel S 
HMBA resin from Rapp Biopolymere, Weinstadt, Germany. The first amino acid was coupled using 5 eq. 
DIC, 5 eq. Fmoc-Ala-OH or Fmoc-Val-OH and 5% DMAP in DCM (30 mL/mmol) for 4 hours. 
Subsequent couplings were performed using 0.5M BOP, 0.5M HOBt, 1.25 M DiPEA and 5 eq. amino acid 
0.5M in NMP for 75 minutes. Fmoc deprotection was accomplished using 2% DBU in NMP (3x 3 min.). 
Capping was done using 0.5M Ac2O, 0.125M DiPEA and 0.015M HOBt in NMP (1x 1 min.). Fmoc 
amino acids used were: Fmoc-Pro-OH, Fmoc-Ser(OTrt)-OH, Fmoc-Lys(TFAc)-OH, Fmoc-Val-OH, 
Fmoc-Ala-OH, Fmoc-Ile-OH, Fmoc-Glu(ODmab)-OH. 
 
β-D-Ribofuranosyl azide (1)15 
 
2,3,5-tri-O-acetyl- β- D- ribofuranosyl azide (2.60 g, 8.63 mmol), was dissolved in MeOH (40 mL) and 
NaOMe (1.54 g, 28.5 mmol) was added. After 30 min. TLC analysis (2 % MeOH/ DCM) indicated 
complete conversion. Amberlite IR120 H+ was added until pH = 6. Filtration and concentration gave the 
title compound as a colourless oil (1.27 g, 7.26 mmol, 85%). 1H-NMR (400 MHz, MeOD-d4) δ: 5.21 (s, 
1H, H1’), 4.89 (s, 3H, OH’s), 4.06 (dd, J = 6.7, 4.8 Hz, 1H, H3’), 4.03 - 3.93 (m, 1H, H4’), 3.83 (dd, J = 
4.5, 1.3 Hz, 1H, H2’), 3.77 (dd, J = 12.0, 3.2 Hz, 1H, H5A’), 3.59 (dd, J = 12.0, 6.0 Hz, 1H, H5B’). 13C-
NMR (100 MHz, MeOD-d4) δ: 96.2 (C1’), 85.2 (C4’), 76.2 (C2’), 71.8 (C3’), 63.8 (C5’). [αD MeOH] = - 
195.8 o. IR: 3330.3, 2113.8, 1706.1, 1234.7, 1019.0, 925.9. 
 
5-tert-Butyldiphenylsilyl-β-D-ribofuranosyl azide (2) 
 
β-D-ribofuranosyl azide 1 (0.55 g, 3.15 mmol) was used without further purification and after 
coevaporation with pyridine dissolved in pyridine (40 mL). TBDPSCl (0.9 mL, 3.46 mmol) was added and 
the reaction mixture was stirred for 16 hours at room temperature. The residue was taken up in DCM, 
washed with 5 % citric acid, dried with MgSO4 and concentrated. Silica gel column chromatography 
yielded the title compound (1.30 g, 3.15 mmol, quantitative) as a colourless oil. 1H-NMR (400 MHz, 
CDCl3) δ: 7.89 - 7.56 (m, 4H, Arom. Ph), 7.55 - 7.33 (m, 6H, Arom. Ph), 5.31 (d, J = 1.7 Hz, 1H, H1’), 
4.37 (dd, J = 6.2, 5.0 Hz, 1H, H3’), 4.05 (dt, J = 6.3, 4.4 Hz, 1H, H4’), 3.98 (dd, J = 4.8, 1.7 Hz, 1H, H2’), 
3.92 - 3.76 (m, 2H, H5’), 1.08 (s, 9H, tBu). 13C-NMR (100 MHz, CDCl3) δ: 135.6 (Arom.), 132.8 (Cq 
Arom.), 129.91, 129.87, 127.84, 127.80 (Arom.), 94.7 (C1’), 83.5 (C2’), 75.5 (C4’), 71.6 (C3’), 63.8 
(C5’), 26.8 (CH3 tBu), 19.2 (Cq tBu). [αD CHCl3] = -61.4 o. IR: 3314.1, 2931.6, 2858.7, 2110.3, 1427.8, 
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5-tert-Butyldiphenylsilyl-2,3-di-O-acetyl-β-D-ribofuranosyl azide (3)  
 
 
Ribofuranosyl azide 2 (4.13 g, 10 mmol) was dissolved in pyridine (20 mL) and a catalytic amount of 
DMAP and acetic anhydride (50 mmol, 4.69 mL) were added. The reaction mixture was stirred for 16 
hours at room temperature. After concentration the residue was taken up in DCM and washed with 5 % 
citric acid, dried with MgSO4 and purified using silica gel column chromatography (PE: EtOAc, 100/0 – 
50/50, v/v). The title compound (4.88 g, 9.8 mmol, 98%) was obtained as a colourless oil. 1H-NMR (400 
MHz, CDCl3) δ: 7.70 (dd, J = 12.5, 4.6 Hz, 4H, Arom. Ph), 7.39 (dd, J = 13.9, 6.6 Hz, 6H, Arom. Ph), 
5.51 (t, J = 5.3 Hz, 1H, H3’), 5.42 (d, J = 2.8 Hz, 1H, H1’), 5.21 (dd, J = 4.7, 3.0 Hz, 1H, H2’), 4.22 (dt, J 
= 5.7, 3.4 Hz, 1H, H4’), 3.86 (dd, J = 11.6, 3.6 Hz, 1H, H5A’), 3.73 (dd, J = 11.2, 3.2 Hz, 1H, H5B’), 2.09 
(s, 3H, OAc), 2.03 (s, 3H, CH3 OAc), 1.09 (s, 9H, tBu). 13C-NMR (100 MHz, CDCl3) δ: 169.4, 169.3 (CO 
OAc), 135.54, 134.50 (Arom.), 132.7 (Cq Arom.), 129.74, 129.67, 127.68, 127.66 (Arom.), 92.6 (C1’), 
82.4 (C4’), 74.6 (C2’), 70.7 (C3’), 63.2 (C5’), 26.6 (CH3 tBu), 20.39, 20.37 (CH3 OAc), 19.0 (Cq tBu). [αD 
CHCl3] = -53.8 o. IR: 2933.1, 2858.7, 2112.2, 1751.8, 1214.1, 1230.2, 1109.6, 701.6, 502.0. HRMS 
[C25H31N3O6Si + Na]+: 520.1866 found, 520.1874 calc. 
 
Nβ -(5-tert-Butyldiphenylsilyl-2,3-di-O-acetyl-α/β-D-ribosyl)-Nα-benzyloxycarbonyl asparagine 
benzyl ester (5a/5b) 
 
Platinum(IV)oxide (110 mg, 0.48 mmol) was added to a solution of azide 3 (1.24 g, 2.5 mmol) in EtOAc 
(20 mL) and purged with argon before hydrogen gas was bubbled through the reaction mixture for 2 hours 
at 10 oC, upon which TLC analysis (3:2, v/v, EtOAc/PE) showed complete disappearance of the starting 
material. The suspension was filtered through a pad of celite and concentrated. The residue was dissolved 
in DCM (30 mL) and EDC.HCl (0.53 g, 2.8 mmol) and Z-Asp-OBn (0.89 g, 2.5 mmol) were added under 
an argon atmosphere. After stirring for 4 hours the reaction mixture was concentrated. The residue was 
taken up in DCM and washed with sat. aq. NaHCO3 and sat. aq. NaCl. The organic layer was dried with 
MgSO4, concentrated and the stereo isomers were separated using silica gel column chromatography (PE: 
EtOAc, 80/20 – 50/50). Compound 5a was obtained as a white foam (0.65 g, 0.80 mmol, 32 %) along with 
the 5b anomer (0.31 g, 0.38 mmol, 15%).  
α-anomer 5a: 1H-NMR (400 MHz, MeOD-d4) δ: 7.87 (s, 1H, NH), 7.68 (td, J = 7.4, 1.5 Hz, 4H, Arom.), 
7.47 - 7.04 (m, 16H, Arom.), 6.04 (d, J = 4.9 Hz, 1H, H1’), 5.54 (t, J = 5.1 Hz, 1H, H3’), 5.44 (t, J = 5.0 
Hz, 1H, H2’), 5.08, 5.16 (2x s, 4H, CH2 Bn, CH2 Cbz), 4.65 (t, J = 6.0 Hz, 1H, H4’), 4.24 - 3.96 (m, 1H, 
CH α- Asn), 3.77 (dd, J = 11.2, 2.8 Hz, 1H, H5A’), 3.72 (dd, J = 11.2, 2.8 Hz, 1H, H5B’), 2.96 - 2.70 (m, 
2H, CH2 β-Asn), 2.09, 2.06 (2x s, 6H, CH3 OAc), 1.07 (s, 9H, tBu). 13C-NMR (100 MHz, CDCl3) δ: 
170.6, 169.5 (CO α-Asn, CO β -Asn), 169.2, 169.0 (CO OAc), 158.2 (CO Cbz), 135.8 (Cq Arom.), 135.4 
(Cq Arom.), 135.5 (Arom.), 132.6, 132.3 (Cq Arom.), 129.7, 128.4 – 127.7 (Arom.), 82.0 (C4’), 78.5 

































Asn), 26.6 (CH3 tBu), 20.6, 20.2 (CH3, OAc), 19.0 (Cq tBu). αD (CHCl3) = + 35.8°. IR: 503.0, 698.4, 
1112.8, 1211.9, 1505.7, 1733.7, 1747.7. LC-MS (50 - 90 % B in 15 min.) Rt = 9.70. HRMS 
[C44H50N2O11Si + H]+ : 811.3263 found, 811.3211 calc. 
β –anomer 5b: 1H-NMR (400 MHz, MeOD-d4) δ: 7.88(s, 1H, NH), 7.76 - 7.55 (m, 4H, Arom.), 7.49 - 7.04 
(m, 16H, Arom.), 5.60 (d, J = 5.8 Hz, 1H, H1’), 5.52 (t, J = 4.9 Hz, 1H, H3’), 5.16 (t, J = 5.6 Hz, 1H, 
H2’), 5.14, 5.07 (2x s, 4H, CH2 Bn, CH2 Cbz), 4.61 (t, J = 5.8 Hz, 1H, H4’), 4.05 (q, J = 4.0 Hz, 1H, CH 
α- Asn), 3.90 - 3.66 (m, 2H, H5’), 2.91 - 2.61 (m, 2H, CH2 β-Asn), 2.07, 2.03 (2x s, 6H, CH3 OAc), 1.04 
(s, 9H, tBu). 13C-NMR (100 MHz, CDCl3) δ: 170.6, 170.1 (CO α-Asn, CO β-Asn), 169.8, 169.7 (CO 
OAc), 156.0 (CO Cbz), 135.4 (Cq Arom.), 135.3 (Arom.), 133.1, 132.0 (Cq Arom.), 130.0, 128.4 – 127.7 
(Arom.), 82.0, 81.9 (C4’, C1’), 74.1 (C2’), 71.2 (C3’), 67.2, 66.8 (CH2 Bn, CH2 Cbz), 63.3 (C5’), 50.2 
(CH α-Asn), 37.1 (CH2 β-Asn), 26.8 (CH3 tBu), 20.5, 20.4 (CH3 OAc), 19.3 (Cq tBu). αD (CHCl3) = 
+12.4°. IR: 503.3, 698.0, 1112.3, 1214.5, 1498.7, 1747.2. LC-MS (50 - 90 % B in 15 min.) Rt = 9.63. 
HRMS [C44H50N2O11Si + H]+: 811.3262 found, 811.3211 calc.  
 
Nγ-(5-tert-Butyldiphenylsilyl-2,3-di-O-acetyl-α/β-D-ribosyl)-Nα-benzyloxycarbonyl glutamine benzyl 
ester (6a/6b) 
 
Platinum(IV)oxide (440 mg, 1.9 mmol) was added to a solution of azide 3 (5 g, 9.6 mmol) in EtOAc (100 
mL) and purged with argon before hydrogen gas was bubbled through the reaction mixture for 2 hours at 
10 0C, upon which TLC analysis (3:2, v/v, EtOAc/PE) showed complete disappearance of the starting 
material. The suspension was filtered through a pad of celite and concentrated. The residue was dissolved 
in DCM (100 mL) and EDC.HCl (1.8 g, 9.4 mmol) and Z-Glu-OBn (3.0 g, 8.1 mmol) were added under 
an argon atmosphere. After stirring for 24 hours the reaction mixture was concentrated. The residue was 
taken up in DCM and washed with 1N HCl and sat. aq. NaCl. The organic layer was dried (MgSO4), 
concentrated and the stereo isomers were separated using silica gel column chromatography (PE: EtOAc, 
100/0 – 65/35). Compound 6a was obtained as a white foam (3,0 g, 3.7 mmol, 46 %) along with 6b (1,0 g, 
1,2 mmol, 15%) and a side product due to migration of the acetyl to 1’ NH and subsequent coupling of Z-
Glu-OBn on the 2’ OH.  
α-anomer 6a: 1H-NMR (CDCl3) δ: 7.69 - 7.66, 7.42 - 7.37, 7.37 - 7.27 (3 x m, 20H, Arom.), 6.72 (d, J = 
9.2 Hz, 1H, NH), 6.10 (dd, J = 5.2, 9.2 Hz, 1H, H1’), 5.82 (d, J = 7.6 Hz, 1H, NH) 5.58 (t, J = 3.2 Hz, 1H, 
H3’), 5.49 (t, J = 5.6 Hz, 1H, H2’), 5.14, 5.07 (2x s, 4H, CH2 Bn, CH2 Cbz), 4.42 (m, 1H, CH α-Gln), 4.10 
(m, 1H, H4’), 3.71 (m, 2H, H5’), 2.33 (m, 2H, CH2 β-Gln), 2.21 (m, 2H, CH2 γ-Gln), 2.09, 2.07 (2x s, 6H, 
OAc), 1.07 (s, 9H, tBu). 13C-NMR (CDCl3) δ: 171.8, 171.5 (CO α-Gln, CO γ -Gln), 169.3, 169.0 (CO Ac), 
156.0 (CO Cbz), 135.9, 135.4 (Cq Arom.), 135.5 (Arom.), 132.7, 132.4 (Cq Arom.), 129.6. 128.4 – 127.6 
(Arom.), 81.6 (C4’), 78.6 (C1’), 72.2 (C3’), 70.1 (C2’), 67.1, 66.8 (CH2 Bn, CH2 Cbz), 63.5 (C5’), 53.4 
(CH α-Gln), 32.4 (CH2 β-Gln), 28.1 (CH2 γ-Gln), 26.6 (tBu), 20.5, 20.3 (CH3 OAc), 18.9 (Cq tBu). TLC 
Rf = 0.4 EtOAc/PE, 4:6, v/v). ESI-MS: m/z 825.20 [M+H]+. LC-MS (10 - 90 % B in 15 min), Rt = 9.94. 
IR: 3328, 2933,2362, 1745, 1520, 1235,1212, 1110, 1049, 741, 698, 604,502. [αD CHCl3] = + 32.6o. 
HRMS [C45H52N2O11Si + H]+: 825.3419 found, 825.3413 calc. 
β–anomer 6b: 1H-NMR (500 MHz, CDCl3) δ: 7.68 - 7.65, 7.40 - 7.25 (2 x m, 20H, Arom.), 6.47, 6.46 (d, 
1H, NH γ), 5.79 (dd, J = 5.7 Hz, 1H, H1’), 5.64 (s, 1H, NH α), 5.56 (dd, J = 5.3 Hz, 1H, H3’), 5.31 (t, J = 
5.3 Hz, 1H, H2’,), 5.12, 5.04 (2x s, 4H, CH2 Bn), 4.31 - 4.27 (m, 1H, CH α), 4.12 - 4.10 (m, 1H, H4’), 
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3.87 (dd, J = 11.2, 2.8Hz, 1H, H5A’), 3.81 (dd, J = 11.6, 2.0 Hz,.1H, H5B’), 2.08, 2.04 (2x s, 6H, OAc), 
1.94 – 1.91 (m, 2H, CH2 β), 2.13 - 2.10, 1.85 - 1.80 (2x m, 2H, CH2 γ), 1.10 (s, 9H, tBu). 13C-NMR (100 
MHz, CDCl3) δ: 172.0, 171.6 (CO Ac), 169.8, 169.7 (CO α-Gln, CO γ-Gln), 156.1 (CO Cbz), 136.0 (Cq 
Arom.), 135.5, 135.4 (Arom.), 135.1, 133.1, 132.2 (Cq Arom.), 130.0, 129.93, 128.5, 128.3, 128.2, 128.0, 
127.9 (Arom.), 81.9 (C1’, C4’), 74.0 (C2’), 71.4 (C3’), 67.2, 66.9 (CH2 Bn, CH2 Cbz), 63.5 (C5’), 53.3 
(CH α-Gln), 31.8 (CH2 β-Gln), 27.7 (CH2 γ-Gln), 26.8 (tBu), 20.6, 20.4 (OAc), 19.3 (Cq tBu). TLC Rf = 
0.5 EtOAc/PE, 4:6, v/v). ESI-MS: m/z 825.20 [M+H]+. LC-MS (10 - 90 % B in 15 min), Rt = 9.88. IR: 
3335.3, 2934.0, 1745.2, 1519.9, 1240.8, 1214.4, 1110.5, 1064.7, 738.9, 699.0, 502.2. [αD CHCl3] = - 0.8 o. 
HRMS [C45H52N2O11Si + H]+: 825.3422 found, 825.3413 calc. 
Migration side-product: 1H-NMR (400 MHz, CDCl3) δ: 7.61 (dd, 4H), 7.51 - 7.18 (m, 6H), 6.51 (d, J = 
9.0 Hz, 1H, NH), 5.62 (d, J = 14.1 Hz, 1H, H3’), 5.34 (t, J = 9.3 Hz, 1H, H1’), 5.08 (2x s, 4H, CH2 
Bn/Cbz), 4.60 (d, J = 9.5 Hz, 1H, H2’), 4.33 (t, J = 7.3 Hz, 1H, CH α), 3.96 - 3.77 (m, 1H, H4’), 3.72 (t, J 
= 10.8 Hz, 1H, H5A’), 3.36 (dd, J = 10.9, 5.1 Hz, 1H, H5B’), 2.21 (s, 3H, NAc), 2.16 (s, 3H, CH2 γ, CH2 
β), 1.90 (s, 3H, OAc), 1.85 (d, J = 6.6 Hz, 1H, CH2 γ), 1.01 (s, 9H, tBu). 13C-NMR (100 MHz, CDCl3) δ 
172.5, 171.7 (CO Ac), 170.7, 170.2 (CO α-Gln, CO γ-Gln), 156.4 (CO Cbz), 136.1, 135.8, 135.6, 135.1, 
133.2, 132.5, 130.2, 128.72, 128.65, 128.59, 128.5, 128.3, 128.2, 128.0, 127.9 (Arom.), 75.3 (C1’), 70.6 
(C3’), 68.8 (C2’), 67.5, 67.23 (CH2 Bn), 67.15 (C4’), 65.6 (C5’), 53.3 (Cα), 32.3 (Cβ), 28.5 (Cγ), 26.8 
(CH3 tBu), 21.0, 20.7 (CH3 Ac), 19.1 (Cq tBu). TLC Rf = 0.6 EtOAc/PE, 4:6, v/v). ESI-MS: m/z 825.33 






Amino acid 5a (1.25 g, 1.54 mmol) was dissolved in MeOH (30 mL), Pd/C (10%, 190 mg ) and a drop of 
conc. HCl were added after purging with argon. A flow of hydrogen gas was passed through the reaction 
mixture for 2 hours. LC-MS analysis (CN-Column, 10 - 90 % B in 26 min.) showed complete 
consumption of the starting material and formation of the unprotected amino acid. Next, NaHCO3 (190 
mg, 2.3 mmol) was added and the reaction mixture was filtered over a pad of celite. The solvent was 
removed and the residue was dissolved in H2O/ acetone (40 mL, 1:1, v/v). Fmoc-OSu (0.51 g, 1.5 mmol) 
and NaHCO3 (0.13 g, 1.5 mmol) were added after which the reaction mixture was stirred at room 
temperature for 2 hours. The mixture was acidified to pH = 2 and acetone was removed under reduced 
pressure. The resulting solution was extracted with DCM, washed with 5% citric acid, H2O, dried with 
MgSO4 and concentrated. Purification using column chromatography (99.9 : 0.1 DCM/AcOH - 89.9/1/0.1 
DCM/MeOH/AcOH) afforded the title compound as a white foam (1.1 g, 1.30 mmol, 84%). 1H-NMR (400 
MHz, MeOD-d4) δ: 7.85 (s, 1H, NH), 7.77 - 6.91 (m, 18H, Arom.), 6.05 (d, J = 4.9 Hz, 1H, H1’), 5.51 (t, J 
= 5.0 Hz, 1H, H3’), 5.43 (t, J = 5.0 Hz, 1H, H2’), 4.41 (d, J = 6.0 Hz, 1H, CH α-Asn), 4.36 - 4.23 (m, 2H, 
CH2 Fmoc), 4.14 (t, J = 6.7 Hz, 1H, CH Fmoc), 4.07 (s, 1H, H4’), 3.65 – 3.63 (m, 2H, H5’), 2.97 - 2.61 
(m, 2H, CH2 β-Asn), 2.06, 2.05 (2x s, 6H, CH3 OAc), 1.01 (s, 9H, tBu).13C-NMR (100 MHz, MeOD-d4) δ: 
173.2, 171.0 (CO β-Asn, CO α-Asn), 170.2, 170.1 (CO OAc), 156.9 (CO Fmoc), 143.8, 143.8 (Cq Fmoc), 
137.5 (Fmoc), 135.4, (Cq TBDPS), 129.7 – 119.6 (Arom. TBDPS, Fmoc), 81.2 (C4’), 79.2 (C1’), 71.5 
(C3’), 70.7 (C2’), 66.8 (C5’), 63.5 (CH2 Fmoc), 50.8 (CH α-Asn), 46.9 (CH Fmoc), 37.5 (CH2 β-Asn), 
1) Pd/C, H2, 2 h, r.t.
2) FmocOSu, NaHCO3,





















26.1 (CH3 tBu), 19.2, 19.1 (CH3 OAc), 18.7 (Cq tBu). αD (CDCl3) = + 56.2°. LC-MS (10 – 90 % B in 15 
min.), Rt = 11.34 min. IR: 503.5, 701.4, 1112.5, 1212.2, 1505.7, 1747.5. HRMS [C44H448N2O11Si + H]+: 





Amino acid 6a (0.2 g, 0.24 mmol) was dissolved in MeOH (5 mL), Pd-C (10%) (30 mg) and a drop of 
conc. HCl were added after which hydrogen gas was passed through the reaction mixture for 5 hours. LC-
MS analysis (CN-Column, 10-90 % B in 26 min.) showed complete consumption of the starting material 
and formation of the unprotected amino acid. After neutralisation using NaHCO3 and filtration over a pad 
of celite the solvent was concentrated and the residue was dissolved in H2O/ acetone/ dioxane (3 mL, 
1:1:2, v/v/v). Fmoc-OSu (80 mg, 0.24 mmol) and NaHCO3 (20 mg, 0.24 mmol) were added after which 
the reaction mixture was stirred for 16 hours. The mixture was acidified to pH = 2 and acetone was 
removed under reduced pressure. The resulting solution was extracted with DCM, washed with 5% citric 
acid, H2O, dried with MgSO4 and concentrated. Purification using column chromatography (99.9 : 0.1 
DCM/AcOH – 99.4 : 0.1 : 0.5 DCM/ AcOH/ MeOH) afforded the title compound as a white foam ( 0.19 g, 
0.23 mmol, 97%). 1H-NMR (400 MHz, MeOD-d4) δ: 7.90 (s, 1H, NH), 7.81 - 7.14 (m, 18H, Arom.), 6.09 
(d, J = 5.0 Hz, 1H, H1’), 5.57 (t, J = 5.0 Hz, 1H, H3’), 5.48 (t, J = 5.1 Hz, 1H, H3’), 4.35 - 4.22 (m, 5H, 
CH Fmoc, H5’, H4’, CH α), 3.79 - 3.71 (m, 2H, CH2 Fmoc), 3.35 - 3.33 (m, 2H, CH2 β), 2.24 - 2.22 (m, 
1H, CH2 γ), 2.09, 2.07 (2x s, 6H, CH3 OAc), 2.08 - 1.89 (m, 1H, CH2 γ), 1.06 (s, 9H, tBu).13C-NMR (100 
MHz, MeOD-d4) δ: 173.9, 173.7 (CO γ-Gln, CO α-Gln), 170.2, 170.0 (CO OAc), 157.2 (CO Fmoc), 
143.9, 143.8, 141.2 (Cq Arom.), 135.4, 135.3 (Arom.), 132.7, 132.6 (Cq Arom.), 129.7 - 119.6 (Arom. 
Fmoc/TBDPS), 81.1 (C4’), 79.2 (C1’), 71.5 (C3’), 70.7 (C2’), 66.7 (C5’), 63.4 (CH2 Fmoc), 53.4 (CH α-
Gln), 47.0 (CH Fmoc), 32.0 (CH2 β-Gln), 27.3 (CH2 γ-Gln), 26.0 (CH3 tBu), 19.3, 19.1 (CH3 OAc), 18.6 
(Cq tBu). ESI-MS: m/z 823.27 [M+H]+. LC-MS (50 - 90 % B in 15 min), Rt = 8.92. IR: 2933.1, 1742.5, 
1519.6, 1212.6, 1108.1, 740.0, 702.8, 502.3. αD (CHCl3) = + 33.4o. HRMS [C45H50N2O11Si + H]+: 
823.3263 found, 823.3256 calc. 
 
Nα-tert-Butoxycarbonyl-4-O-benzyl-L-tyrosine fluorenylmethyl ester (9) 
 
Boc-Tyr(Bzl)-OH (0.74 g, 2.0 mmol) was coevaporated with MeCN and dissolved in DCM (40 mL) under 
an argon atmosphere. To this solution were added 9-fluorenylmethanol (0.43 g, 2.2 mmol), EDC.HCl 
(0,42 g, 2.2 mmol) and DMAP (32 mg, 0.2 mmol). The solution was stirred at room temperature for 2 
hours, washed with 5% citric acid and H2O. The combined organic layers were dried using MgSO4 and 
concentrated. The crude compound was purified by silica gel column chromatography (PE/EtOAc, 95/5) 
1) Pd/C, H2, 2 h, r.t.
2) FmocOSu, NaHCO3,
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to give compound 9 as a white powder (0.84 g, 76%). 1H-NMR (400 MHz, CDCl3) δ: 7.80 - 7.69 (m, 2H, 
Arom. Bn/Fm), 7.50 (t, J = 8.1 Hz, 2H, Arom. Bn/Fm), 7.42 - 7.24 (m, 9H, Arom. Bn/Fm), 6.97 (d, J = 
8.5 Hz, 2H, Arom. Tyr.), 6.83 (d, J = 8.5 Hz, 2H, Arom. Tyr.), 5.06 (s, 1H, NH α-Tyr), 4.91 (s, 2H, CH2 
Bn), 4.61 (dd, J = 13.9, 6.0 Hz, 1H, CH α-Tyr), 4.48 - 4.31 (m, 2H, CH2 Fm), 4.13 (t, J = 6.1 Hz, 1H, CH 
Fm), 3.00 – 2.89 (m, 2H, CH2 β-Tyr), 1.43 (s, 9H, tBu). 13C-NMR (100 MHz, CDCl3): δ: 171.9 (CO α-
Tyr), 157.8 (Cq Tyr.), 155.1 (CO Boc), 143.5, 143.4, 141.2 (Cq Fm), 136.9 (Cq Bn), 130.24 (Arom. Tyr.), 
128.5 (Arom. Bn/Fm), 127.9 (Cq Tyr.), 127.3, 127.1 (Arom. Bn/Fm), 125.0, 120.0 (Arom. Fm), 114.9 
(Arom. Tyr.), 79.8 (Cq Boc), 69.8 (CH2 Bn), 67.0 (CH2 Fm), 54.6 (CH α Tyr.), 46.6 (CH Fm), 37.4 (CH2 
β Tyr.), 28.3 (CH3 Boc). IR (cm-1): 3348, 2931, 1733, 1686, 1527, 1512, 1242, 1163, 1048, 736, 549. αD 
(CHCl3) = 0.2°. LC-MS (50 - 90 % B in 15 min), Rt = 9.62. HRMS [C35H35NO5 + H]+: 550.2585 found, 
550.2588 calc. 
 
Nα-tert-Butoxycarbonyl-L-tyrosine fluorenylmethyl ester (10) 
 
Compound 9 (0.58 g, 1.1 mmol) was coevaporated with MeCN and dissolved in n-propanol/EtOAc (30 
mL, 9:1 v/v). The solution was purged with argon prior to addition of Pd-C (10%, 100 mg) and conc. HCl 
(89 µL, 1.17 mmol). Hydrogen gas was bubbled trough the solution for 1 hour after which the reaction 
mixture was filtered over celite, concentrated and purified by silica gel column chromatography 
(PE/EtOAc, 90/10  80/20) to give compound 10 as a white powder (0.36 g, 73%). 1H-NMR (400 MHz, 
CDCl3): δ 7.70 (d, J = 6.7 Hz, 2H, Arom. Fm), 7.48 (t, J = 8.0 Hz, 2H, Arom. Fm), 7.36 - 7.32 (m, 2H, 
Arom. Fm), 7.28 - 23 (m, 2H, Arom. Fm), 6.92 - 6.86 (m, 2H, Arom. Fm), 6.74 - 6.69 (m, 2H, Arom. 
Tyr), 5.11 (d, J = 8.4 Hz, 1H, NH α-Tyr), 4.59 (dd, J = 13.8, 6.2 Hz, 1H, CH α-Tyr), 4.46 - 4.24 (m, 2H, 
CH2 Fm), 4.11 (t, J = 6.7 Hz, 1H, CH Fm), 2.97 - 2.87 (m, 2H, CH2 β-Tyr), 1.41 (s, 9H, tBu). 13C-NMR 
(100 MHz, CDCl3): δ 172.2 (CO α-Tyr), 155.4, (CO Boc), 143.5, 143.3, 141.3, 141.3 (Cq Fm), 130.4 
(Arom. Tyr), 127.9, 127.9 (Arom. Fm), 127.4 (Cq Tyr), 127.2, 125.1 (Arom. Fm), 120.1, 115.6 (Arom. 
Tyr), 80.3 (Cq Boc), 67.2 (CH2 Fm), 54.7 (CH α Tyr), 46.7 (CH Fm), 37.5 (CH2 β Tyr), 28.3 (CH3 Boc). 
IR: 3367, 2979, 1686, 1516, 1244, 1163, 530. αD (CHCl3) = -1.0°. LC-MS (50 - 90 % B in 15 min), Rt = 
5.62. HRMS [C28H29NO5 + H]+: 460.2116 found, 460.2118 calc. 
 
Nα-tert-Butoxycarbonyl-4-O-benzyloxycarbonyl-L-tyrosine fluorenylmethyl ester (11) 
 
Compound 10 (0.31 g, 0.68 mmol) was coevaporated with MeCN and dissolved in DCM (3.5 mL) under 
an argon atmosphere. To this solution were added benzylchloroformate (0.1 mL, 0.75 mmol) and DiPEA 
(0.12 mL, 0.75 mmol). The solution was stirred at room temperature for 2 hours, washed with 5% citric 
acid and H2O. The combined organic layers were dried and concentrated. The crude compound was 
purified by silica gel column chromatography (PE/EtOAc, 90/10  80/20) to give compound 11 as a 
white powder (0.34 g, 84%). 1H-NMR (400 MHz, CDCl3): δ 7.73 (dd, J = 7.5, 2.0 Hz, 2H, Arom. Fm), 
7.52 (t, J = 7.6 Hz, 2H, Arom. Fm), 7.43 - 7.32 (m, 7H, Arom. Fm/Cbz), 7.28 (t, J = 7.5 Hz, 2H, Arom. 



























(dd, J = 13.2, 6.1 Hz, 1H, CH α-Tyr), 4.50 - 4.27 (m, 2H, CH2 Fm), 4.14 (t, J = 6.6 Hz, 1H, CH Fm), 3.02 
(dd, J = 14.0, 6.0 Hz, 1H, CH2 β-Tyr), 2.89 (dd, J = 14.0, 6.0 Hz, 1H, CH2 β-Tyr), 1.41 (s, 9H, tBu). 13C-
NMR (100 MHz, CDCl3): δ: 171.4 (CO α-Tyr), 154.9, 153.3 (CO Cbz, CO Boc), 149.9 (Cq Tyr) 143.2, 
143.1, 141.0, 141.0 (Cq Fm), 134.5 (Cq Cbz.), 133.7 (Cq Tyr), 130.2 (Arom. Tyr), 128.5, 128.4, 127.6, 
126.9 (Arom. Fm/Cbz), 124.7, 120.8 (Arom. Fm), 119.8 (Arom. Tyr), 79.7 (Cq Boc), 70.0 (CH2 Cbz), 
66.8 (CH2 Fm), 54.1 (CH α Tyr), 46.4 (CH Fm), 37.1 (CH2 β Tyr), 28.0 (CH3 Boc). αD (CHCl3) = + 0.4°. 
IR: 3351, 1748, 1683, 523, 1267, 1161, 738, 545. LC-MS (50 - 90 % B in 15 min), Rt = 9.34. HRMS 
[C36H35NO7 + H]+: 616.2301 found, 616.2305 calc. 
 
Nβ-(5-tert-Butyldiphenylsilyl-2,3-di-O-acetyl-α-D-ribosyl)-Nα-fluorenylmethoxycarbonyl 
asparaginyl-(4-O-benzyloxycarbonyl)-L-tyrosine fluorenylmethyl ester (12) 
 
Compound 11 (0.33 g, 0.55 mmol) was dissolved in 3 M HCl/EtOAc and stirred at room temperature for 
30 min. The reaction mixture was concentrated and coevaporated with toluene. The residue was dissolved 
in DCM (10 mL) and a solution of 7 (0.5 mmol) in DCM (2.5 mL) was added, followed by EDC.HCl (0.12 
g, 0.6 mmol) and DiPEA (0.6 mmol, 0.1 mL). After stirring at room temperature for 1.5 hours the reaction 
mixture was washed with 5% citric acid and water. The organic layer was dried with MgSO4 and 
concentrated. The crude compound was purified by silica gel column chromatography (PE/EtOAc, 100/0 
 35/65) to give compound 12 as a white powder (0.59 g, 0.46 mmol, 84%). 1H-NMR (400 MHz, 
CDCl3): δ 7.76 - 7.71 (m, 4H), 7.67 - 7.63 (m, 4H), 7.58 - 7.45 (m, 5H), 7.44 - 7.24 (m, 18H), 7.15 - 6.91 
(m, 4H, Arom. Tyr), 6.69 (d, J = 8.7 Hz, 1H, NH β-Tyr), 6.23 (d, J = 5.9 Hz, 1H, NH α-Asn), 6.05 (dd, J = 
9.3, 5.6 Hz, 1H, H1’), 5.61 - 5.52 (m, 1H, H3’), 5.47 (t, J = 5.4 Hz, 1H, H2’), 5.16 (s, 2H, CH2 Cbz), 4.76 
(dd, J = 13.0, 6.5 Hz, 1H, CH α-Asn), 4.53 - 4.51 (m, 1H, CH α-Tyr), 4.45 - 4.47 (m, 2H, CH2 Fmoc), 4.34 
- 4.31 (m, 2H, CH2 Fm), 4.19 - 4.15 (m, 2H, CH Fmoc, CH Fm), 4.12 - 4.11 (m, 1H, H4’), 3.72 - 3.68 (m, 
2H, H5’), 3.15 - 2.55 (m, 4H, CH2 β-Asn, β-Tyr), 2.09, 2.07 (2x s, 6H, CH3 OAc), 1.06 (s, 9H, tBu). 13C-
NMR (100 MHz, CDCl3): δ 171.3 (CO α-Tyr), 170.9, 170.6 (CO OAc), 169.6, 169.2 (CO α-Asn, CO β-
Asn), 156.2 (CO Fmoc), 153.5 (CO Cbz), 150.3 (Cq Tyr), 143.8, 143.7, 143.5, 143.4, 141.4, 141.3 (Cq 
Fm, Cq Fmoc), 135.7 (Arom. TBDPS), 134.8 (Cq Cbz), 133.6 (Cq Tyr), 132.9, 132.7 (Cq TBDPS), 130.4, 
129.9, 128.8, 128.7, 128.5, 128.0, 127.9, 127.8, 127.3, 127.2, 125.2, 125.0, 121.2, 120.0 (Arom. Fmoc, 
Arom. Fm, Arom. TBDPS, Arom. Cbz), 82.2 (C4’), 78.7 (C1’), 72.4 (C3’), 70.3 (CH2 Cbz), 70.2 (C2’) 
67.5, 67.2 (CH2 Fmoc, CH2 Fm), 63.7 (C5’), 53.7 (Cα Tyr), 51.3 (Cα Asn), 47.1, 46.7 (CH Fmoc, CH 
Fm), 38.0 (CH2 β-Asn), 37.0 (CH2 β-Tyr), 26.8 (CH3 TBDPS), 20.8, 20.6 (CH3 OAc), 19.2 (Cq tBu). αD 
(CHCl3) = +29.6°. IR : 3278, 2933, 2360, 1747, 1696, 1648, 1534, 1211, 1104, 737, 699, 503. HRMS 
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Nβ-(2,3-di-O-acetyl-α-D-ribosyl)- Nα -fluorenylmethoxycarbonyl asparaginyl-(4-O-
benzyloxycarbonyl)-L-tyrosine fluorenylmethyl ester (13) 
 
Fully protected 12 (0.61 g, 0.47 mmol) was dissolved in pyridine (10 mL) and treated with a HF/pyridine 
solution (1.0 mL) for 1 hour at room temperature. The reaction was quenched with sat. aq. NaHCO3 and 
extracted with DCM. After washing with water the organic layer was dried with MgSO4 and concentrated. 
The crude compound was purified by silica gel column chromatography (DCM/MeOH, 99/1) to give 
compound 13 as a white powder (0.42 g, 0.4 mmol, 85%). 1H-NMR (400 MHz, CDCl3): δ 7.77 - 7.72, 
7.58 - 7.51, 7.42 - 7.29 (m, 21H, Arom. Fmoc, Arom. Fm, Arom. Cbz), 7.08 - 7.04 (m, 4H, Arom. Tyr.), 
6.69 (d, J = 8.8 Hz, 1H, NH), 6.23 (d, J = 7.2 Hz, 1H, NH), 5.95 (m, 1H, H1’), 5.40 - 5.38 (m, 1H, H2’), 
5.33 - 5.29 (m, 1H, H3’), 5.25 (s, 2H, CH2 Cbz), 4.79 - 4.77 (m, 1H, H α-Asn), 4.56 - 4.53 (m, 1H, H α-
Tyr), 4.51 - 4.49 (m, 2H, CH2 Fmoc), 4.38 - 4.36 (m, 2H, CH2 Fm), 4.24 - 4.20 (m, 2H, CH Fmoc, CH 
Fm), 4.12 (m, 1H, H4’), 3.87 - 3.64 (m, 2H, H5’), 3.03 - 2.56 (m, 4H, CH2 β Asn, CH2 β Tyr) 2.14, 2.12 
(2x s, 6H, CH3 OAc).13C-NMR (100 MHz, DMSO-d6): δ 172.0, 171.6, 170.0, 169.9, 169.8 (CO α-Tyr, CO 
OAc, CO α-Asn, CO γ-Asn), 156.2 (CO Fmoc), 153.4 (CO Cbz), 149.9 (Cq Tyr.), 144.3, 144.1, 143.9, 
141.3, 141.2, 141.1 (Cq Fm, Cq Fmoc), 135.48 (Cq Cbz), 135.45 (Cq Tyr.), 130.7, 129.0, 128.8, 128.2, 
128.1, 127.8, 127.7, 127.6, 125.8, 125.6, 121.4, 120.6 (Arom. Fmoc, Arom. Fm, Arom. Cbz), 80.5 (C4’), 
79.1 (C1’), 71.5 (C3’), 70.7 (C2’), 70.2 (CH2 Cbz), 66.7, 66.3 (CH2 Fmoc, CH2 Fm), 61.4 (C5’), 54.2 (Cα 
Tyr), 51.6 (Cα Asn), 47.0, 46.7 (CH Fmoc, CH Fm), 38.0 (CH2 β-Asn), 36.0 (CH2 β-Tyr), 20.9 (CH3 
OAc). αD (CHCl3) = + 26.8°. IR: 3288, 2924, 2360, 1746, 1652, 1538, 1269, 1212, 1046, 736. LC-MS (10 







To a cooled (0 oC) solution of 16 (0.46 g, 1.0 mmol)19 and 14 (0.63 g, 1.3 mmol) in MeCN (15 mL) was 
slowly added a solution of DCI (0.15 g, 1.25 mmol) in MeCN (5 mL). After 20 min complete 
disappearance of 14 (31P-NMR; 148.5) and formation of the corresponding triester (31P-NMR; 141.8) was 
observed. Next, a solution of iodine in pyridine (2.0 mL, 0.5 M) was added to the reaction mixture until 
the solution kept its brown color. After 30 min of additional stirring the reaction mixture containing 

















































Compound 19: H-Asn(Nβ [5’-adenosine diphosphate-α-D-ribosyl])-Tyr-OH bis triethylammonium 
salt. 
 
Ribosylated dipeptide 13 (100 mg, 0.1 mmol) was dissolved in dioxane/ MeCN (4 mL, 1:1 v/v) and cooled 
to 0 oC. Di(p-methoxybenzyl)-N,N-diisopropylphosphoramidite (43 μL, 0.11 mmol) and a solution of DCI 
(13 mg, 0.11 mmol) in 200 μL MeCN were added after which the reaction mixture was kept at 0 oC for 1 
hour. 100 µl of tBuO2H (5.5 M solution in nonane) was added and stirred for an additional hour at 0 oC. 
After trituration with hexane, the residue was treated with 3% TFA in DCM to yield intermediate 15. N6-
Benzoyl-2’, 3’-di-O-isobutyryladenylyl-5-phosporimidazolidate 17 (0.2 mmol) was added to the reaction 
mixture and stirred at room temperature for 16 hours. A silica column with isocratic elution (30% 
MeOH/DCM) and RP-HPLC purification 80 – 90 % MeOH in 20 mM NH4OAc over 5 CV yielded 18 
(26.2 mg, 15.4 µmol, 15.4% based on 13).To a solution of 18 (14.5 mg, 8.5 µmol) in dioxane/MeCN (1:1, 
2 ml) 5 eq. DBU (43 µmol, 6.5 µl) was added and reacted for 30 min at room temperature. A solution of 
aqueous ammonia /dioxane (2:1, 6 ml) was added and reacted for 16 hours at room temperature. After 
concentration the title compound was obtained by means of gel filtration using a HW40-column and 
aqueous triethyl ammoniumacetate as eluent, followed by lyophilisation of the appropriate fractions (4.1 
mg, 4.9 µmol, 58% based on 18).31P-NMR (161 MHz, D2O): δ -10.45, -10.58, -10.75, -10.88. LC-MS (0 - 






























































Synthesis of Mono-ADP-Ribosylated Oligopeptides Using Ribosylated Amino Acid Building Blocks 
69 
 
Compound 25; Ac-Val-Ala-Asn(Nγ [5’-adenosine diphosphate-α-D-ribosyl])-Ile-Glu-Val-OMe bis 
ammonium salt. 
 
Intermediate 20 was prepared starting from Tentagel S HMBA resin (100 mg, 23 μmol) via standard Fmoc 
based solid phase peptide synthesis, using BOP/HOBt as coupling reagent and a five fold excess of the 
appropriate amino acid, using Fmoc-Val-OH, Fmoc-Ala-OH, compound 7, Fmoc-Ile-OH and Fmoc-
Glu(Dmab)-OH. An analytical sample was deprotected and cleaved off the resin using the method 
described below, to determing quality of 20.The resin was treated with 0.36 mL HF/pyridine diluted with 
pyridine (3 mL) (0 oC  r.t., 75 min). The resin was filtered and washed with pyridine and MeCN to give 
intermediate 21.  
The resin (80 mg, 18 µmol) was coevaporated with MeCN and subsequently MeCN (3 mL), di(p-
methoxybenzyl)-N,N-diisopropylphosphoramidite (0.23 mmol, 90 μL) and a solution of DCI (0.23 mmol, 
27 mg) in 1 mL MeCN were added after which the reaction mixture was kept at 0 oC for 1 hour. A 0.5 M 
solution of I2 in pyridine was added until the reaction mixture kept the dark brown colour and stirred for 
an additional hour at 0 oC.  
N6-benzoyl-2’, 3’-di-O-isobutyryladenylyl-5’-phosphate monoester 23 (0.23 mmol, 0.14 g) was added 
to the reaction mixture and stirred at room temperature for 24 hours.  
The resin was filtered and washed with MeCN and treated with 2% hydrazine hydrate in DMF (3 times 
5 min.), followed by 5 mM NaOH in MeOH/H2O for 3 hrs. The resin was washed with MeCN and treated 
with 7N NH3/MeOH (10 mL) for 16 hours. Subsequent filtration into cold Et2O and centrifuging (6.5 min 
at 4000 RPM) followed by decantation of the supernatant resulted in the crude title compound. RP-HPLC 
using a gradient of 0 - 60% MeCN in 1% TFA in H2O followed by a gradient RP-HPLC using a gradient 
of 0 - 60% MeCN of 10 mM NH4OAc, followed by lyophilisation of the appropriate fractions yielded the 
title compound 25 ( 0.78 mg, 0.6 μmol, 3.4% based on initial loading of the resin). 31P-NMR (161 MHz, 
D2O): δ -11.04, -11.17, -11.31, -11.44 . (EDTA was added to sharpen the signals). LC-MS (0 - 50 % 





































Compound 32: Ac-Pro-Gln-(Nδ [5’-adenosine diphosphate-α-D-ribosyl])-Pro-Ser-Lys-Ser-Ala-NH2 
bis ammonium salt. 
 
 
Starting from Tentagel S HMBA resin (150 mg, 65 μmol) using standard Fmoc based solid phase peptide 
synthesis intermediate 26 was prepared using Fmoc-Pro-OH, Fmoc-Ser(Trt)-OH, Fmoc-Lys(TFAc)-OH 
and Fmoc-Ala-OH. The resin was repeatedly treated with 5% TFA in DCM until no yellow colour 
appeared upon addition of the fresh TFA solution. After washing with DCM, acetic anhydride (0.5 M, 200 
μL) and DMAP (0.05 M, 16 mg) in 2 mL NMP were added and the resin was shaken for 25 min. The resin 
was washed with NMP and DCM prior to coupling of the last two amino acids; compound 8, and Fmoc-
Pro-OH using the standard cycle to obtain 28. An analytical sample was deprotected and cleaved off the 
resin using the method described below, to determine the quality. 
The resin was coevaporated with MeCN and treated with a HF/pyridine (0.9 mL) diluted with pyridine 
(7.5 mL) (0 oC  r.t., 75 min). The resin was filtered and washed with pyridine and MeCN to obtain 
intermeditate 29.  
The resin was coevaporated with MeCN and subsequently MeCN (8 mL), di(p-methoxybenzyl)-N,N-
diisopropylphosphoramidite (10 eq., 250 μL), dry 3Å molsieves and a solution of DCI (10 eq., 75 mg) in 1 
mL MeCN were added after which the reaction mixture was kept at 0 oC for 1 hour. Next the phosphite 
was oxidized using 5.5 M tBuO2H (1.1 mL) in nonane for 1 hour at room temperature followed by 
addition of 3% TFA for 10 min. to deprotect the phosphotriester. 
 N6-Benzoyl-2’, 3’-di-O-isobutyryladenylyl-5-phosporimidazolidate 17 (0.4 mmol, 6 eq.) in 1 mL 
MeCN was added to the reaction mixture and stirred at room temperature for 16 hours. 
The resin was filtered, washed with MeCN and treated with 7N NH3/MeOH (10 mL) for 16 hours. 
Subsequent filtration into cold Et2O and centrifuging (6.5 min at 4000 RPM) followed by decantation of 
the supernatant resulted in the crude title compound. Preparative RP-HPLC using a gradient of 2.5 - 40% 
MeCN in 10 mM aq. NH4OAc, followed by lyophilisation of the appropriate fractions yielded the title 
compound (1.3 mg, 1.0 μmol, 1.5% based on initial loading of the resin). 31P-NMR (161 MHz, D2O): δ -
10.46, -10.59, -10.74, -10.87. LC-MS (0 - 50 % MeCN [1% TFA] over 15 min), Rt = 4.49. HRMS 
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Ribosylation of Adenosine: An Orthogonally Protected Building 








In Chapter 3 the synthesis of mono-ADP-ribosylated peptides is described, in which ADP-
ribose is linked to a peptide via an asparagine or glutamine residue.2 In the literature some 
reports have appeared that describe the preparation of oxime linked analogues of mono-ADP-
ribosylated peptides3 or the use of enzymatical techniques to access ADP-ribosyl peptides.4 The 
development of methods to prepare well defined ADP-ribosylated peptides and analogues is 
important to deepen the insight in the functioning of ADP-ribosylated proteins and associated 
enzymes. To enable the future synthesis of more advanced ADP-ribosyl derivatives containing 
more than one adenosine diphosphate ribose residue (see Figure 1, n > 0), the availability of a 
suitably protected ribosylated adenosine building block is crucial. Synthetic challenges in the 
construction of such a building block are the formation of the α-glycosidic bond between the 
ribofuranose and the 2’-hydroxyl of adenosine and the development of a suitable protective 
group strategy. O-Glycosylated nucleosides in general are difficult to synthesize5,6, as in 
glycosylation reactions the nucleobase is often more nucleophilic than the target hydroxyl. As a 
result side reactions at the nucleobase may occur that can lead to depurination of the nucleoside 
in the case of adenosine and guanosine. Consequently, yields are often low for such 
glycosylation reactions.5 Shimofuridin,7-9 bearing a 2’-O-β-fucopyranosyl moiety, and 
adenophostin,10-16 bearing a 3’-O-α-glucopyranosyl moiety, are examples of glycosylated 
nucleosides that have been synthesized. Although several nucleosides decorated with O-β-
linked furanosyl groups have been synthesized,6,17-19 only one synthesis of 2’-O-α-ribosyl 








Poly-ADP-ribose polymer attached to target protein. 
This procedure involves a 1,2-trans selective coupling of an 2’-O-acyl protected 
arabinofuranose building block to an adenosine derivative, followed by protective group 
manipulation and inversion of the stereochemistry at the 2’-position of the arabinofuranose 
moiety via an oxidation/reduction protocol. Although 2’-O-α-ribosyl adenosine was obtained 
for the first time, no strategy for the orthogonal protection of both primary hydroxyl groups was 
proposed, limiting the usefulness of this procedure in the synthesis of poly-ADP-ribosylated 
peptides. 
 
Results and discussion 
In order to synthesize 2’-O-α-ribosyl adenosine bearing orthogonal protective groups on the 
primary hydroxyl functions, an approach involving α-glycosylation of an adenosine derivative 
with a suitable ribofuranosyl donor is considered to be the most convenient. The use of 2’,3’-
isopropylidene25 or 2’,3’-benzylidene26 protection groups on the ribofuranosyl donor, which are 
convenient protective groups due to the ease of introduction and cleavage, leads to anomeric 
mixtures. Application of acyl based protective groups would result in exclusive formation of the 
unwanted β-riboside due to neighboring group participation. Therefore, 2’,3’,5’-tri-O-benzyl-D-
ribofuranose was chosen as glycosyl donor, since it is known that non-participating benzyl 
protection on the ribofuranosyl donor in glycosylation reactions are a prerequisite for the 
formation of mainly or exclusively the α-riboside.21-24 Several explanations for the 
predisposition of ribofuranosyl donors, equipped with nonparticipating protective groups, to 
couple with high α-selectivity have been reported.22,23,24,27 The group of Woerpel studied the 
factors controlling the α-selective C-glycosylation of benzylated furanose donors and presented 
a model for preferential nucleophilic attack on furanosyl oxocarbenium ions, that occur as two 
inter-converting envelop conformers.23,24 Oxocarbenium ions are widely accepted as possible 
intermediates in Lewis acid promoted nucleophilic substitution on furanosyl donors.27,28 The 
stereo-chemical outcome of the glycosylation reaction is dictated by at least two factors; the 
face of attack of the incoming nucleophile and the lowest energy conformer of the two possible 




































nX = S, N or O
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An incoming nucleophile attacks preferentially from inside the oxocarbenium ion envelope 
due to favorable staggered interactions between the substituents at C2’ and the incoming 
nucleophile at C1’, in contrast to the disfavored eclipsed interactions that accompany an attack 
from the outside-face of the envelope (see Figure 2).24 In addition rehybridization of C1’ from 
trigonal planar in the oxocarbenium ion to tetrahedral in the product proceeds via a envelope 
intermediate in the case of inside attack versus a less energetically favorable twist intermediate 




Nucleophilic attack on furanosyl oxocarbenium ions  
Which of two accessible oxocarbenium ions is the lowest energy conformer is largely 
governed by the substitution pattern on the furanose scaffold. Alkoxy substituents on the C3’-
position, for instance, prefer a pseudo-axial orientation thereby placing the oxygen of the 
substituent in close proximity to the cationic carbon of the oxocarbenium ion intermediate, 
stabilizing the ion (see Figure 3).23 Conformer I will thus be lower in energy then conformer II 
and therefore be subjected to nucleophilic attack giving rise to mostly the 1,3-cis product. In the 
case of ribofuranose oxocarbenium ions the high 1,3-cis selectivity is mainly attributed to the 
pseudo-axial placement of 3’-alkoxy substituent and C2’-alkoxy substituents are believed to 
play a minor role.  
Figure 3 
 
Ribofuranosyl oxocarbenium ion conformers  
 
Having selected the donor, 3’,5-O-TIPDS protected N6-benzoyl adenosine 2 seemed a 
suitable acceptor in the glycosylation reaction (see Scheme 1).30 Since adenosine may 



































basis attention was directed on the procedure of Mukaiyama22, who revealed that activation of 1 
(see Scheme 1) with diphosphonium salts and ensuing base-assisted glycosylation resulted in a 
high yielding and α-selective ribofuranosylation of unhindered alcohols.32 However, the use of 
sterically demanding compound 2 as the acceptor under the reported conditions was 
unproductive.33 When performing the glycosylation with a larger excess of base a product 
different from the expected compound 4 was formed. It appeared that N-glycosylation of the 
nucleobase had occurred since the ribose C1’ was found to resonate at 86 ppm in NMR-
analysis, which is typical for hemi-aminal ethers rather than around 100 pm which is 
characteristic for a hemi-acetal such as in 4. Vorbrüggen has postulated the involvement of N1, 
N3and N7 glycosylated adenosine intermediates en route to the thermodynamic N9 product in 
acid catalyzed adenosine synthesis.34 It is reported that in ribosylation of the nucleobase 
adenine, N1 glycosylation precedes isomerisation towards the N9-linked adenosine.35 An 
intermediate in this process is the N1,N9- bis-ribosyladenosine, which could be isolated.36 
Therefore the product isolated after coupling 1 with 2 under Mukaiyama conditions, is 
postulated to be 5. Formation of this product can be explained by the increase in nucleophilicity 
of the N1 position of the adenine moiety caused by deprotonation of the exocyclic amide by the 
excess of base, followed by nucleophilic attack on the oxocarbenium ion of 2’,3’,5’-tri-O-Bn-
ribofuranose. Consistent with the structure of 5 are the NOESY NMR data supporting the 
presence of an α-glycosidic linkage and HMBC NMR data indicating the presence of the 
ribosyl moiety on N1 of adenosine. 37 This interesting side reaction resulting in compound 5 may 
be valuable for the construction of cADPR analogues.38 In an attempt to avoid N-glycosylation 
N6,N6-dibenzoylated adenosine (3)39 was used as acceptor (see Scheme 1). Acceptor 3 appeared 
to be insufficiently reactive under these conditions and the glycosylation proved to be 
unproductive. 
Scheme 1. Phosphonium salt mediated glycosylations 
 
Reagents and conditions; i. Activating agent, DCE, 0 oC, 2 h, ii. 1 equiv. DIPEA, acceptor 2, 16 h, r.t., no product 















































2 R1 = H, R2 = Bz
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Dehydrative coupling conditions employing activation of the donor with Ph2SO and Tf2O 
gave intramolecular Friedel-Crafts alkylation with the 2’-OBn of the donor.40 When using a 
carbonylimidazole donor41 or a di-butylphosphate donor42 only trace amounts of the product 
were obtained. After screening these methods, imidate donor 6 in combination with TMSOTf as 
promoter was found to be the most efficient glycosylating reagent (see Scheme 2).43 Imidate 6 
was prepared in 92% yield by reacting 2’,3’,5’-tri-O-Bn-ribofuranose with Cs2CO3 and 
Cl(C=NPh)CF3. Activation of imidate 6 with TMSOTf in the presence of acceptor 3 resulted in 
formation of 7, containing the desired α-ribofuranosyl linkage in good yield.44 Complete 
deprotection of 7 using TBAF and NH3/MeOH and finally palladium catalyzed hydrogenation 
gave access to 8, the spectroscopic and physical properties of which were in complete 
accordance with the published data.20  
The inherent orthogonality between silyl and benzyl ethers allows selective manipulation of 
the primary OH-groups in 7. To exemplify this orthogonality the adenosine hydroxyls were 
deprotected by cleaving the silyl protective group using TBAF. Due to the alkaline nature of 
TBAF one of the two benzoyl groups on the exocyclic amine of adenosine was partially cleaved 
to give a monobenzoylated side product. In order to avoid this partial deprotection and the need 
for an extra purification step, compound 7 was first treated with MeNH2 to completely remove 
one benzoyl while leaving the other benzoyl in place and then perform the TBAF treatment to 
give 9 (Scheme 2).45  
Scheme 2. Key glycosylation using imidate 6 
 
Reagents and conditions; i. Cs2CO3 Cl(C=NPh)CF3, acetone/water, 3 h, r.t., (92%), ii. TMSOTf, acceptor 3 (Scheme 1), 
0 oC, 1.5 h., (60%), iii. TBAF, iv. NH3, MeOH, v., Pd/C, H2, MeOH, 48 h, r.t., (16% over three steps), vi. MeNH2, 0 oC, 
































































Similarly the hydroxyl groups on the ribose moiety were deprotected while leaving all the 
protective groups on adenosine in place. The obvious choice to remove benzyl ethers involves 
palladium catalyzed hydrogenation with Pd/C in an alcoholic solvent, which however, 
proceeded sluggishly. Therefore compound 7 was treated with BCl3 at -78 oC to rapidly afford 
compound 10.  
To generate building block 12 equipped with orthogonal protective groups on the primary 
hydroxyls, compound 10 was chosen as starting material (see Scheme 3). Acyl protective 
groups that are orthogonal to the two primary hydroxyl protective groups were envisioned as 
protective groups for all other functionalities. Straightforward conversion of 10 by protecting 
the primary hydroxyl of ribose with DMT and subsequent acetylation of the remaining 
secondary hydroxyls (see Scheme 3) gave 11. Cleavage of one benzoyl group in 11, removal of 
the TIPDS protection, introduction of a TBDPS on the primary hydroxyl of adenosine, and 
subsequent acetylation of the secondary hydroxyls and the exocyclic nitrogen of adenosine gave 
fully protected compound 12. The thus formed compound 12 bears orthogonal protective 
groups on both primary hydroxyl functions, which allows the future synthesis of poly-ADP-
ribosylated peptides using the methodology as reported in Chapter 3.2,46  
Scheme 3. Introduction of orthogonal protective groups 
 
Reagents and conditions; i. DMTCl, DMAP, pyr., 4 h, 40 oC, ii. Ac2O, pyr., 16 h, 40 oC (55% over two steps), iii. 
MeNH2, DCM/MeOH, 30 min, 0 oC, iv.TBAF, THF, 2 h, r.t., v. TBDPSCl, DMAP, pyr. 48 h, 50 oC, vi. Ac2O, pyr. 16 
h, r.t. (49% over four steps) 
 
Conclusion 
A method for α-selective ribosylation of adenosine at the 2’-OH function is presented using the 
anomeric trifluoroimidate of 2’,3’,5’-tri-O-benzyl ribose and trimethylsilyl triflate as activating 
agent. Protective groups on the ribose donor and adenosine acceptor not only dictated α-
selectivity but also allowed selective deprotection of either the adenosine hydroxyls or the 
ribose hydroxyls. These properties were further exploited in the synthesis of compound 12, 
which is equipped with a TBDPS and DMT on the two primary hydroxyls, respectively. This 
protective group pattern may allow a stepwise synthesis of poly-ADP-ribosyl modified peptides 
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General: All chemicals were used as received. EtOAc, pyridine, n-PrOH and MeCN were stored over 
activated 4Å molecular sieves and MeOH was stored over activated 3Å molecular sieves for at least 24 
hours prior to use. DCM was distilled over CaH2 and dioxane over LiAlH4 prior to use. Solvents were 
removed by rotary evaporation under reduced pressure at a temperature not exceeding 40°C. Optical 
rotations are measured in CHCl3 or MeOH at a concentration of 10 mg/mL at 25 0C. TLC analysis, silica 
gel column chromatography, NMR, LCMS, HPLC and HRMS techniques were used as described in 
Chapter 2. In the notation of NMR spectra ribose-proton and carbon atoms are reported as H’ and C’, 
wereas protons and carbons belonging to the adenosine sugar are reported as H” and C” and atoms 
belonging to the nucleobase as H and C. 
 
N6-Benzoyl-9-[3, 5-(1, 1, 3, 3-tetra-isopropyldisiloxane-1, 3-diyl)-N1-(2, 3, 5-tri-O-benzyl-α-D-
ribofuranosyl)-β-D-ribofuranosyl]-adenine (5) 
 
n-Bu3PO (1.96 g, 9.0 mmol) was coevaporated with DCE three times prior to dissolving in freshly distilled 
DCE (40 mL) at 0 ºC. Triflic anhydride (700 µL, 4.2 mmol) was slowly added to the reaction mixture over 
a period of 10 min. After 30 min the reaction mixture was checked with 31P-NMR (161 MHz, 119.5 ppm, 
acetone-d6 capillary was used as the external lock). Activated 4 Å molecular sieves were added prior to 
addition of 2,3,5-tri-O-Bn-ribose (0.77g, 1.83 mmol) and DiPEA (0.8 mL, 4.9 mmol) in DCE (40 mL), 
using a canule. After 2 hours 31P-NMR shows formation of the putative activated species (161 MHz, 98 
ppm and 94 ppm, acetone-d6 capillary was used as the external lock). Acceptor N6-Benzoyl-9-[3, 5-(1, 1, 
3, 3-tetraisopropyldisiloxane-1, 3-diyl)- β-D-ribofuranosyl]-adenine 2 (0.71 g, 1.15 mmol) and DiPEA 
(0.8 mL, 4.9 mmol) were dissolved in 40 mL DCE and added to the reaction mixture. The reaction mixture 
was stirred at room temperature over night and subsequently washed with 5% citric acid, dried with 
MgSO4 and concentrated. The crude material was purified with silica gel column chromatography using a 
gradient of PE in EtOAc (100 : 0– 50/50, v/v) to afford the title compound as a white foam (865 mg, 0.85 
mmol, 74% based on the donor). 1H-NMR (400 MHz, CDCl3) δ: 8.22 (s, 1H, H2), 8.16 – 8.03 (m, 2H, 
Arom. Bz), 7.75 (s, 1H, H8), 7.48 (t, J = 7.4 Hz, 1H, Arom. Bz), 7.39 (t, J = 7.5 Hz, 3H, Arom. Bz), 7.35 - 
7.25 (m, 10H, Arom. Bn), 7.18 - 7.01 (m, 5H, Arom. Bn), 6.75 (d, J = 3.7 Hz, 1H, H1’), 5.84 (d, J = 1.2 
Hz, 1H. H1”), 4.90 (t, J = 6.4 Hz, 1H, H3”), 4.68 - 4.33 (m, 9H, CH2 Bn’s, H2’, H4’, H2”), 4.21 (dd, J = 
7.9, 4.3 Hz, 1H, H3’), 4.07 - 3.95 (m, 3H, H4”, H5”), 3.76 (dd, J = 12.0, 2.0 Hz, 1H, H5A’), 3.59 (dd, J = 
10.8, 3.6 Hz, 1H, H5B’), 3.17 (s, 1H, OH), 1.13 - 0.95 (m, 28H, iPr).13C-NMR (101 MHz, CDCl3) δ: 176.5 
(CO Bz), 147.0 (C6), 145.4 (C2), 144.7 (C4), 138.6 (C8), 137.8, 137.2, 137.1 (Cq Bn), 135.8 (Cq Bz), 
131.9 (Arom. Bz), 129.8, 128.6, 128.5, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7 (Arom. Bz/Bn), 122.0 
(C5), 89.6 (C1”), 87.1 (C1’), 82.3 (C4”), 81.1 (C4’), 78.0 (C3’), 75.6 (C2’), 75.3 (C2”), 74.4, 73.6, 73.0 
(CH2 Bn), 71.2 (C3”), 69.0 (C5’), 62.1 (C5”), 17.5, 17.40, 17.35, 17.2, 17.1, 17.0 (CH3 iPr), 13.3, 13.1, 
12.9, 12.7 (CH iPr). αD (CDCl3) = -59 °. IR: 2866, 2924, 1636, 1454, 1246, 1124, 1035, 885, 695. HRMS 




























(N-Phenyl)-2,2,2-trifluoroacetimido-2, 3, 5-tri-O-benzyl-β-D-ribofuranose (6) 
 
2,3,5-O-Benzyl-D-ribose (0.84 g, 2.0 mmol) was dissolved in acetone (8 mL) and water (100 µL). Cs2CO3 
(0.72 g, 2.2 mmol) and ClC(=NPh)CF3 (0.6 mL, 1.2 mmol) were added and the reaction mixture was 
stirred at room temperature for 3 hours. After filtration over celite, the solvents were removed and the 
residue was purified with silica gel column chromatography using a gradient of PE in EtOAc (100 : 0 – 
90/10, v/v) to afford the title compound as a colourless oil (1.06 g, 1.80 mmol, 90%). 1H-NMR (400 MHz, 
CDCl3, T=303K) δ: 7.60 - 7.16 (m, 17H, Arom. Bn/Ph), 7.10 (t, J = 7.4 Hz, 1H, Arom. Bn/Ph), 6.80 (d, J 
= 7.7 Hz, 2H, Arom. Bn/Ph), 6.29 (s, 1H, H1’), 4.79 - 4.37 (m, 7H, CH2 Bn’s, H4’), 4.15 (dd, J = 7.3, 4.7 
Hz, 1H, H3’), 4.07 (d, J = 4.2 Hz, 1H, H2’), 3.70 (dd, J = 11.2, 3.2 Hz, 1H, H5A’), 3.63 (dd, J = 15.6, 4.8 
Hz, 1H, H5B’). 13C-NMR (101 MHz, CDCl3) δ: 143.8 (C=N), 138.1, 137.5, 137.3(Cq Arom.), 128.7, 
128.4, 128.4, 128.3, 128.1, 128.0, 127.9, 127.8, 127.5, 124.2, 119.6 (Arom.), 102.4 (C1’), 82.2 (C4’), 78.6 
(C2’), 77.3 (C3’), 73.3, 72.7, 72.3 9 (CH2 Bn), 70.0 (C5’). αD (CDCl3) = + 47.2°. IR: 3033, 2866, 1710, 
1599, 1454, 1205, 1149, 1088, 906, 751, 694. HRMS [C34H32NO5 + H]+: found 592.2298, calc. 592.2305  
 
N6,N6-di-Benzoyl-9-[3, 5-(1, 1, 3, 3-tetra-isopropyldisiloxane-1, 3-diyl)-2-O-(2, 3, 5-tri-O-benzyl-α-D-
ribofuranosyl)-β-D-ribofuranosyl]-adenine (7) 
 
Acceptor 3 (250 mg, 0.35 mmol) and donor 6 (300 mg, 0.5 mmol) were coevaporated with toluene three 
times prior to dissolving in DCE (10 mL). Freshly activated 4 Å molecular sieves were added and the 
solution was stirred under an argon atmosphere for 20 min. The reaction mixture was cooled to 0 ºC and 
TMSOTf (65 µL, 0.35 mmol) was slowly added over a period of 15 min. After 90 min. the reaction 
mixture was allowed to warm to room temperature and quenched using 100 µL TEA. After evaporation of 
the solvent the crude material was purified with silica gel column chromatography using a gradient of 
DCM/PE/Acetone (80 : 20: 0 – 78/20/2, v/v/v) to afford the title compound as a white foam (230 mg, 0.21 
mmol, 60% based on acceptor). 1H-NMR (400 MHz, CDCl3) δ: 8.61 (s, 1H, H2), 8.25 (s, 1H, H8), 7.85 (d, 
4H, Arom. Bz), 7.45 (t, J = 7.5 Hz, 2H, Arom. Bz), 7.37 - 7.15 (m, 17H, Arom. Bn), 6.10 (s, 1H, H1”), 
5.41 (d, J = 3.9 Hz, 1H, H1’), 4.71 - 4.54 (m, 7H, CH2 Bn’s, H3”, H2”), 4.51 - 4.36 (m, 4H, CH2 Bn’s, 
H4’), 4.28 (d, J = 9.2 Hz, 1H, H4”), 4.20 (d, J = 14.4 Hz, 1H, H5A”), 3.99 (dd, J = 13.2, 2.0 Hz, 1H, 
H5B”), 3.93 - 3.82 (m, 2H, H2’, H3’), 3.42 - 3.37 (m, 2H, H5’), 1.41 - 0.66 (m, 28H, iPr). 13C-NMR (101 
MHz, CDCl3) δ: 172.3 (CO Bz), 152.17 (C2), 152.16 (C6), 151.7 (C4), 143.4 (C8), 138.5, 138.0, 137.8 
(Cq Bn), 134.2 (Cq Bz), 133.0, 129.5, 128.8, 128.6, 128.4, 128.3, 128.06, 128.04, 128.01, 127.7, 127.65, 
127.61 (CH Arom.), 101.2 (C1’), 89.7 (C1”), 82.2 (C4’), 81.6 (C4”), 79.8 (C2”), 78.1 C2’), 74.8(C3’), 
73.5, 72.7, 72.1 (CH2 Bn’s), 69.8 (C5’), 68.0 (C3”), 59.6 (C5”), 17.6, 17.5, 17.4, 17.24, 17.18, 17.15, 
17.07 (CH3 iPr), 13.5, 13.0, 12.9, 12.8 (CH iPr). αD (CDCl3) = + 9.2°. IR: 2944, 2867, 1702, 1590, 1576, 


































DCE, 90 min., 0 oC





Compound 7 (0.23 g, 0.2 mmol) was dissolved in THF (10 mL) and treated with TBAF (1 M in THF, 0.5 
mmol) at room temperature for 1 hour. The reaction mixture was concentrated, redissolved in DCM 
washed with brine, 1N HCl, dried with MgSO4 and concentrated. The crude de-silylated intermediate was 
dissolved in 7N MeOH/NH3 (20 mL) and heated for 6 hours at 35 ºC. Concentration and coevaporation 
with toluene afforded the free amine. After dissolving in 15 mL MeOH and 0.5 ml AcOH, the reaction 
mixture was purged with argon, Pd/C (10% on activated charcoal) was added and the reaction mixture was 
brought under a H2 atmosphere, were it was left at room temperature for 48 hours. Filtration over celite 
and RP-HPLC using a gradient of 0 – 40% MeCN in 0.1% aq. TFA, followed by lyophilisation of the 
appropriate fractions yielded the title compound in an overall yield of 16% (12.7 mg, 31.8 µmol). 1H-
NMR (400 MHz, D2O) δ: 8.25 (s, 1H, H8), 8.05 (s, 1H, H2), 6.11 (d, J = 6.2 Hz, 1H, H1”), 5.03 (d, J = 
4.0 Hz, 1H, H1’), 4.81 (1H, H2”),4.48 (dd, J = 5.0, 3.1 Hz, 1H, H3”), 4.26 (q, J = 2.9 Hz, 1H, H4”), 4.20 - 
4.13 (m, 1H, H4’), 4.06 - 3.95 (m, 2H, H2’, H3’), 3.87 (dd, J = 12.9, 2.6 Hz, 1H, H5A”), 3.79 (dd, J =12.9, 
3.4 Hz, 1H, H5B”), 3.63 (dd, J = 12.4, 3.5 Hz, 1H, H5A’), 3.56 (dd, J = 12.4, 4.7 Hz, 1H, H5B’). 13C-NMR 
(101 MHz, D2O) δ 158.0 (C6), 155.0 (C2), 150.8 (C4), 143.1 (C8), 121.5 (C5), 104.4 (C1’), 89.4(C1”), 
88.7 (C4”), 87.9 (C4’), 81.6 (C2”), 74.0 (C2’), 73.4 (C3”), 72.2 (C3’), 64.04, 64.01(C5’, C5”). IR: 3318, 
2932, 1652, 1480, 1418, 1334, 1090, 1032. HRMS [C15H21N5O8 + H]+: found 400.1462, calc. 400.1463. 
 
N6,N6-di-Benzoyl-9-[2-O-(2, 3, 5-tri-O-benzyl-α-D-ribofuranosyl)-β-D-ribofuranosyl]-adenine (9) 
 
Compound 7 (0.13 g, 112 µmol) was dissolved in DCM/MeOH (10 mL, 4:1 v/v) and treated with 
methylamine (8M solution in EtOH, 40 µL) at 0 ºC. After 2 hours the reaction mixture was concentrated 
and redissolved in THF (10 mL). Treatment with TBAF (1M sol. in THF, 300 µL) at room temperature for 
1.5 hours, concentration and purification using silica gel column chromatography with a gradient of 
PE/EtOAc/MeOH (100/ 0/ 0 – 0/95/5, v/v/v) afforded the title compound as a colourless syrup (60 mg, 78 
µmol, 69%). 1H-NMR (400 MHz, CDCl3) δ 9.16 (s, 1H, NH), 8.77 (s, 1H, H2), 8.03 (m, 2H, H8, Arom. 
Bz), 7.61 (t, J = 7.4 Hz, 1H, Arom. Bz), 7.52 (t, J = 7.6 Hz, 2H, Arom. Bz), 7.36 - 7.21 (m, 14H, Arom. 
Bn), 7.17 - 7.10 (m, 2H, Arom. Bn), 6.06 (d, J = 7.5 Hz, 1H, H1”), 6.01 (d, J = 10.5 Hz, 1H, 5” OH), 4.98 
(dd, J = 7.4, 4.7 Hz, 1H, H2”), 4.92 (d, J = 3.1 Hz, 1H, H1’), 4.75 (d, J = 12.0 Hz, 1H, CH2 Bn), 4.61 (d, J 
= 12.0 Hz, 1H, CH2 Bn), 4.57 - 4.54 (m, 1H, H3”), 4.52 (d, J = 12.4 Hz, 1H, CH2 Bn), 4.49 (d, J = 12.0 

























i. TBAF, 1 hrs., r.t.
ii. 7 N NH3/ MeOH, 6 hrs., 35 oC















i. MeNH2, MeOH/DCM, 2 hrs., 0 oC














3.98 (d, J = 12.9 Hz, 1H, H5B”), 3.93 - 3.84 (m, 2H, H2’, H3’), 3.77 (t, J = 11.8 Hz, 1H, H5A”), 3.37 - 
3.20 (m, 2H, H5’). 13C-NMR (101 MHz, CDCl3) δ: 164.6 (CO Bz), 152.3 (C2), 150.8 (C6), 150.4 (C4), 
143.6 (C8), 137.7, 137.5, 137.2 (Cq Bn), 133.5 (Cq Bz), 133.1, 129.1, 128.6, 128.6, 128.58, 128.55, 
128.24, 128.21, 128.0, 127.9, 127.6, 124.8 (CH Arom.), 100.7 (C1’), 89.7 (C1”), 88.3 (C4”), 83.5 (C4’), 
79.1, 78.7, 76.8 (C2’,C3’ C2”), 73.6, 73.3, 73.0 (CH2 Bn), 72.9 (C3”), 70.0 (C5’), 63.5 (C5”). IR: 3304, 
2930, 1700, 1609, 1582, 1455, 1247, 1218,1072, 1026, 744, 696. αD (CDCl3) = + 9.6°. HRMS 
[C43H43N5O9 + H]+: found 774.3140, calc. 774.3134. 
 




Ribosyl adenosine 7 (240 mg, 215 µmol) was dissolved in dry DCM (15 mL) and cooled to -78 oC. 
Borontrichloride (1M solution in DCM, 1 mL) was slowly added and the reaction mixture was left to stir 
for 4.5 hours. The reaction was quenched with MeOH/TEA (400 µL, 1:1 v/v) at -78 oC. Concentration of 
the crude product followed by coevaporation with toluene (3x) and purification using silica gel column 
chromatography with a gradient of PE/DCM/MeOH (20 : 80 : 0 – 20 : 79 : 1, v/v/v) afforded the title 
compound as a colourless syrup (82 mg, 96 µmol, 45%). 1H-NMR (400 MHz, CDCl3) δ: 8.65 (s, 1H, H2), 
8.31 (s, 1H, H8), 7.94 - 7.81 (m, 4H, Arom. Bz), 7.48 (t, J = 7.5 Hz, 2H, Arom. Bz), 7.36 (t, J = 7.7 Hz, 
4H, Arom. Bz), 6.14 (s, 1H, H1”), 5.51 (d, J = 3.6 Hz, 1H, H1’), 4.79 (t, J = 5.2 Hz, 1H, H2”), 4.75 (t, J = 
5.2 Hz, 1H, H3”), 4.35 - 4.08 (m, 4H, H5”A, H4’, H4”, H2’), 4.05 - 3.94 (m, 2H, H5”B, H3’), 3.71 (dd, J = 
12.0, 3.2 Hz, 1H, H5A’), 3.66 (dd, J = 12.0, 4.0 Hz, 1H, H5B’), 3.36 (d, J = 10.5 Hz, 1H, H5’-OH), 3.08 (s, 
1H, OH), 2.02 (s, 1H, OH), 1.10 - 1.00 (m, 28H, iPr). 13C-NMR (101 MHz, CDCl3) δ: 172.5 (CO Bz), 
152.5 (C2), 152.1, 152.0 (C6, C4), 142.9 (C8), 134.2 (Cq Bz), 133.2, 129.6, 128.9 (Arom. Bz), 128.3 (C5), 
100.1 (C1’), 88.2 (C1”), 86.9 (C4’), 82.1 (C4”), 76.5 (C2”), 72.9 (C2’), 72.0 (C3’), 67.9 (C3”), 62.9 (C5’), 
59.4 (C5”), 17.6, 17.5, 17.4, 17.2, 17.1, 16.9 (CH3 iPr), 13.7, 13.1, 13.0, 12.8 (CH iPr). αD (CDCl3) = + 
2.2°. IR: 3466, 2923,2867, 1700, 1600, 1576, 1450, 1237, 1119, 1036, 885, 693. HRMS [C41H55N5O11Si2 
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N6,N6-di-Benzoyl-9-[3, 5-(1, 1, 3, 3-tetra-isopropyldisiloxane-1, 3-diyl)-2-O-(5-O-dimethoxytrityl- 2, 
3-di-O-acetyl-α-D-ribofuranosyl)-β-D-ribofuranosyl]-adenine (11) 
 
Nucleoside 10 (96 µmol) was dissolved in pyridine (5 mL) and reacted with DMTCl (5 eq., 150 mg) and a 
catalytic amount of DMAP at 40 ºC for 4 hours. Subsequently Ac2O (500 µL) was added and the reaction 
mixture was left at 40 ºC for 16 hours. Concentration of the crude followed by purification using a silica 
gel column pre-neutralized using TEA and a gradient of Hexane/ EtOAc (100 : 0 – 60 : 40, v/v) afforded 
the title compound as a colourless syrup (64 mg, 52 µmol, 55%). 1H-NMR (400 MHz, CDCl3) δ: 8.67 (s, 
1H, H2), 8.33 (s, 1H, H8), 7.85 (d, J = 7.7 Hz, 4H, Arom.), 7.59 - 7.01 (m, 15H, Arom.), 6.81 (d, J = 8.8 
Hz, 4H, Arom.), 6.01 (s, 1H, H1”), 5.78 (d, J = 4.3 Hz, 1H, H1’), 5.36 (dd, J = 7.2, 3.4 Hz, 1H, H3’), 5.13 
(dd, J = 7.1, 4.3 Hz, 1H, H2’), 4.65 (dd, J = 9.2, 4.9 Hz, 1H, H3”), 4.60 (d, J = 4.9 Hz, 1H, H2”), 4.39 (dd, 
J = 6.9, 3.4 Hz, 1H, H4’), 4.23 (d, J = 13.3 Hz, 1H, H5A”), 4.14 (d, J = 9.2 Hz, 1H, H4”), 4.02 (dd, J = 
13.3, 2.2 Hz, 1H, H5B”), 3.78 (s, 6H, OMe’s DMT), 3.30 (dd, J = 10.0, 2.0 Hz, 1H, H5A’), 3.17 (dd, J = 
10.0, 3.6 Hz, 1H, H5B’), 2.10, 2.09 (2x s, 6H, CH3 OAc’s), 1.28 - 0.84 (m, 28H, iPr). 13C-NMR (101 MHz, 
CDCl3) δ: 172.4 (CO Bz), 170.4, 170.1 (CO Ac), 158.6 (Cq DMT), 152.4 (C4), 152.2 (C2), 151.9 (C6), 
144.7 (Cq DMT), 143.1 (C8), 135.9, 135.8, 134.2, 133.0, 130.2, 129.6, 128.8, 128.4, 128.3, 128.0, 126.9 
(Arom. Bz, DMT), 113.3 (Arom. DMT), 100.0 (C1’), 89.1 (C1”), 86.3 (Cq DMT), 81.9 (C4”), 81.0 (C4’), 
79.4 9 (C2”), 71.7 (C2’), 70.5 (C3’), 68.1 (C3”), 63.0 (C5’), 59.8 (C5”), 55.4 (OMe DMT), 20.8, 20.7 
(CH3 OAc), 17.6, 17.4, 17.2, 17.1 (CH3 iPr.), 13.6, 13.1, 12.9, 12.7 (CH iPr). IR: 2946,2867, 1744, 1700, 
1599, 1576, 1508, 1448, 1237, 1034, 726, 694. HRMS [C66H77N5O15Si2 + H]+: found 1236.5048, calc. 
1236.5028 
 









Nucleoside 11 (52 µmol) was dissolved in 4:1 DCM/MeOH (5 mL) at 0 ºC and treated with 8M MeNH2 in 
EtOH (30 µL) for 30 min. After TLC analysis showed the complete conversion of the starting material 
into a lower running spot the reaction mixture was concentrated, redissolved in THF (5 mL) and treated 
with 1M TBAF in THF (300 µL) for 2 hours. The reaction mixture was concentrated, coevaporated with 
pyridine and redissolved in pyridine (5 mL). TBDPSCl (10 eq., 140 µL) and catalytic DMAP were added 
and the reaction mixture was stirred at 50 ºC for 48 hours. Subsequently Ac2O (200 µL) was added and the 
reaction mixture was left at room temperature for 16 hours. Concentration of the crude was followed by 
i. DMTCl, pyr., DMAP, 40 oC, 4 hrs.





















































i. MeNH2, MeOH/DCM, 30 min., 0 oC
ii. TBAF, THF, 2 hrs., r.t.
iii. TBDPSCl, pyr., DMAP, 48 hrs., 50 oC





purification using a silica gel column pre-neutralized using TEA and a gradient of Hexane/ EtOAc (100 : 0 
– 20 : 80) afforded a colourless syrup (42 mg) containing the title compound 12 (85% as determined by 
LCMS, 30 µmol) and the product lacking the N-acetyl group (15% as determined by LCMS, 6 µmol). This 
mixture was purified to allow complete analysis of the target compound 12 using RP-HPLC to afford 13 
mg (11 µmol) of pure 12 (32%). 1H-NMR (400 MHz, CDCl3) δ: 8.62 (s, 1H, H2), 8.33 (s, 1H, H8), 7.71 
(d, J = 7.2 Hz, 2H, Arom.), 7.68 - 7.59 (m, 4H, Arom.), 7.52 - 7.12 (m, 18H, Arom.), 6.81 (d, J = 8.6 Hz, 
4H, Arom.), 6.21 (d, J = 6.0 Hz, 1H, H1”), 5.63 - 5.53 (m, 1H, H3”), 5.35 (d, J = 4.6 Hz, 1H, H1’), 5.31 
(dd, J = 6.9, 3.0 Hz, 1H, H3’), 5.06 (t, J = 5.6 Hz, 1H, H2”), 4.99 (dd, J = 6.9, 4.6 Hz, 1H, H2’), 4.25 - 
4.22 (m, 1H, H4”), 4.18 - 4.17 (m, 1H, H4’), 4.00 (dd, J = 11.6, 2.8 Hz, 1H, H5A”), 3.86 (dd, J = 11.6, 2.8 
Hz, 1H, H5B”), 3.77 (s, 6H, OMe DMT), 3.34 (dd, J = 10.4, 3.2 Hz, 1H, H5A’), 3.13 (dd, J = 10.4, 3.2 Hz, 
1H, H5B’), 2.60 (s, 3H, NAc), 2.10 (s, 3H, OAc), 2.05 (s, 3H, OAc), 1.74 (s, 3H OAc), 1.09 (s, 9H, tBu 
TBDPS).13C-NMR (101 MHz, CDCl3) δ: 172.7 (CO Bz), 172.0 (CO N-Ac), 170.2, 169.8, 169.6 (CO O-
Ac), 158.6 (Cq DMT), 153.3 (C4), 152.4 (C2), 151.1 (C6), 149.9, 144.6 (Cq Arom.), 143.6 (C8), 135.9, 
135.7, 135.6, 135.6, 134.3, 132.9, 132.7, 132.4, 130.2, 130.2, 130.1, 129.4, 129.2, 128.7, 128.2, 128.09, 
128.08, 128.0, 127.0 (Arom. Bz, DMT, TBDPS), 113.3 (Arom. DMT), 101.6 (C1’), 86.4 (Cq DMT, C1”), 
83.8 (C4”), 81.8 (C4’), 78.7 (C2”), 71.7 (C3”), 71.50 (C2’), 70.48 (C3’), 63.3, 63.2 (C5’, C5”), 55.3 (OMe 
DMT), 27.1 (CH3 tBu TBDPS), 25.6 (CH3 NAc), 21.0, 20.9, 20.3 (CH3 OAc), 19.4 (Cq tBu). αD (CDCl3) 
= + 11.2°. IR: 2928, 2361, 2342, 1744, 1601, 1508, 1222, 1114, 1037, 910. HRMS [C67H69N5O15Si + H]+: 
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A General Synthetic Method Towards Uridylylated 








Picornaviridae are single stranded, positive sense RNA viruses sub-classified in the genera: 
Enterovirus, Rhinovirus, Hepatovirus, Parechovirus, Kobuvirus, Erbovirus, Cardiovirus, 
Aphtovirus and Teschovirus.1 Well-know examples of notorious human pathogens from this 
family of viruses are Rhinovirus, Hepatitis A virus and Poliovirus, which cause the common 
cold2, acute liver infection3 and inflammation of the central neural system4, respectively. Other 
members of this family of viruses are known agricultural pathogens, such as Foot-and-mouth-
disease virus which causes high fever and blisters in the mouth and on the feet of cloven-hoofed 
animals.5 Encephalomyocarditis virus6 and Theiler’s virus7, which cause inflammation of the 
heart muscle and brain in rodents, are other examples. 
All these viruses share the same genomic structure; a 5’ non-translated region (NTR) with an 
internal ribosome entry site and specific cloverleaf structure, an open reading frame coding for 
all viral capsid and replication proteins, a 3’ NTR and a 3’ poly(A)-tail.1 In addition, the most 
intriguing feature is that picornaviruses carry a small VPg-protein (Viral Protein genome-
linked) at the 5’-end of their genome whereas in other species the 5’-end of the RNA is 
commonly protected with a cap structure such as the modified nucleotide 7-methyl guanylate, 
which is attached via an 5’ - 5’ triphosphate linkage.8,9 The VPg protein is a 22-24 amino acid 
sequence that is highly conserved in all picornaviruses, and plays a crucial role in viral 
replication.4  
Upon infection by picornaviruses the viral genome is transcribed by the host ribosome 
generating viral replication proteins, amongst which the protein VPg. The positive sense 
genome is copied using its own replication proteins into a negative sense RNA strand, which 




more (+) strand RNA is formed than (-) strand RNA the replication is called asymmetric, 
indicating multiple replication mechanisms must be involved.  
Since both strands are 5’ capped with the VPg protein, it was long believed that uridylylated 
VPg was involved as primer in both (+) and (-) strand synthesis.12 However, it is now proposed 
that this uridylylated VPg only acts as an essential primer in the synthesis of progeny (+) strand 
RNA, using the 3’- poly(A)-tail of the genome as template. The viral 3D polymerase is 
responsible for uridylylating VPg using a functional domain in the viral genome called the cis-
replication element (CRE) as template.13,14 In contrast, (-) strand RNA synthesis is now believed 
to be primed by the non-uridylylated VPg-protein.15,16 These findings, suggesting a different 
primer for (-) and (+) strand formation, seem more in line with the asymmetric replication found 
for picornaviruses. The exact mode of action in this replication process, however, remains 
unclear. 
Outbreaks of picornavirus related diseases are rapid due to their high virulence and ease of 
communicability. The consequences can be severe, as demonstrated by the outbreak of Foot-
and-mouth-disease virus (FMDV) among United Kingdom farm animals in 2001.17 
Understanding the role of the RNA linked VPg protein in viral replication in more detail might 
give insight in the development of new vaccines and drugs against diseases caused by these 
viruses. Synthetically made VPgpU and VPgpUpU proved to be useful tools in the elucidation 
of Poliovirus replication.18,19 
 


















R 5 a: R = H (VPg)
b: R = pU (VPgpU)
1 a: R = H (VPg)
b: R = pU (VPgpU)
2 a: R = H (VPg)
b: R = pU (VPgpU)
3 a: R = H (VPg)
b: R = pU (VPgpU)
4 a: R = H (VPg)
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Previous reports describe the synthesis of Poliovirus VPgpU using a block condensation 
strategy20 and the online SPPS synthesis of Poliovirus, Coxsackie B3 and Cowpea mosaic virus 
VPgpU’s.21 As an extension of the latter procedure this chapter describes the solid phase 
synthesis of the VPg proteins as well as the VPgpU nucleoproteins from two additional 
coxsackie strands (CX A24 and CX B3W), human enterovirus 71 (HEV71), Poliovirus (PV1) 
and a consensus sequence for human enterovirus (conHEV)22 (see Figure 1). It was envisaged 
that the application of a pre-uridylylated tyrosine building block would result in a universal 
solid phase synthesis strategy for all Tyr-O4 linked VPgpU’s. 
Results and Discussion 
Guided by an earlier synthesis, uridylylated tyrosine building block 11 was selected for the 
solid phase synthesis of the target VPgpU’s (see Scheme 1).20 A modified route of synthesis to 
11 was undertaken that started with the protection of commercially available Fmoc-Tyr(tBu)-
OH 6 as its allyl ester. When cesium carbonate and allyl bromide were used to introduce the 
allyl ester, the Fmoc group in 6 was found to be cleaved. To avoid this unwanted side-reaction 
silver carbonate was used as a base and 7 was obtained in quantitative yield. Subsequent 
removal of the t-butyl ether using TFA gave phenol 8. Phosphitylation of 8 with uridine-5’-
phosphoramidite 9 under the agency of 4,5-dicyanoimidazole and subsequent oxidation of the 
intermediate phosphite using t-BuOOH yielded fully protected tyrosine 10. Liberation of the 
acid functionality by palladium catalyzed removal of the allyl protecting group gave target 
tyrosine derivative 11. In this reaction tributyltin hydride acts as a nucleophile, a process 




Reagents and conditions: i. Ag2CO3, DMF, r.t., 15 min; then All-Br, 2.5 h, r.t., (quantitative), ii. 70% TFA in DCM, 30 
min, r.t., (quantitative), iii. 4,5-dicyanoimidazole, MeCN, 30 min, r.t., iv. t-BuOOH, 45 min, rt, (90% based on 8), v. 




































The solid phase synthesis of VPgpU’s 1b – 5b started with immobilization of the first 
glutamic acid residue via its side chain acid moiety to Rink amide resin (Tentagel RAM).21 This 
was achieved by HATU mediated coupling of Fmoc-Glu-OtBu to the resin. During the final 
acidic cleavage of the VPgpU from the resin a carboxamide was generated, converting the 
initially attached glutamic acid into the desired C-terminal glutamine residue (see Scheme 2).  
 Scheme 2. SPPS for Coxsackie A24 VPg 1a and VPgpU 1b  
 
 
Preparation of Coxsackie A24 VPgpU 1b is elaborated by removal of the Fmoc protection 
and repetitive elongation of the resin bound glutamine using standard automated Fmoc solid 
phase peptide synthesis and HATU as coupling reagent, to give the immobilized 19-mer peptide 
12. The immobilized peptide 12 was elongated performing a manual double coupling protocol 
using Fmoc-Tyr(pU)-OH 11 and BOP/HOBt as activating agents. Subsequent piperidine 
treatment liberated the terminal amine, and concomitantly cleaved the cyanoethyl group 
resulting in the formation of a phosphodiester. The presence of the phosphodiester gave no 
problems in the subsequent attachment of the last two N-terminal amino acids, as no side 
reactions were detected. Final removal of the Fmoc group followed by treatment with a mixture 
of 95% TFA, 2.5 % TIS and 2.5% H2O, to effectuate removal of acid labile protective groups 
and release from the solid support yielded crude partially protected VPgpU. An alkaline 




























13 a: R = H





















A General Synthetic Method Towards Uridylylated Picornavirus VPg Proteins 
93 
 
residue yielded the completely deprotected crude nucleopeptide, which was purified using RP-
HPLC to afford homogeneous Coxsackie A24 VPgpU nucleoprotein 1b.  
Elongation of resin bound peptide 12 with Fmoc-Tyr(tBu)-OH, Fmoc-Ala-OH and Fmoc-
Gly-OH gave protected VPg peptide 13a. A final Fmoc deprotection step and acid treatment 
followed by RP-HPLC purification afforded Coxsackie A24 VPg protein 1a. 
In a similar fashion, using uridilylated tyrosine 11 or commercially available Fmoc-Tyr(tBu)-
OH the preparation of nucleoproteins 2b – 5b and proteins 2a – 5a, respectively, proceeded 
uneventfully in a yield between 3 and 35%.24  
 
Conclusion 
In this chapter suitably protected pre-uridylylated Fmoc tyrosine building block 11 is 
synthesized. The general applicability of a sequential solid phase based strategy is demonstrated 
by the successful synthesis of five picornavirus VPg proteins 1a – 5a and five uridylylated VPg 

























General: All chemicals were used as received. MeCN and THF were stored over activated 4Å molecular 
sieves at least 24 hours prior to use. DCM was distilled over CaH2 prior to use. Solvents were removed by 
rotary evaporation under reduced pressure at a temperature not exceeding 40°C. TLC analysis, silica gel 
column chromatography, NMR, LCMS, HPLC and HRMS techniques used are described in Chapter 2.  
 
Procedure for solid phase peptide synthesis: The peptides were prepared on an ABI-433A (Applied 
Biosystems, division of Perkin-Elmer) automated peptide synthesizer using the Fmoc based peptide 
synthesis protocol. The peptides were prepared on 50 μmol scale starting from Tentagel S RAM resin 
(with the exception of Coxsackie A24 VPg and VPgpU; 100 μmol). The first amino acid (Fmoc-Glu-
OtBu) was coupled to the resin via the side-chain and converted in a Gln residue in course of the final 
cleavage off the resin. The consecutive steps performed in each cycle were: 
- Deprotection of the Fmoc-group with 20 % piperidine in NMP for 5 x 1 min. 
- Coupling of the appropriate amino acid applying a five-fold excess. Generally the amino acid (0.25 
mmol) was dissolved in NMP (0.5 mL) and subsequently 0.25 mmol of HATU (0.25 M in DMF/NMP, 
1/1, v/v) and 0.32 mmol of DiPEA (1.0 M in NMP) were added. The resulting solution was transferred 
to the reaction vessel, which was shaken for 1 hour. 
- The unreacted amine functions were capped using 0.5 M acetic anhydride, 0.125 M DiPEA and 0.015 
M HOBt in NMP. The resulting suspension was shaken for 1 min.  
 
Double couplings were conducted on β-branched amino acids and on Fmoc-Asn(Trt)-OH and Fmoc-
Arg(Pbf)-OH.  
 
The 19-mer peptide containing resin was split in two equal portions of which one portion was elongated 
on the automated peptide synthesizer using a double coupling protocol for the last three AA’s to obtain 
VPg peptides 1a – 5a. In the synthesis of the VPgpU’s 1b – 5b the last three amino acids, Fmoc-Tyr(pU)-
OH, Fmoc-Ala-OH and Fmoc-Gly-OH, were attached manually using a double coupling protocol. The 
consecutive steps performed in each cycle were: 
- Deprotection of the Fmoc-group with 2 % DBU in DMF for 5 x 1 min. 
- Coupling of the appropriate amino acid applying a five-fold excess. Generally the amino acid (0.25 
mmol) was dissolved in NMP (0.5 mL) and subsequently 0.25 mmol of BOP/HOBt (0.5 M BOP/ 0.5 M 
HOBt in DMF/NMP, 1/1, v/v) and 0.32 mmol of DiPEA (1.25 M in NMP) were added. The resulting 
solution was transferred to the reaction vessel, which was shaken for 1 hour.  
- The unreacted amine functions were capped using 0.5 M acetic anhydride, 0.125 M DiPEA and 0.015 
M HOBt in NMP. The resulting suspension was shaken for 1 min. 
After final Fmoc deprotection, the peptide was cleaved off the resin using TFA/TIS/H2O (95/5/5, v/v/v, 10 
mL) by shaking for 4 hours. After filtration into cold Et2O (35 ml) the precipitate was collected and 
coevaporated with toluene (2 x 5 mL) and then treated with 25% aq. ammonia (2.5 mL) in 1,4-dioxane 
(2.5 mL). After stirring for 4 hours concentration of the reaction mixture afforded the crude title 
compound. RP-HPLC purification was conducted on a Gilson automated HPLC supplied with a semi-
preparative Phenomenex Gemini C18 column (250 x 10.00 mm, 5 μ, flow: 4 mL/min). The applied eluent 
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To a solution of Nα- Fmoc-(O-tert-butyl)-tyrosine 6 (2.3 g, 5.0 mmol) in DMF (25 mL) at 0 oC was added 
Ag2CO3 (2.7 g, 9.8 mmol) under exclusion of light. The reaction mixture was warmed to room 
temperature and stirred for 15 min. prior to addition of allylbromide (2.0 mL, 23 mmol). After 2.5 hours 
TLC analysis (70/29/1 EtOAc: PE: AcOH) indicated complete consumption of the starting material. The 
reaction mixture was filtered over celite and the filtrate was diluted in 100 mL EtOAc. The organic phase 
was subsequently washed with 10% KHSO4 (2 x 25 mL) and water (2 x 30 mL), dried (MgSO4) and 
concentrated. The residue was applied to a silica gel column and eluted with a gradient of EtOAc in PE 
(0/100 – 40/60, v/v) to yield the title compound quantitatively. 1H-NMR (400 MHz, CDCl3) δ 7.75 (d, J = 
7.5 Hz, 2H, Arom. Fmoc), 7.61 - 7.52 (m, 2H, Arom. Fmoc), 7.38 (t, J = 7.4 Hz, 2H, Arom. Fmoc), 7.30 
(t, J = 7.3 Hz, 2H, Arom. Fmoc), 7.11 - 6.95 (m, 2H, Arom. Tyr.), 6.89 (d, J = 7.7 Hz, 2H, Arom. Tyr.), 
5.84 (ddd, J = 21.2, 10.2, 5.0 Hz, 1H, CH Allyl), 5.36 (d, J = 8.2 Hz, 1H, NH), 5.33 - 5.15 (m, 3H, CH2 
Allyl), 4.74 - 4.49 (m, 3H, CH α, CH2 Allyl), 4.47 - 4.29 (m, 2H, CH2 Fmoc), 4.19 (t, J = 6.8 Hz, 1H, CH 
Fmoc), 3.19 - 2.96 (m, 2H, CH2 β), 1.31 (s, 9H, CH2 tBu). 13C-NMR (101 MHz, CDCl3) δ 171.3 (CO α), 
155.6, 154.5 (CO Fmoc, Cq Tyr.), 143.9, 143.8, 141.3 (Cq Arom. Fmoc), 131.5 (CH Allyl), 130.5 (Cq 
Tyr.), 129.87 (Arom. Tyr.), 129.82, 127.76, 127.1, 125.2, 125.1, 124.2, (Arom. Fmoc), 120.0 (CH2 Allyl), 
119.1 (Arom. Tyr.) 78.4 (Cq tBu), 67.0 (CH2 Fmoc), 66.1 (CH2 Allyl), 54.9 (CH α, 47.2 (CH Fmoc), 37.7 
(CH2 β), 28.9 (CH3 tBu). IR: 2980, 1718, 1506, 1236, 1161, 757, 740. αD (CHCl3) = + 14.6°. HRMS: 
[C31H33NO5 + H]+; calcd. 500.2432, found 500.2431. 
 






Allyl ester 7 was dissolved in 30 mL TFA/DCM (7:3, v/v) and stirred for 30 min. at room temperature. 
Toluene (50 mL) was added and the solvents were removed. The residue was applied to a silica gel 
column and eluted with a gradient of EtOAc in toluene (0/100 – 10/90, v/v) to yield the title compound 
quantitatively. 1H-NMR (400 MHz, CDCl3) δ 7.73 (d, J = 7.5 Hz, 2H, Arom. Fmoc), 7.58 – 7.47 (m, 2H, 
Arom. Fmoc), 7.37 (t, J = 7.4 Hz, 2H, Arom. Fmoc), 7.28 (t, J = 7.3 Hz, 2H, Arom. Fmoc), 6.92 (d, J = 
8.0 Hz, 2H, Arom. Tyr.), 6.70 (d, J = 8.0 Hz, 2H, Arom. Tyr.), 6.36 (s, 1H, OH), 5.90 - 5.81 (m, 1H, CH 
Allyl), 5.40 (d, J = 8.3 Hz, 1H, NH), 5.36 - 5.19 (m, 2H, CH2 Allyl), 4.77 - 4.49 (m, 3H, CH2 Allyl, CH 
α), 4.42 - 4.32 (m, 2H, CH2 Fmoc), 4.17 (t, J = 6.8 Hz, 1H, CH Fmoc), 3.09 - 2.97 (m, 1H, CH2 β). 13C-
NMR (101 MHz, CDCl3) δ 171.7 (CO α), 156.0, 155.3 (CO Fmoc, Cq Tyr.), 143.8, 143.7, 141.4 (Cq 
Arom. Fmoc), 130.5(CH Allyl), 127.8 (Arom. Tyr.), 127.2, 125.2, 125.15, 120.1 (Arom. Fmoc), 119.4 
(CH2 Allyl), 115.6(Arom. Tyr.), 67.2 (CH2 Fmoc), 66.3 (CH2 Allyl), 55.1 (CH α), 47.2 (CH Fmoc), 37.5 
(CH2 β). IR: 3317, 1689, 1516, 1450, 1214, 758, 739. αD (CHCl3) = + 16.8°. HRMS: [C27H25NO5 + H]+; 

































Phosphoramidite 9 was prepared by reacting 2’, 3’-di-O-acetyluridine (0.98 g, 3 mmol), coevaporated with 
MeCN (2 x 7.5 mL) in DCM (15 mL), containing TEA (1.4 mL, 10 mmol) with 2-cyanoethoxy-N,N-
diisopropylaminochlorophosphine (0.75 mL, 3.75 mmol) under an argon atmosphere. The reaction 
mixture was stirred for 45 min at room temperature. After 31P NMR showed complete consumption of the 
aminochlorophosphine and formation of phosphoramidite 9 (161 MHz, CDCl3; δ 150.49, 148.68), 30 mL 
DCM was added and the reaction mixture was washed with water (20 mL) and 5% NaHCO3 (10 mL). The 
organic phase was dried (MgSO4) and concentrated. Approximately 0.6 mmol 9 was added to a solution of 
Nα- Fmoc-tyrosine-allyl ester (8) (0.21 g, 0.47 mmol) in 1 MeCN (10 mL). 4,5-Dicyanoimidazole (0.15 g, 
0.6 mmol) was added and the reaction mixture was stirred for 30 min. until 31P NMR showed complete 
consumption of the phosphoramidite and formation of the phosphite (161 MHz, CDCl3; δ 135.12, 134.97). 
A solution of tBuOOH (5.5 M in nonane) was added to the reaction mixture until after 45 minutes 31P 
NMR showed complete consumption of the phospite and formation of the phospho triester (161 MHz, 
CDCl3; δ -6.48, -6.83). The reaction mixture was diluted in 20 mL DCM and washed with 5% Na2S2O3 
and water. The organic phase was dried with MgSO4 and concentrated. The residue was applied to a silica 
gel column and eluted with a gradient of MeOH in DCM (0/100 – 2/98, v/v), to yield the title compound 
as a mixture of epimers at P as a white foam in 90 % (0.37 g, 0.42 mmol) based on 8. 1H-NMR (400 MHz, 
CDCl3); δ 9.78 (d, J = 10.0 Hz, 1H, NH U), 7.76 (ap. d, J = 7.5 Hz, 2H, Arom. Fmoc), 7.62 - 7.53 (m, 2H, 
Arom. Fmoc), 7.45 - 7.35 (m, 3H, Arom. Fmoc, H6), 7.34 - 7.26 (m, 2H, Arom. Fmoc), 7.20 - 7.04 (m, 
4H, Arom. Tyr), 6.13 - 6.00 (m, 1H, H1’), 5.96 - 5.82 (m, 1H, CH Allyl), 5.79 - 5.58 (m, 2H, H5, NH α), 
5.45 - 5.37 (m, 1H, H3’), 5.37 - 5.12 (m, 3H, H2’, CH2 Allyl), 4.71- 4.25 (m, 10H, 4’, 5’, CH2 All, CH2 
CNEO, CH2 Fmoc, CH α), 4.20 (t, J = 7.0 Hz, 1H, CH Fmoc), 3.21 - 3.01 (m, 2H, CH2 β), 2.86 - 2.61 (m, 
2H, CH2 CNEO), 2.18 - 2.02 (m, 6H, OAc’s). 13C-NMR (101 MHz, CDCl3); δ 171.1, 171.0 (CO α), 
169.83, 169.80, 169.73, 169.71 (CO Ac), 163.2, 163.1 (C4), 155.7 (CO Fmoc), 150.5 (C2), 149.03, 148.96 
(Cq Tyr.), 143.84, 143.75, 141.29 (Cq Fmoc), 139.9, 139.7 (C6), 133.8 (Cq Tyr.), 131.4, 131.12 (Arom. 
Tyr.), 127.76, 127.09, 125.16, 125.11 (Aro. Fmoc), 120.0 (Arom. Tyr.), 119.3 (Arom. Fmoc), 117.9 (CH2 
Allyl), 117.87, 116.44 (CN), 103.5 (C5), 87.3, 87.0 (C1’), 80.59, 80.54, 80.52, 80.47 (C4’), 72.5 (C3’), 
69.83, 69.82 (C2’), 67.36, 67.30, 67.24, 66.92, 66.88, 66.21, 66.17 (CH2 Allyl, CH2 CNEO, CH2 Fmoc), 
63.18, 63.08 (C5’), 54.8 (CH α), 47.1 (CH Fmoc), 37.3 (CH2 β), 20.56, 20.54, 20.4 (CH3 Ac), 19.7, 19.6 
(CH2 CNEO). 31P-NMR (81 MHz, CDCl3); δ -6.48, -6.83. IR: 3067, 1694, 1506, 1452, 1378, 1211, 1037, 
961. LCMS (10 - 90 % B in 15 min), Rt = 8.91. ESI-MS; m/z 887.40 [M + H]+. HRMS: [C43H43N4O15P + 
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To a stirred solution of 10 (2.15 g, 2.4 mmol) coevaporated with MeCN (7.5 mL x 2) in 1:1 THF/DCM 
(10 mL, v/v), containing AcOH (0.6 mL, 11 mmol), was added Bu3SnH (1.3 mL, 4.9 mmol) and 
Pd(PPh3)4 (115 mg, 0.1 mmol) under an argon atmosphere. After one hour TLC analysis (10% 
MeOH/DCM) revealed complete consumption of the starting material. The reaction mixture was 
concentrated and purified using a silica gel column with a gradient of MeOH in DCM (0/100 – 4/96), to 
yield the title compound as a mixture of epimers as white foam in 62 % (1.26 g, 1.49 mmol). 1H-NMR 
(400 MHz, CDCl3) δ 9.99 (s, 1H), 7.73 – 7.13 ( m, 13H), 6.00 (dd, J = 15.1, 5.3 Hz, 1H), 5.94 – 5.80 (m, 
1H), 5.61 (dd, J = 56.2, 8.0 Hz, 1H), 5.49 – 5.36 (m, 1H), 5.35 – 5.27 (m, 1H), 4.68 – 4.62 (m, 1H), 4.51 – 
4.37 (m, 3H), 4.37 – 4.23 (m, 4H), 4.21 – 4.08 (m, 1H), 3.26 – 3.00 (m, 2H), 2.82 – 2.55 (m, 2H), 2.19 – 
1.95 (m, 6H). 13C-NMR (100 MHz, CDCl3); δ 173.4 (CO α), 169.77, 169.75, 169.7, 169.6 (CO Acetyl), 
164.2, 164.0 (Ur. 4), 155.7 (CO Fmoc), 150.24, 150.17 (Ur. 6), 148.83, 148.77 (Cq Tyr.), 143.8, 143.7, 
141.2 (Cq Fmoc), 134.0 (Cq Tyr.), 131.2, 131.1 (Arom. Tyr.), 127.6, 127.0, 125.1 (Arom. Fmoc), 119.9, 
119.7 (Arom. Fmoc, Arom. Tyr.), 116.5 (CN), 103.0, 102.9 (Ur. 5), 87.7, 87.3 (C1’), 80.5, 80.4 (C4’), 
72.6, 72.5 (C2’), 69.7, 69.6 (C3’), 67.3, 67.1 (CH2 Fmoc), 66.8 (C5’), 63.2, 63.1 (CH2 CNEO), 54.6 (Cα), 
47.1 (CH Fmoc), 37.0 (Cβ), 20.40, 20.37, 20.3 (CH3 OAc), 19.53, 19.45 (CH2 CNEO). 31P-NMR (162 
MHz, CDCl3); δ -6.59, -6.95. ESI-MS: m/z 847.40 [M+H]+. LCMS (10 – 90 B in 15 min.), Rt = 7.75. 
HRMS: [C40H39N4O15P + H]+; calcd. 847.2222, found 847.2229. 
 
Coxsackie A24 Virus VPg, (H-Gly-Ala-Tyr-Thr-Gly-Leu-Pro-Asn-Lys-Lys-Pro-Ser-Val-Pro-Thr-
Val-Arg-Thr-Ala-Lys-Val-Gln-OH), (1a) 
HPLC gradient: 10 - 60 % B in 3 CV. The appropriate fractions were lyophilized, yielding 22.47 mg, 7.79 
μmol (16 % based on original loading of resin) of the nucleopeptide as TFA salt. LCMS (0 – 50 % B in 15 
min.), Rt = 6.54 min. ESI-MS: m/z 771.47 [M + 2H]2+, 1157.13 [M + 3H]3+. HRMS [C103H174N30O30 + 
2H]2+; calcd. 1156.6578, found 1156.6577, [C103H174N30O30 + 3H]3+; calcd. 771.4410, found 771.4407, 
[C103H174N30O30 + 4H]4+; calcd. 578.8325 , found 578.8323, [C103H174N30O30 + 5H]5+; calcd. 463.2675, 
found 463.2674. 1H NMR (600 MHz, D2O) δ 7.17 (d, J = 8.5 Hz, 2H), 6.83 (d, J = 8.6 Hz, 2H), 4.70 - 
4.61 (m, 2H), 4.58 (ap. dd, J = 8.7, 5.5 Hz, 1H), 4.54 - 4.46 (m, 4H), 4.45 - 4.40 (m, 2H), 4.39 - 4.28 (m, 
7H), 4.28 - 4.19 (m, 3H), 4.19 - 4.10 (m, 3H), 3.92 - 3.80 (m, 8H), 3.77 - 3.70 (m, 1H), 3.70 - 3.61 (m, 
2H), 3.22 (ap. t, J = 7.0 Hz, 2H), 3.14 - 2.92 (m, 8H), 2.89 - 2.68 (m, 2H), 2.44 - 2.25 (m, 5H), 2.20 - 1.42 
(m, 41H), 1.40 (ap. d, J = 7.2 Hz, 5H), 1.33 (ap. d, J = 7.2 Hz, 3H), 1.23 (ap. dd, J = 8.3, 6.5 Hz, 7H), 1.17 
(ap. d, J = 6.4 Hz, 3H), 1.00 (ap. d, J = 6.7 Hz, 4H), 0.97 - 0.89 (m, 19H). 
 
Coxsackie A24 Virus VPgpU, (H-Gly-Ala-Tyr(pU)-Thr-Gly-Leu-Pro-Asn-Lys-Lys-Pro-Ser-Val-Pro-
Thr-Val-Arg-Thr-Ala-Lys-Val-Gln-OH), (1b) 
HPLC gradient: 10 - 60 % B in 3 CV. The appropriate fractions were lyophilized, yielding 54.72 mg, 
17.19 μmol (34 % based on original loading of resin) of the nucleopeptide as TFA salt. LCMS (0 – 50 % B 
in 15 min.), Rt = 6.32 min. ESI-MS: m/z 1310.13 [M+2H]2+, 873.73 [M+3H]3+. HRMS [C112H185N32O38P+ 
2H]2+; calcd. 1309.6705, found 1309.6705, [C112H185N32O38P + 3H]3+; calcd. 873.4494, found 873.4499, 
[C112H185N32O38P + 4H]4+; calcd. 655.3389, found 655.3401, [C112H185N32O38P+ 5H]5+; calcd. 524.4725, 
found 524.4721. 31P-NMR (162 MHz, D2O); δ – 4.28. 1H NMR (600 MHz, D2O) δ 7.69 (d, J = 8.1 Hz, 

































Hz, 1H), 4.73 - 4.67 (m, 1H), 4.67 - 4.62 (m, 1H), 4.62 - 4.56 (m, 1H), 4.54 - 4.38 (m, 6H), 4.38 - 4.25 (m, 
12H), 4.25 - 4.11 (m, 6H), 3.97 - 3.79 (m, 9H), 3.76 - 3.69 (m, 1H), 3.69 - 3.62 (m, 2H), 3.21 (ap. t, J = 
7.0 Hz, 2H), 3.12 (ap. dd, J = 13.9, 6.9 Hz, 1H), 3.01 (ap. dd, J = 17.6, 7.9 Hz, 7H), 2.89 - 2.72 (m, 2H), 
2.37 (ap. t, J = 7.7 Hz, 4H), 2.35 - 1.42 (m, 42H), 1.40 (ap. d, J = 7.2 Hz, 7H), 1.31 (ap. d, J = 7.2 Hz, 3H), 
1.22 (ap. dd, J = 8.1, 6.6 Hz, 6H), 1.19 (ap. d, J = 6.4 Hz, 3H), 0.99 (ap. d, J = 6.7 Hz, 4H), 1.04 - 0.79 (m, 
24H). 
 
Coxsackie B3 Virus Woodruff strain VPg, (H-Gly-Ala-Tyr-Thr-Gly-Ile-Pro-Asn-Gln-Lys-Pro-Lys-
Val-Pro-Thr-Leu-Arg-Gln-Ala-Lys-Val-Gln-OH), (2a)  
HPLC gradient: 10 - 30 % B in 3 CV. The appropriate fractions were lyophilized, yielding 11.47 mg, 3.87 
μmol (16 % based on original loading of resin) of the nucleopeptide as TFA salt. LCMS (0 – 50 % B in 15 
min.), Rt = 6.54 min. ESI-MS: m/z 1198.20 [M+2H]2+, 799.13 [M+3H]3+. HRMS [C107H180N32O30 + 
2H]2+; calcd. 1197.6844, found 1197.6846, [C107H180N32O30 + 3H]3+; calcd. 798.7920, found 798.7920, 
[C107H180N32O30 + 4H]4+; calcd.599.3458, found 599.3457, [C107H180N32O30 + 5H]5+; calcd. 479.6781, 
found 479.6780. 1H NMR (600 MHz, D2O) δ 7.16 (d, J = 8.5 Hz, 2H), 6.83 (d, J = 8.5 Hz, 2H), 4.67 (ap. t, 
J = 8.0 Hz, 1H), 4.65 - 4.60 (m, 1H), 4.57 (ap. dd, J = 9.1, 5.1 Hz, 1H), 4.47 (ap.dd, J = 16.1, 7.8 Hz, 3H), 
4.42 (ap.dd, J = 7.9, 6.6 Hz, 2H), 4.40 - 4.24 (m, 11H), 4.24 - 4.19 (m, 1H), 4.19 - 4.14 (m, 1H), 4.13 
(ap.d, J = 7.9 Hz, 1H), 3.99 - 3.81 (m, 7H), 3.77 - 3.68 (m, 2H), 3.68 - 3.59 (m, 1H), 3.21 (ap.t, J = 7.0 Hz, 
2H), 3.10 - 2.97 (m, 8H), 2.85 - 2.77 (m, 2H), 2.43 - 2.23 (m, 9H), 2.20 - 1.41 (m, 46H), 1.39 (ap.d, J = 7.2 
Hz, 5H), 1.33 (ap.d, J = 7.2 Hz, 3H), 1.24 (ap.d, J = 6.4 Hz, 3H), 1.17 (ap.d, J = 6.4 Hz, 4H), 1.00 (ap.d, J 
= 6.8 Hz, 3H), 1.01 - 0.92 (m, 18H), 0.88 (ap. t, J = 6.4 Hz, 6H). 
 
Coxsackie B3 Virus Woodruff strain VPgpU, (H-Gly-Ala-Tyr(pU)-Thr-Gly-Ile-Pro-Asn-Gln-Lys-
Pro-Lys-Val-Pro-Thr-Leu-Arg-Gln-Ala-Lys-Val-Gln-OH), (2b)  
HPLC gradient: 15 - 25 % B in 3 CV. The appropriate fractions were lyophilized, yielding 2.76 mg, 0.84 
μmol (3 % based on original loading of resin) of the nucleopeptide as TFA salt. LCMS (0 – 50 % B in 15 
min.), Rt = 6.39 min. ESI-MS: m/z 1351.13 [M+2H]2+, 900.93 [M+3H]3+. HRMS [C116H191N34O38P + 
2H]2+; calcd. 1350.6970, found 1350.6971, [C116H191N34O38P + 3H]3+; calcd. 900.8004, found 900.8004. 
31P-NMR (162 MHz, D2O); δ – 4.27. 1H NMR (600 MHz, D2O) δ 7.69 (d, J = 8.1 Hz, 1H), 7.19 (d, J = 8.5 
Hz, 2H), 7.11 (d, J = 8.2 Hz, 2H), 5.94 (d, J = 4.6 Hz, 1H), 5.68 (d, J = 8.1 Hz, 1H), 4.70 (ap. t, J = 7.6 
Hz, 1H), 4.64 - 4.55 (m, 2H), 4.47 (ap. dd, J = 14.8, 7.8 Hz, 3H), 4.44 - 4.40 (m, 2H), 4.40 - 4.26 (m, 
13H), 4.23 - 4.14 (m, 4H), 4.13 (ap. d, J = 7.9 Hz, 1H), 3.99 - 3.78 (m, 7H), 3.78 - 3.67 (m, 2H), 3.67 - 
3.60 (m, 1H), 3.21 (ap. t, J = 7.0 Hz, 2H), 3.12 (ap. dd, J = 13.9, 6.9 Hz, 1H), 3.01 (ap. dd, J = 16.6, 7.6 
Hz, 7H), 2.89 - 2.73 (m, 2H), 2.47 - 2.23 (m, 10H), 2.21 - 1.41 (m, 47H), 1.39 (ap. d, J = 7.2 Hz, 5H), 1.31 
(ap. d, J = 7.2 Hz, 3H), 1.24 (ap. d, J = 6.4 Hz, 3H), 1.19 (ap. d, J = 6.5 Hz, 4H), 1.00 (ap. d, J = 6.7 Hz, 
3H), 0.98 - 0.92 (m, 14H), 0.88 (ap. dd, J = 13.2, 6.1 Hz, 7H). 
 
Human Entero Virus 71 VPg, (H-Gly-Ala-Tyr-Ser-Gly-Ala-Pro-Lys-Gln-Val-Leu-Lys-Lys-Pro-Ala-
Leu-Arg-Thr-Ala-Thr-Val-Gln-OH), (3a) 
HPLC gradient: 10 - 30 % B in 3 CV. The appropriate fractions were lyophilized, yielding 10.89 mg, 3.98 
μmol (16 % based on original loading of resin) of the nucleopeptide as TFA salt. LCMS (0 – 50 % B in 15 
min.), Rt = 6.36 min. ESI-MS: m/z 1143.13 [M+2H]2+, 762.40 [M+3H]3+. HRMS [C102H174N30O29 + 
2H]2+; calcd. 1142.6604, found 1142.6608, [C102H174N30O29 + 3H]3+; calcd. 762.1093, found 762.1093. 1H 
NMR (600 MHz, D2O) δ 7.16 (d, J = 8.5 Hz, 2H), 6.84 (d, J = 8.5 Hz, 2H), 4.67 - 4.56 (m, 3H), 4.49 - 
4.29 (m, 13H), 4.27 - 4.23 (m 3H), 4.21 - 4.13 (m, 2H), 4.09 (ap. d, J = 8.3 Hz, 1H), 3.90 (ap. d, J = 5.0 
Hz, 2H), 3.87 - 3.81 (m, 5H), 3.78 (ap. dd, J = 11.6, 5.2 Hz, 1H), 3.65 (ap. dd, J = 17.0, 7.0 Hz, 2H), 3.23 
(ap. t, J = 6.9 Hz, 2H), 3.13 - 2.91 (m, 8H), 2.42 - 2.26 (m, 6H), 2.23 - 1.45 (m, 40H), 1.43 (ap. d, J = 7.2 
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Hz, 5H), 1.37 (ap. dd, J = 13.1, 7.1 Hz, 7H), 1.33 (ap. d, J = 7.2 Hz, 3H), 1.22 (ap. dd, J = 6.3, 4.8 Hz, 
6H), 1.05 - 0.91 (m, 19H), 0.89 (ap. dd, J = 11.0, 6.1 Hz, 7H). 
 
Human Entero Virus 71 VPgpU, (H-Gly-Ala-Tyr(pU)-Ser-Gly-Ala-Pro-Lys-Gln-Val-Leu-Lys-Lys-
Pro-Ala-Leu-Arg-Thr-Ala-Thr-Val-Gln-OH), (3b)  
HPLC gradient: 10 - 30 % B in 3 CV. The appropriate fractions were lyophilized, yielding 2.35 mg, 0.67 
μmol (3 % based on original loading of resin) of the nucleopeptide as TFA salt. LCMS (0 – 50 % B in 15 
min.), Rt = 6.24 min. ESI-MS: m/z 1296.07 [M+2H]2+, 864.47 [M+3H]3+. HRMS [C111H185N32O37P + 
2H]2+; calcd. 1295.6730, found 1295.6745, [C111H185N32O37P + 3H]3+; calcd. 864.1178, found 864.1173. 
31P-NMR (162 MHz, D2O); δ – 4.29. 1H NMR (600 MHz, D2O) δ 7.69 (d, J = 8.1 Hz, 1H), 7.19 (d, J = 8.6 
Hz, 2H), 7.12 (d, J = 8.3 Hz, 2H), 5.94 (d, J = 4.8 Hz, 1H), 5.67 (d, J = 8.1 Hz, 1H), 4.65 (ap. t, J = 7.6 
Hz, 1H), 4.60 (ap. dt, J = 9.6, 6.1 Hz, 2H), 4.45 - 4.22 (m, 18H), 4.22 - 4.12 (m, 4H), 4.09 (ap. d, J = 8.2 
Hz, 1H), 3.99 - 3.88 (m, 2H), 3.88 - 3.76 (m, 5H), 3.68 - 3.62 (m, 2H), 3.23 (ap. t, J = 6.9 Hz, 2H), 3.10 
(ap. dd, J = 13.9, 7.1 Hz, 1H), 3.07 - 2.92 (m, 7H), 2.41 - 2.21 (m, 7H), 2.19 - 1.46 (m, 41H), 1.43 (ap. d, J 
= 7.2 Hz, 6H), 1.37 (ap. dd, J = 13.7, 7.1 Hz, 6H), 1.31 (ap., J = 7.2 Hz, 3H), 1.22 (ap. dd, J = 6.3, 4.3 Hz, 
7H), 1.01 - 0.90 (m, 19H), 0.88 (ap. dd, J = 11.1, 6.1 Hz, 6H). 
 
Consensus Human Entero Virus VPg, (H-Gly-Ala-Tyr-Thr-Gly-Leu-Pro-Asn-Gln-Lys-Pro-Lys-Val-
Pro-Thr-Ile-Arg-Thr-Ala-Lys-Val-Gln-OH), (4a) 
HPLC gradient: 10 - 35 % B in 3 CV. The appropriate fractions were lyophilized, yielding 11.25 mg, 3.83 
μmol (15 % based on original loading of resin) of the nucleopeptide as TFA salt. LCMS (0 – 50 % B in 15 
min.), Rt = 6.56 min. ESI-MS: m/z 1184.07 [M+2H]2+, 790.33 [M+3H]3+. HRMS [C106H179N31O30 + 
2H]2+; calcd. 1184.1789, found 1184.1789, [C106H179N31O30 + 3H]3+; calcd. 789.7884, found 789.7887, 
[C106H179N31O30 + 4H]4+; calcd. 592.5931, found 592.5937, [C106H179N31O30 + 5H]5+; calcd. 474.2759, 
found 474.2766. 1H NMR (600 MHz, D2O) δ 7.16 (d, J = 8.6 Hz, 1H), 6.83 (d, J = 8.6 Hz, 1H), 4.67 (t, J 
= 8.0 Hz, 1H), 4.65 - 4.59 (m, 1H), 4.57 (dd, J = 9.1, 5.2 Hz, 1H), 4.53 - 4.39 (m, 3H), 4.38 - 4.27 (m, 
5H), 4.25 - 4.18 (m, 2H), 4.18 - 4.11 (m, 1H), 3.95 - 3.80 (m, 3H), 3.80 - 3.58 (m, 2H), 3.21 (ap. t, J = 7.0 
Hz, 1H), 3.09 - 2.96 (m, 4H), 2.89 - 2.75 (m, 1H), 2.35 (ap. t, J = 7.8 Hz, 3H), 2.33 - 2.24 (m, 1H), 2.20 - 
1.95 (m, 7H), 1.40 (ap. d, J = 7.2 Hz, 2H), 1.33 (ap. d, J = 7.2 Hz, 2H), 1.22 (ap. t, J = 5.9 Hz, 3H), 1.17 
(ap. d, J = 6.4 Hz, 2H), 1.00 (ap. d, J = 6.8 Hz, 2H), 0.98 - 0.93 (m, 8H), 0.91 (ap. d, J = 6.8 Hz, 2H), 0.87 
(ap. t, J = 7.4 Hz, 2H). 
 
Consensus Human Entero Virus VPgpU, (H-Gly-Ala-Tyr(pU)-Thr-Gly-Leu-Pro-Asn-Gln-Lys-Pro-
Lys-Val-Pro-Thr-Ile-Arg-Thr-Ala-Lys-Val-Gln-OH), (4b)  
HPLC gradient: 10 - 30 % B in 3 CV. The appropriate fractions were lyophilized, yielding 8.2 mg, 2.43 
μmol (10 % based on original loading of resin) of the nucleopeptide as TFA salt. LCMS (0 – 50 % B in 15 
min.), Rt = 6.44 min. ESI-MS: m/z 1338.13 [M+2H]2+, 892.13 [M+3H]3+. HRMS [C115H190N33O38P + 
2H]2+; calcd. 1337.1916, found 1337.1926, [C115H190N33O38P + 3H]3+; calcd. 891.7968, found 891.7974, 
[C115H190N33O38P + 4H]4+; calcd. 669.0994, found 669.0998. 31P-NMR (162 MHz, D2O); δ – 4.27. 1H 
NMR (600 MHz, D2O) δ 7.69 (d, J = 8.1 Hz, 1H), 7.19 (d, J = 8.5 Hz, 2H), 7.12 (d, J = 8.3 Hz, 2H), 5.94 
(d, J = 4.6 Hz, 1H), 5.68 (d, J = 8.1 Hz, 1H), 4.74 - 4.68 (m, 1H), 4.67 - 4.56 (m, 2H), 4.51 - 4.39 (m, 5H), 
4.39 - 4.26 (m, 12H), 4.26 - 4.16 (m, 5H), 4.16 - 4.10 (m, 2H), 3.93 (s, 2H), 3.92 - 3.77 (m, 5H), 3.76 - 
3.70 (m, 1H), 3.69 - 3.59 (m, 2H), 3.21 (ap. t, J = 7.0 Hz, 2H), 3.12 (ap. dd, J = 14.0, 6.8 Hz, 1H), 3.01 
(ap. dd, J = 15.8, 7.9 Hz, 7H), 2.89 - 2.75 (m, 2H), 2.44 - 2.24 (m, 7H), 2.19 - 1.41 (m, 44H), 1.40 (ap. d, J 
= 7.2 Hz, 4H), 1.31 (ap. d, J = 7.2 Hz, 3H), 1.22 (ap. t, J = 6.0 Hz, 6H), 1.19 (ap. d, J = 6.4 Hz, 4H), 1.00 








HPLC gradient: 10 - 30 % B in 3 CV. The appropriate fractions were lyophilized, yielding 48.57 mg, 
17.29 μmol (35 % based on original loading of resin) of the nucleopeptide as TFA salt. LCMS (0 – 50 % B 
in 15 min.), Rt = 6.48 min. ESI-MS: m/z 1178.13 [M+2H]2+, 785.47 [M+3H]3+. HRMS [C105H177N31O30 + 
2H]2+; calcd. 1177.1711, found 1177.1690, [C105H177N31O30 + 3H]3+; calcd. 785.1165, found 785.1156, 
[C105H177N31O30 + 4H]4+; calcd. 589.0892, found 589.0900, [C105H177N31O30 + 5H]5+; calcd. 471.4728, 
found 471.4736. 1H NMR (600 MHz, D2O) δ 7.16 (d, J = 8.5 Hz, 2H), 6.83 (d, J = 8.5 Hz, 2H), 4.74 - 
4.60 (m, 3H), 4.58 (ap. dd, J = 8.7, 5.4 Hz, 1H), 4.52 - 4.45 (m, 2H), 4.45 - 4.40 (m, 3H), 4.40 - 4.27 (m, 
8H), 4.26 - 4.19 (m, 3H), 4.19 - 4.10 (m, 2H), 3.95 - 3.78 (m, 7H), 3.78 - 3.70 (m, 1H), 3.70 - 3.61 (m, 
2H), 3.21 (ap. t, J = 7.0 Hz, 2H), 3.14 - 2.94 (m, 8H), 2.92 - 2.68 (m, 4H), 2.40 - 2.23 (m, 5H), 2.20 - 1.43 
(m, 40H), 1.40 (ap. d, J = 7.2 Hz, 7H), 1.33 (ap. d, J = 7.2 Hz, 3H), 1.27 - 1.19 (m, 7H), 1.17 (ap. d, J = 
6.4 Hz, 3H), 1.00 - 0.89 (m, 21H), 0.87 (ap. t, J = 7.4 Hz, 3H). 
 
Poliovirus VPgpU, (H-Gly-Ala-Tyr(pU)-Thr-Gly-Leu-Pro-Asn-Lys-Lys-Pro-Asn-Val-Pro-Thr-Ile-
Arg-Thr-Ala-Lys-Val-Gln-OH), (5b)  
HPLC gradient: 10 - 50 % B in 3 CV. The appropriate fractions were lyophilized, yielding 13.29 mg, 4.26 
μmol (17 % based on original loading of resin) of the nucleopeptide as TFA salt. LCMS (0 – 50 % B in 15 
min.), Rt = 6.38 min. ESI-MS: m/z 1330.07 [M+2H]2+, 887.40 [M+3H]3+. HRMS [C114H189N33O38P + 
2H]2+; calcd. 1330.1838, found 1330.1826, [C114H189N33O38P + 3H]3+; calcd. 887.1255, found 887.1248, 
[C114H189N33O38P + 4H]4+; calcd. 665.5955, found 665.5960, [C114H189N33O38P + 5H]5+; calcd. 532.6778, 
found 532.6768. 31P-NMR (162 MHz, D2O); δ – 4.28. 1H NMR (600 MHz, D2O) δ 7.69 (d, J = 8.1 Hz, 
1H), 7.19 (d, J = 8.5 Hz, 2H), 7.12 (d, J = 8.3 Hz, 2H), 5.94 (d, J = 4.6 Hz, 1H), 5.68 (d, J = 8.1 Hz, 1H), 
4.73 - 4.66 (m, 1H), 4.66 - 4.61 (m, 2H), 4.60 (ap. dd, J = 8.8, 5.3 Hz, 1H), 4.52 - 4.39 (m, 5H), 4.39 - 4.26 
(m, 12H), 4.25 - 4.09 (m, 6H), 3.98 - 3.80 (m, 7H), 3.77 - 3.69 (m, 1H), 3.69 - 3.63 (m, 2H), 3.21 (ap. t, J 
= 7.1 Hz, 2H), 3.12 (ap. dd, J = 13.9, 6.9 Hz, 1H), 3.05 - 2.93 (m, 7H), 2.89 - 2.69 (m, 4H), 2.37 (ap. t, J = 
7.6 Hz, 4H), 2.36 - 2.24 (m, 3H), 2.24 - 2.16 (m, 1H), 2.14 - 1.97 (m, 9H), 1.97 - 1.43 (m, 29H), 1.40 (ap. 
d, J = 7.2 Hz, 4H), 1.31 (ap. d, J = 7.2 Hz, 3H), 1.27 - 1.20 (m, 7H), 1.19 (ap. d, J = 6.4 Hz, 3H), 1.01 - 






















A General Synthetic Method Towards Uridylylated Picornavirus VPg Proteins 
101 
 
Notes and References 
1 Steil, B. P; Barton, D. J.; Virus Res., 2009, 139,240 - 252. 
2 Arden, K. E.; Mackay, I. M.; Rev. Med. Virol., 2010, 20, 156 - 176. 
3 Ajmera, V.; Xia, G.; Vaughan, G.; Forbi, J. C.; Ganova-Raeva, L. M.; Khudyakov, Y.; Opio, C. K.; 
Taylor, R.; Restrepo, R.; Munoz, S.; Fontana, R. J.; Lee, W. M.; J. Viral Hepatitis, 2011, 18, e167 - 
e174. 
4 Nathanson, N.; Advances in Virus Research, 2008, 71, 1 - 50. 
5 Longjam, N.; Deb, R.; Sarmah, A. K.; Tayo, T.; Awachat, V. B.; Saxena, V. K.; Veterinary Medicine 
International, 2011, 905768. 
6 Doi, K.; J. Comp. Path., 2011, 144, 25 - 40. 
7 Buckwalter, M. R.; Nga, P. T.; Gouilh, M. A.; Fiette, L.; Bureau, J.; Laird, M. E.; Buchrieser, J.; Ozden, 
S.; Cheval, J.; Eloit, M.; Manuguerra, J.; Gessain, A.; Brey, P. T.; Fontanet, A.; Albert, M. L.; J. Virol., 
2011, 85, 6893 - 6905. 
8 Rothberg, P. G.; Harris, T. J. R.; Nomoto, A.; Wimmer, E.; Proc. Natl. Acad. Sci. USA, 1978, 75, 4868 - 
2872. 
9 Ambros, V.; Balimore, D.; J. Biol. Chem., 1978, 253, 5263 - 5266. 
10 Schein, C. H.; Volk, D. E.; Oezguen, N.; Paul, A.; Proteins, 2006, 63, 719 - 726. 
11 Novak, J. E.; Kirkegaard, K.; J. Virol., 1991, 65, 3384 - 3387. 
12 Steil, B. P.; Barton, D. J.; J. Virol., 2009, 83, 12660 - 12670.  
13 Paul, A. V.; Rieder, E.; Kim, D. W.; van Boom, J. H.; Wimmer, E.; J. Virol., 2000, 74, 10359 - 10370.  
14 Rieder, E.; Paul, A. V.; Kim, D. W.; van Boom, J. H.; Wimmer, E.; J. Virol., 2000, 74, 10371 - 10380.  
15 Murray, K. E.; Barton, D. J.; J. Virol., 2003, 77, 4739 - 4750. 
16 Morasco, B. J.; Nidhi, S.; Parilla, J.; Flanegan, J. B.; J. Virol., 2003, 77, 5136 - 5144. 
17 Cottam, E. M.; Haydon, D. T.; Paton, D. J.; Gloster, J.; Wilesmith, J. W.; Ferris, N. P.; Hutchings, G. 
H.; King, D. P.; J. Virol., 2006, 80, 11274 - 11282. 
18 Schein, C. H.; Oezguen, N.; van der Heden van Noort, G. J.; Filippov, D. V.; Paul, A.; Kumar, E.; 
Braun, W.; Peptides, 2010, 31, 1441 - 1448.  
19 Paul, A. V.; van Boom, J. H.; Filippov, D. V.; Wimmer, E.; Nature, 1998, 393, 280 - 284. 
20 Filippov, D. V.; Kuyl-Yeheskiely, E.; van der Marel, G. A.; Tesser, G. I.; van Boom, J. H.; Tetrahedron 
Lett., 1998, 39, 3597 - 3600.  
21 Kriek, N. M. A. J.; Filippov, D. V.; van den Elst, H.; Meeuwenoord, N. J.; Tesser, G. I.; van Boom, J. 
H.; van der Marel, G. A.; Tetrahedron, 2003, 59, 1589 - 1597.  
22 The consensus HEV VPg was designed using software that used 33 aligned HEV-VPg’s to assign the 




Schein, C. H.; Proceedings of the Biotechnology and Bio-informatics Symposium (BIOT-2011), October 
2011, Rice University, Housten (Tx), United States of America.  
23 Dangles, O.; Guibe, F.; Balavoine, G.; Lavielle, S.; Marquet, A.; J. Org. Chem., 1987, 52, 4984 - 4993. 
24 Preliminary results indicate that all synthetically prepared VPg’s, including the consensus HEV protein, 
were recognized as substrate by viral 3D polymerases based on their ability to be uridylylated. 
Poliovirus and coxsackie A virus polymerases showed a preference for their own VPg with respect to 
other viral strand VPg’s, but the consensus VPg was found to be uridylylated as well or even beter as 





































Nucleotidylation of proteins is a widespread post-translational modification.2-5 For example, 
adenylylation of tyrosine has been recognized as an important regulatory event, both in bacteria 
and in higher organisms.6,7 A number of RNA viruses use the uridylylated or guanylylated form 
of VPg (Viral Protein genome-linked) proteins to initiate the replication of the genome.8 
Perhaps the most investigated protein nucleotidylation process takes place in Picornaviridae as 
described in Chapter 5.9 These viruses share the presence of a small VPg, that is covalently 
linked to the 5’-end of the viral genome.10 Although the mechanism of replication of picorna 
viruses has not been clarified completely, extensive research has shown that VPg and/or its 
uridylylated forms VPgpU or VPgpUpU can act as primers in both negative and positive strand 
RNA synthesis.11-15 VPgpU and VPgpUpU, in turn, are presumably formed by uridylylation at 
the O-4 of tyrosine-3 of the 22 amino acid long VPg protein of poliovirus under influence of a 
cis-acting replication element (CRE) within the viral RNA.16-20 It has been shown that the 
introduction of point mutations in this CRE motif led to 3D polymerase mediated reaction of 
CTP, ATP or GTP with O-4 tyrosine of VPg to produce VPgpC, VPgpA and VPgpG 
respectively.16 Although all four nucleosides can be incorporated, suggesting that the 3D 
polymerase is not specific for UTP as incoming nucleotide donor, VPgpG and VpgpA are not 
elongated towards the dinucleotide and VPgpC only in moderate amount when compared to 









As part of a program to develop synthetic routes towards nucleotidylated proteins and 
derivatives thereof a solid phase synthesis to obtain nucleotidylated VPg proteins, containing all 
four naturally occurring ribonucleotides was undertaken. The approach presented in Chapter 5 
to synthesize a pre-uridylylated tyrosine building block is adapted here towards the preparation 
of adenylylated, guanylylated and cytidylated Fmoc-tyrosine building blocks that were 
subsequently used in the synthesis of Poliovirus VPgpA, VPgpC and VPgpG (see Figure 1). 
 





Results and Discussion 
A solid phase synthesis using pre-nucleotidylated Fmoc-tyrosine building blocks, as was 
described for VPgpU in Chapter 5, is considered to be most convenient for the synthesis of 
poliovirus derived VPgpC, VPgpA and VPgpG.21 Key to the success of such a strategy is the 
choice of the protecting groups for the exocyclic amino functions of the nucleobases. Such 
protecting groups should be stable during the solid phase peptide synthesis and leave the 
peptide intact during deprotection at the end of the synthesis. Acyl protective groups are an 
obvious choice as these are well established in the field of nucleopeptide synthesis.22,23 Because 
the stability of acyl protecting groups depends on the nature of the nucleobase, the benzoyl 
group was selected to protect the exocyclic amino functions of both cytidine and adenosine 
while guanosine was equipped with the more labile phenoxyacetyl group.24 
The syntheses of protected nucleotidylated tyrosine building blocks 16-18 are shown in 
Scheme 1. Known N4-benzoylcytidine 425, N6-benzoyladenosine 526 and N2-
phenoxyacetylguanosine 627 were selectively silylated with TBDMSCl in pyridine, treated with 
isobutyric anhydride and subsequently desilylated with acid to give partially protected 
nucleosides 7, 8 and 9, respectively. 
Treatment of 7, 8 and 9 with 2-cyanoethoxy-N,N-diisopropylaminochlorophosphine in the 
presence of triethylamine as base led to 5’-phosphoramidites 10, 11 and 12. Tetrazole mediated 
phosphitylation of the free hydroxyl function on the side chain of Fmoc-Tyr-OAll with amidites 
10, 11 and 12 and oxidation of the intermediate phosphite triesters with m-CPBA was followed 
by liberation of the acid by palladium catalyzed removal of the allyl protective group to give the 
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Scheme 1. Synthesis of Fmoc-tyrosine derivates 
 
Reagents and conditions: i. TBDMSCl, pyr., ii. iBu2O, pyr., iii. pTsOH, iv. 2-cyanoethoxy-N,N-
diisopropylaminochlorophosphine, TEA, DCM, 45 min, v. Fmoc-Tyr-OAll, tetrazole, MeCN/DCM, 45 min, r.t., vi. 
mCPBA, 0 oC, vii. Pd(PPh3)4, SnBu3H, THF/DCM, AcOH, r.t., 2h. 
The solid phase synthesis of target compounds 1 - 3 started with the synthesis of the protected 
and immobilized 19-mer peptide 19, a common intermediate en route to VPgpC, VPgpA and 
VPgpG (Scheme 2). Tentagel S RAM resin was functionalized with the first amino acid by 
attachment of Fmoc-Glu-OtBu via the side chain acid moiety.22 Automated solid phase peptide 
synthesis based on Fmoc chemistry, using commercially available amino acid building blocks 
and HCTU as condensing agent proceeded uneventfully. 
Immobilized 19-mer 19 was manually elongated by the sequential incorporation of the 
nucleotidylated tyrosine 16, Fmoc protected Ala and Gly using BOP/HOBt to give the fully 
protected VPgpC (20, Scheme 2). TFA mediated cleavage of the nucleopeptide from the resin 
and concomitant unmasking of the amino acid side chains, deprotection of exocyclic amine of 
cytosine with 25% aq. ammonia and final purification with RP-HPLC afforded homogeneous 






4 NPG = CBz
5 NPG = ABz
6 NPG = GPac
7 NPG = CBz (63%)
8 NPG = ABz (78%)


















13 NPG = CBz (74%)
14 NPG = ABz (64%)
15 NPG = GPac (63%)
10 NPG = CBz
11 NPG = ABz
12 NPG = GPac
16 NPG = CBz (56%)
17 NPG = ABz (85%)
18 NPG = GPac (56%)
R = OH














Scheme 2. Solid Phase Synthesis of VPgpC, VPgpA and VPgpG 
 
Reagents and conditions: i. SPPS using a repetative cycle of a) 20% piperidine/DMF, b) Fmoc-AA-OH, HCTU, DiPEA, 
NMP, c) Ac2O, DiPEA, HOBt, NMP, ii. SPPS using a repetitive cycle of a) 2% DBU/DMF, b) Fmoc-AA-OH, 
BOP/HOBt or HATU, DiPEA, NMP, c) Ac2O, DiPEA, HOBt, NMP, iii. TFA/TIS/H2O, 2.5 h, r.t., iv. 25% aq. 
ammonia/dioxane, 4 h, r.t. 
A similar sequence of reactions as described for the formation of 20, using in this case 
adenylylated tyrosine 17 gave immobilized partially protected VPgpA 21. In the first instance, 
cleavage from the solid support, removal of all protecting groups and purification did not result 
in homogeneous VPgpA. It turned out that despite the relatively high acid stability of the 
glycosidic linkages of ribonucleosides, TFA treatment of fully protected VPgpA 21 was 
accompanied by depurination of the adenosine moiety.29 This was unexpected because the 5’-
phosphorylated adenosine residue was reported to be stable to TFA treatment30 and 5’-adenylyl 
O-tyrosine, specifically, is known to withstand a treatment with strong acid (0.3 N HCl, 37 ºC, 
3h).31 Homogeneous VPgpA 2 could be obtained in 10% yield based on initial loading of the 
resin by acidolysis, RP-HPLC purification of the intermediate nucleopeptide 21, ammonia 
treatment of the partially protected nucleopeptide and finally a second RP-HPLC purification.  
Adoption of the procedure of VPgpC for the synthesis of VPgpG using guanylated tyrosine 18 
and LCMS analysis of the crude product showed the presence of truncated sequences while 
depurination products were lacking. Guided by the work of Bae and Lakshman32,33, who 
showed that BOP and PyBOP mediated condensations may lead to side reactions at the C-6 of 
the guanine base, the last three amino acids in the synthesis of VPgpG were incorporated using 
HATU as coupling reagent.34 Subsequently, acid mediated cleavage from the solid support and 
20; NPG = CBz
21; NPG = ABz
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deprotection using TFA followed by a 25% aq. ammonia treatment and RP-HPLC purification, 
afforded VPgpG in 29% based on initial loading of the resin.  
 
Conclusion 
In conclusion, three unprecedented nucleotidylated amino acid building blocks were prepared 
and applied in the solid phase synthesis of poliovirus derived proteins VPgpC, VPgpA and 
VPgpG. This methodology opens the way to the synthesis of more elaborated nucleotidylated 
proteins such as VPgpG of Norovirus.35 The synthetic, well defined constructs of this type may 




























General: All chemicals were used as received. MeCN and THF were stored over activated 4Å molecular 
sieves for at least 24 hours prior to use. DCM was distilled over CaH2 prior to use. Solvents were removed 
by rotary evaporation under reduced pressure at a temperature not exceeding 40°C. TLC analysis, silica 
gel column chromatography, NMR, LCMS, HPLC and HRMS techniques were used as described in 
Chapter 2.  
 
Procedure for solid phase peptide synthesis: The protected peptide 19 was prepared via solid phase 
peptide synthesis on an ABI-433A (Applied Biosystems, division of Perkin-Elmer) automated peptide 
synthesizer using the Fmoc based peptide synthesis protocol starting from Tentagel S RAM resin (200 mg, 
50 μmol) to which Fmoc-Glu-OtBu was attached via the side-chain carboxylic acid functionality. As 
repetitive cycle were used: 
- Fmoc cleavage using 20% piperidine in NMP. 
- Coupling of the appropriate amino acid applying a five-fold excess, activation by 5 eq. HCTU in NMP 
(0.25M) and 12.5 eq. DiPEA in NMP (1.25 M) for 1 hour. 
- Capping using 0.5 M acetic anhydride, 0.125 M DiPEA and 0.015 M HOBt in NMP for 1 min.  
 
The last three amino acids were introduced manually on 25 μmol 19 by a double coupling protocol: 
- Fmoc cleavage using 2% DBU in DMF. 
- Coupling of the appropriate amino acid applying a five-fold excess, activation by 5 eq. BOP/HOBt (in 
the preparation of 1 and 2) or HATU (in the preparation of 3) in NMP and 12.5 eq. DiPEA in NMP 
(1.25 M) for 1 hour. 
- Capping using 0.5 M acetic anhydride, 0.125 M DiPEA and 0.015 M HOBt in NMP for 1 min. 
 




Cytidine 4 (1.0 g, 2.9 mmol) was dissolved in pyridine (5 mL) after coevaporation with pyridine. TBDMS-
Cl (0.87 g, 5.8 mmol) was added and the reaction mixture was stirred until it became a clear solution. 
After this, isobutyric anhydride (11.6 mmol, 1.93 mL) was added and the reaction mixture was stirred at 
room temperature for 16 hours, upon which TLC analysis (10% MeOH/DCM) indicated complete 
conversion of the starting material. The reaction mixture was concentrated and taken up in EtOAc. After 
washing with sat. aq. NaHCO3, 5% citric acid and H2O the organic phase was dried (MgSO4) and 
concentrated. The residue was taken up in 4:1 v/v MeCN/ H2O (30 mL), p-TsOH (0.55 g, 2.9 mmol) was 
added and the reaction mixture was stirred overnight at room temperature. The reaction mixture was 
concentrated and purified using silica gel column chromatography with a gradient of DCM/MeOH (100/0 
– 98/2) to afford the title compound as a white solid (0.88 g, 1.8 mmol, 63 %). 1H-NMR (400 MHz, 
CDCl3) δ 8.36 (d, J = 7.5 Hz, 1H, H6), 7.88 (d, J = 7.5 Hz, 2H, Arom. Bz), 7.59 - 7.56 (m, 2H, H5, Arom 
Bz), 7.47 (t, J = 7.7 Hz, 2H, Arom. Bz), 6.17 (d, J = 5.1 Hz, 1H, H1’), 5.62 (t, J = 5.3 Hz, 1H, H2’), 5.58 - 
5.51 (m, 1H, H3’), 4.38 - 4.17 (m, 1H, H4’), 4.01 (dd, J = 12.4, 1.9 Hz, 1H, H5A’), 3.87 (dd, J = 12.4, 1.9 
Hz, 1H, H5B’), 2.74 - 2.42 (m, 2H, CH iBu), 1.21 - 1.08 (m, 12H, CH3 iBu). 13C-NMR (100 MHz, CDCl3); 
δ 175.6, 175.3 (CO iBu), 167.0 (C2), 162.94 (CO Bz), 155.8 (C6), 145.0 (C4), 132.7 (Cq Bz), 132.6, 
128.3, 127.6 (Bz), 97.6 (C5), 88.0 (C1’), 83.6 (C4’), 74.0 (C3’), 70.0 (C2’), 60.6 (C5’), 33.4, 33.3 (CH 
iBu), 18.5, 18.3, 18.28, 18.2 (CH3 iBu). IR: 1743, 1653, 1624, 1558, 1481, 1311, 1244, 1099. LCMS (10-









Bz i. TBDMSCl, pyr., r.t.
ii. iBu2O, 16 h, r.t.
iii. pTsOH, MeCN/H2O, 16 h, r.t.
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Adenosine 5 (1.8 g, 4.8 mmol) was dissolved in pyridine (25 mL) after coevaporation with pyridine. 
TBDMS-Cl (1.5 g, 10 mmol) was added and the reaction mixture was stirred for 1 hour at room 
temperature. After this, isobutyric anhydride (20 mmol, 3.7 mL) was added and the reaction mixture was 
stirred for 48 hours. The reaction mixture was concentrated and taken up in DCM. After washing with 5% 
citric acid and H2O the organic phase was dried (MgSO4) and concentrated. The residue was taken up in 
4:1 v/v MeCN/ H2O (50 mL) and p-TsOH (0.8 g, 5 mmol) was added after which the reaction mixture was 
stirred at room temperature for 2 hours. The reaction mixture was concentrated and purified with silica gel 
column chromatography using a gradient of EtOAc/PE (0/100 – 45/55) to afford the title compound as a 
white foam (1.9 g, 3.9 mmol, 78%). 1H-NMR (400 MHz, CDCl3) δ 9.82 (s, 1H, NH), 8.66 (s, 1H, H8), 
8.31 (s, 1H, H2), 8.01 (d, J = 7.6 Hz, 2H, Arom. Bz), 7.53 (t, J = 7.3 Hz, 1H, Arom. Bz), 7.43 (t, J = 7.5 
Hz, 2H, Arom. Bz), 6.21 (d, J = 7.1 Hz, 1H, H1’), 6.04 - 5.92 (m, 1H, H2’), 5.91 (s, 1H, 5’-OH), 5.69 (d, J 
= 5.2 Hz, 1H, H3’), 4.31 (s, 1H, H4’), 4.09 - 3.73 (m, 2H, H5’), 2.75 - 2.56 (m, 1H, CH iBu), 2.56 - 2.38 
(m, 1H, CH iBu), 1.21 – 1.07 (m, 12H, CH3 iBu).13C-NMR (100 MHz, CDCl3); δ 175.6, 175.1 (CO iBu), 
164.6 (CO Bz), 152.3 (C2), 150.9, 150.2 (C4, C6), 142.2 (C8), 133.3 (Cq Bz), 132.8 (Arom. Bz), 128.8 
(Arom. Bz), 127.9 (Arom. Bz), 124.4 (C5), 88.4 (C1’), 86.3 (C4’), 72.8 (C2’), 72.2 (C3’), 62.4 (C5’), 
33.8, 33.5 (CH iBu), 18.89, 18.75, 18.67, 18.59 (CH3 iBu). IR: 3274, 2977, 1743, 1701, 1609, 1582, 1454, 
1246, 1153, 1095. LCMS (10-90% B in 15 min), Rt = 6.57 . ESI-MS: m/z 512.2 [M + H]+. HRMS 
[C25H29N5O7 + H]+; calcd. 512.2135, found 512.2139. 
 




Guanosine 6 (4.17 g, 10 mmol ) was dissolved in pyridine (50 mL) after coevaporation with pyridine. 
TBDMSCl (3.0 g, 20.0 mmol) was added and the reaction mixture was stirred at room temperature until 
TLC analysis indicated complete consumption of the starting material. Isobutyric anhydride (6.6 mL, 40.0 
mmol) was added and the reaction mixture was stirred overnight. After concentration the residue was 
redissolved in EtOAc (100 mL) and washed with sat. aq. NaHCO3, 5% citric acid and water. The organic 
layer was dried (MgSO4) and directly desilylated without further purification. Towards this end the residue 
was dissolved in MeCN/water (100 mL, 4:1, v/v) and excess p-TsOH (2.4 g, 14.8 mmol) was added. After 
concentration the residue was taken up in EtOAc and washed with sat. aq. NaHCO3 and water. Silica gel 
column chromatography purification using a gradient of EtOAc in toluene (0/100 – 70/30) yielded the title 
compound as an off-white powder (4.5 g, 8.5 mmol, 85 %). 1H-NMR (400 MHz, CDCl3) δ 7.78 (s, 1H, 
H8), 7.37 (dd, J = 8.5, 7.6 Hz, 2H, Arom. Pac), 7.09 (t, J = 7.4 Hz, 1H, Arom. Pac), 7.05 (d, J = 7.9 Hz, 
2H, Arom. Pac), 5.95 (d, J = 7.2 Hz, 1H, H1’), 5.89 (dd, J = 7.1, 5.5 Hz, 1H, H2’), 5.71 (dd, J = 5.3, 2.2 
Hz, 1H, H3’), 4.92 (s, 1H, NH), 4.72 (s, 2H, CH2 Pac), 4.31 (d, J = 1.9 Hz, 1H, H4’), 4.12 - 3.79 (m, 2H, 
H5’), 2.76 - 2.58 (m, 1H, CH iBu), 2.58 - 2.45 (m, 1H, CH iBu), 1.23 – 1.11 (m, 12H, CH3 iBu). 13C-NMR 
(100 MHz, CDCl3); δ 175.7, 175.2 (CO iBu), 169.9 (CO Pac), 156.4 (Cq Pac), 155.0 (C6), 147.0, 146.5 
(C2, C4), 138.9 (C8), 129.7, 122.6, 114.7 (Arom. Pac), 87.5 (C1’), 85.0 (C4’), 72.6 (C2’), 71.4 (C3’), 66.5 
(CH2 Pac), 61.9 (C5’), 33.7, 33.5 (CH iBu), 18.8, 18.7, 18.6, 18.5 (CH3 iBu). IR: 2974, 1684, 1608, 1558, 
1471, 1407, 1188, 1150, 1096. LCMS (10-90% B in 15 min), Rt = 7.94. ESI-MS: m/z 558.0 [M+H]+. 









Bz i. TBDMSCl, pyr., r.t.
ii. iBu2O, 16 h, r.t.









Pac i. TBDMSCl, pyr., r.t.
ii. iBu2O, 16 h, r.t.











To a stirred solution of 7 (0.89 g, 1.8 mmol), coevaporated with MeCN, in DCM (5 mL), containing 
distilled TEA (0.84 mL, 5.9 mmol), 2-cyanoethoxy-N,N-di-isopropylaminochlorophosphine (0.50 mL, 
2.25 mmol) was added under an argon atmosphere. The reaction mixture was stirred for 45 min at room 
temperature. After 31P-NMR showed complete consumption of the 2-cyanoethoxy-N,N-di-
isopropylaminochlorophosphine (80 MHz, CDCl3; δ 180.4) and formation of the phosphoramidite (80 
MHz, CDCl3; δ 150.3, 149.6), 30 mL DCM was added and the reaction mixture was washed with water 
and 5% NaHCO3. The organic phase was dried (MgSO4) and concentrated. The residue was applied on a 
pre-neutralized (1%TEA in PE) silica gel column and eluted with a gradient of EtOAc in PE (50/50 – 
100/0) to yield the title compound as an off-white foam. 1H-NMR (400 MHz, CDCl3); δ 8.18 (t, J = 7.8 
Hz 1H, H6), 7.94 – 7.76 (m, 2H, Bz), 7.44 - 7.32 (m, 3H, H5, Bz), 6.24 (d, J = 5.7 Hz, 1H, H1’), 6.17 (d, J 
= 4.5 Hz, 1H, H1’), 5.38 (dd, J = 5.1, 3.7 Hz, 1H, H2’), 5.33 - 5.28 (m, 1H, H3’,), 4.08 - 3.80 (m, 4H, H5’, 
CH2 CNEO), 3.69 - 3.62 (m, 2H, CH iPr), 2.76 - 2.69 (m, 2H, CH2 CNEO), 2.63 - 2.55 (m, 2H, CH iBu), 
1.27 - 1.14 (m, 24H, CH3 iBu, CH3 iPr). 13C-NMR (100 MHz, CDCl3); δ 175.6, 175.5, 175.3, 175.2 (CO 
iBu), 167.3 (C2), 162.7 (CO Bz), 154.6, 144.4, 144.3 (C6, C4), 133.6 (Cq Bz), 133.1, 128.7, 127.8 (Bz), 
117.7 (CN), 97.4 (C5), 87.6, 87.1 (C1’), 82.8, 82.7, 82.4, 82.3 (C4’), 74.1, 74.0 (C2’), 70.8, 70.5 (C3’), 
62.9, 62.7, 62.6, 62.4 (C5’), 58.8, 58.6, 58.4 (CH2 CNEO), 43.2, 43.2, 43.1, 43.0 (CH iPr), 33.69, 33.66, 
33.55(CH iBu), 24.7, 24.6, 24.5, 24.5 (CH3 iPr), 20.4, 20.3, 20.2 (CH2 CNEO), 19.0 (CH3 iBu).31P-NMR 
(161 MHz, CDCl3); δ 150.3, 149.6. IR: 2980, 1746, 1666, 1624, 1556, 1481, 1310, 1245, 1153. LCMS 
(10-90% B in 15 min), Rt = 6.80, ESI-MS: m/z 605.1 [M + H]+ of the corresponding H-Phosphonate. 
TLCMS: 688.5 [M + H]+. HRMS of the corresponding H-Phosphonate: [C27H33N4O10 + H]+ calcd. 
605.2007, found 605.2005. 
 
2-cyanoethoxy-N,N´-di-isopropylamino-(N6-benzoyl-2’,3’-di-O-isobutyryl-β-D-adenyl-5’- 





To a stirred solution of 8 (1.3 g, 2.6 mmol), coevaporated with MeCN, in DCM (15 mL), containing 
distilled TEA (1.2 mL, 8.5 mmol), 2- cyanoethoxy-N,N-di-isopropylaminochlorophosphine (0.7 mL, 3.2 
mmol) was added under an argon atmosphere. The reaction mixture was stirred for 45 min at room 
temperature. After 31P-NMR showed complete consumption of the 2-cyanoethoxy-N,N-di-
isopropylaminochlorophosphine (161 MHz, CDCl3; δ 180.4) and formation of the product (161 MHz, 
CDCl3; δ 150.0, 149.5), 30 mL DCM was added and the reaction mixture was washed with water and 5% 
NaHCO3. The organic phase was dried (MgSO4) and concentrated. The residue was applied on a pre-
neutralized (1%TEA in PE) silica gel column and eluted with a gradient of EtOAc in PE (50/50 – 100/0) 
to yield the title compound as an off-white foam (1.1 g, 1.6 mmol, 60%). 1H NMR (400 MHz, CDCl3) δ 
9.64 (s, 1H, NH), 8.75 (d, J = 4.1 Hz, 1H, H2), 8.53 (d, J = 8.1 Hz, 1H, H8), 8.02 (d, J = 7.3 Hz, 2H, 
Arom. Bz), 7.56 (t, J = 7.2 Hz, 1H, Arom. Bz), 7.47 (t, J = 7.3 Hz, 2H, Arom. Bz), 6.45, 6.40 (2x d, J = 
6.6 Hz, 1H, H1’), 6.00 - 5.79 (m, 1H, H2’), 5.76 - 5.50 (m, 1H, H3’), 4.42 (m, 1H, H4’), 4.09 - 3.77 (m, 
4H, H5’, CH2 CNEO), 3.74 - 3.56 (m, 2H, CH iPr), 2.79 - 2.43 (m, 4H, CH2 CNEO, CH iBu ), 1.31 - 1.00 
(m, 24H, CH3 iBu, CH3 iPr). 13C-NMR (100 MHz, CDCl3); δ 175.91, 175.86, 175.4, 175.3 (CO iBu), 
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128.8, 127.8 (Arom. Bz), 122.9 (C5), 117.7, 117.6 (CN), 85.4, 85.0 (C1’), 83.9, 83.8, 83.6, 83.5 (C4’), 
74.0, 73.9 (C2’), 72.0, 71.7 (C3’), 63.2, 63.0, 63.0, 62.8 (C5’), 58.8, 58.6, 58.4 (CH2 CNEO), 43.2, 43.1 
(CH iPr), 33.9, 33.8, 33.59, 33.57 (CH iBu), 24.7, 24.6 (CH3 iPr), 20.40, 20.36, 20.32, 20.29 (CH2 
CNEO), 18.9, 18.8, 18.7, 18.6 (CH3 iBu).31P-NMR (161 MHz, CDCl3); δ 150.0, 149.5. IR: 2968, 1746, 
1702, 1610, 1582, 1508, 1458, 1245, 1184, 1153. LCMS (10-90% B in 15 min), Rt = 7.37. ESI-MS: m/z 
629.1 [M + H]+ of the corresponding H-Phosphonate. TLCMS: 712.6 [M + H]+. HRMS: [C35H48N7O10P + 
H]+; 712.3218 calcd., 712.3229 found. 
 
2-cyanoethoxy-N,N´-di-isopropylamino-(N2-phenoxyacetyl-2’,3’-di-O-isobutyryl-β-D-guanyl 




To a stirred solution of 9 (0.94 g, 1.77 mmol), coevaporated with MeCN in DCM (10 mL), containing 
freshly distilled TEA (0.8 mL, 5.8 mmol), 2-cyanoethoxy-N,N-di-isopropylaminochlorophosphine (0.5 
mL, 2.2 mmol) was added under an argon atmosphere. The reaction mixture was subsequently stirred for 
45 min at room temperature. After 31P-NMR showed complete consumption of the 2-cyanoethoxy-N,N-
diisopropylaminochlorophosphine (80 MHz, CDCl3; δ 180.4) and formation of the phosphoramidite (31P-
NMR, 80 MHz: δ 150.0, 149.1), 20 mL DCM was added and the reaction mixture was washed with water 
and 5% NaHCO3. The organic phase was dried (MgSO4) and concentrated.The residue was applied on a 
pre-neutralized (1%TEA in PE) silica gel column and eluted with a gradient of EtOAc in PE (50/50 – 
100/0) to yield the title compound as an off-white foam (1.1 g, 1.4 mmol, 78%). 1H-NMR (400 MHz, 
CDCl3); δ 8.14 (s, 0.5 H, C2), 8.13 (s, 0.5 H, C2), 7.49 – 7.31 (m, 2H, Arom. Pac), 7.13 (t, J = 7.4 Hz, 1H, 
Arom. Pac), 7.08 – 6.94 (m, 2H, Arom. Pac), 6.11 (dd, J = 9.5, 6.1 Hz, 1H, H1’), 5.88 (dd, J = 10.5, 4.9 
Hz, 1H, H2’), 5.72 (td, J = 5.6, 3.4 Hz, 1H, H3’), 4.73 (s, 2H, CH2 Pac), 4.39 - 3.38, (m, 3H, H4’), 3.99 - 
3.80 (m, 4H, H5’, CH2 CNEO), 3.67 - 2.60 (m, 2H, CH iPr), 2.75 - 2.54 (m, 3H, CH iBu, CH2 CNEO), 
1.24 - 1.05 (m, 24H, CH3 iBu, CH3 iPr). 13C-NMR (100 MHz, CDCl3); δ 175.82, 175.76, 175.2, 175.1 (CO 
iBu), 169.6, 169.45 (CO Pac), 156.5, 156.4 (C6), 155.4 (Cq Pac), 148.0, 147.9 (C4), 146.4, 138.1, 137.7, 
130.02 (Arom. Pac), 129.97 (Arom. Pac), 123.05(Arom. Pac), 122.98 (Arom. Pac), 117.7, 114.9 (Arom. 
Pac), 85.7, 85.3 (C1’), 83.3, 83.2, 82.9, 82.8 (C4’), 73.44, 73.37 (C2’), 71.4, 71.3 (C3’), 67.0 (CH2 Pac), 
62.92, 62.85, 62.75, 62.67 (C5’), 58.7, 58.5, 58.3 (CH2 CNEO), 43.26, 43.21, 43.13, 43.08 (CH iPr), 33.8, 
33.6, (CH iBu), 24.71, 24.67, 24.64, 24.60 (CH3 iPr), 20.39, 20.35, 20.31 20.28 (CH2 CNEO), 18.91, 
18.87, 18.8, 18.6 (CH3 iBu).31P-NMR (161 MHz, CDCl3); δ 150.1, 149.7. IR: 2972, 1745, 1685, 1599, 
1560, 1497, 1388, 1364, 1183, 1154. LCMS (10-90% B in 15 min), Rt = 7.93. ESI-MS: m/z 674.9 [M+H]+ 
of the corresponding H-Phosphonate. TLCMS: 758.5 [M+H]+. HRMS: [C35H48N7O10P + H]+; 758.3273 










































Nα- Fmoc-tyrosine-allyl ester (0.33 g, 0.75 mmol) was added to compound 10 (0.50 g, 0.72 mmol) and the 
two compounds were coevaporated with MeCN and DCE and then dissolved in 1:1 v/v MeCN/DCM (5 
mL). Tetrazole (200 mg, 2.88 mmol) was added and the reaction mixture was stirred for 45 min until 31P-
NMR (161 MHz: δ 135.36, 134.91) showed complete consumption of the phosphoramidite. The reaction 
mixture was cooled to 0 oC and m-CPBA was added in portions until 31P-NMR showed complete 
consumption of the phosphite and formation of the phosphotriester (161 MHz: δ -6.17, -6.31). The 
reaction mixture was diluted in 20 mL DCM and washed with 5% Na2S2O3 and water. The organic phase 
was dried (MgSO4) and concentrated. The residue was applied to a silica gel column and eluted with a 
gradient of EtOAc in PE (50/50 – 100/0) to yield the title compound as a colourless oil in 74 % (0.55 g, 
0.53 mmol). 1H-NMR (400 MHz, CDCl3); δ 8.18 - 7.06 (m, 18H, H6, Arom. Fmoc, Arom. Bz, Arom. 
Tyr.), 6.39 (d, J = 8.2 Hz, 0.5H, H1’), 6.30 (d, J = 8.2 Hz, 0.5H, H1’), 6.19 (d, J = 6.5 Hz, 1H, H5), 6.10 - 
5.79 (m, 1H, CH Allyl), 5.73 (d, J = 8.2 Hz, 0.5H, NH), 5.57 (d, J = 8.2 Hz, 0.5H, NH),), 5.41 - 5.18 (m, 
4H, H3’, H2’, CH2 Allyl), 4.74 (m, 1H, CH α), 4.40 - 4.26 (m, 10H, H4’, H5’, CH2 Fmoc, CH2 Allyl, CH2 
CNEO, CH Fmoc), 3.16 - 3.06 (m, 2H, CH2 β), 2.59 - 2.55 (m, 2H, CH2 CNEO), 2.61 - 2.53 (m, 2H, CH 
iBu), 1.21 - 1.14 (m, 12H, CH3 iBu). 13C-NMR (100 MHz, CDCl3); δ 175.62, 175.55, 175.4 (CO iBu), 
171.2 (CO α), 167.2 (C2), 163.1, 163.0 (CO Bz), 155.9, 155.8 (CO Fmoc), 154.8 (C6), 149.1, 149.0 (Cq 
Arom. Tyr.), 144.6, 144.3 (C4), 143.8, 143.7, 141.2 (Cq Fmoc), 134.3, 134.1 (Cq Arom. Tyr.), 133.03, 
132.99 (Bz), 132.7 (Cq Bz), 131.5 (CH Allyl), 131.0 (Arom. Tyr.), 128.7 (Bz), 128.0 (Arom. Fmoc), 127.7 
(Bz), 127.0, 125.1 (Arom. Fmoc), 119.9 (Arom. Fmoc, Arom. Tyr.), 118.9 (CH2 Allyl), 116.7 (CN), 97.7 
(C5), 89.5, 88.9 (C1’), 80.8, 80.7 (C4’), 73.5 (C2’), 69.63, 69.55 (C3’), 67.1, 66.9, 66.0 (CH2 Fmoc, CH2 
Allyl, C5’), 63.3, 63.2 (CH2 CNEO), 55.0 (CH α), 47.0, 46.4 (CH Fmoc), 37.1 (CH2 β), 33.7 (CH iBu), 
19.62, 19.55 (CH2 CNEO), 18.80, 18.78, 18.75, 18.68 (CH3 iBu). 31P-NMR (161 MHz, CDCl3); δ -5.86, - 
5.89. IR: 2980, 1740, 1700, 1668, 1626, 1556, 1506, 1481, 1250, 1188, 1036. LCMS (50 – 90 % B in 15 
min), Rt = 6.26. ESI-MS: m/z 1046.5 [M+H]+. HRMS: [C54H56N5O15P + H]+; calcd. 1046.3583, found 
1046.3593. 
 







Nα-Fmoc-tyrosine-allyl ester (0.26 g, 0.58 mmol) was added to amidite 11 (0.40 g, 0.58 mmol) and the two 
compounds were coevaporated with MeCN and DCE and then dissolved in 1:1 v/v MeCN/DCM (10 mL). 
Tetrazole (0.12 g, 1.74 mmol) was added and the reaction mixture was stirred for 45 minutes until 31P-
NMR (161 MHz: δ 135.36, 134.91) showed complete consumption of the phosphoramidite (161 MHz, 
CDCl3; δ 150.31, 148.83). The reaction mixture was cooled to 0 oC and m-CPBA was added in portions 
until 31P-NMR (161 MHz: δ -6.17, -6.31) showed complete consumption of the phosphite. The reaction 
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mixture was diluted in DCM and washed with 5% Na2S2O3 and water. The organic phase was dried 
(MgSO4) and concentrated. The residue was applied to a silica gel column and eluted with a gradient of 
EtOAc in PE (50/50 – 100/0) to yield the title compound as a colourless oil (0.39 g, 0.37 mmol, 64%) 1H-
NMR (400 MHz, CDCl3); δ 9.30, 9.28 (m, 1H, H2), 8.78 (2x s, 1H, H8), 7.95 - 6.89 (m, 17H), 6.53 (d, J = 
8.0 Hz, 1H, NH), 6.37 - 6.33 (m, 1H, H1’), 5.92 - 5.68 (m, 1H, CH Allyl, H3’), 5.54 - 5.51 (m, 1H, H2’), 
5.28 - 5.15 (m, 2H, CH2 Allyl), 4.65 - 4.60 (m, 1H, CH α), 4.56 - 4.32 (m, 9H, C4’, C5’, CH2 Fmoc, CH2 
Allyl, CH2 CNEO), 4.27 - 3.98 (m, 1H, CH Fmoc), 3.12 - 3.03 (m, 2H, CH2 β), 2.92 - 2.88 (m, 2H, CH2 
CNEO), 2.82 - 2.47 (m, 2H, CH iBu), 1.26 - 1.04 (m, 12H, CH3 iBu). 13C-NMR (100 MHz, CDCl3); δ 
175.7, 175.5, 175.2, 175.0 (CO iBu), 171.0, 170.8 (CO α), 165.0, 164.8 (CO Bz), 155.6 (CO Fmoc), 152.7 
(C2), 151.3, 151.1 (C4, C6), 149.5, 148.8 (Cq Tyr.), 143.6, 143.2, 141.22, 141.15, 140.9, 140.5 (Cq 
Fmoc), 139.6 (C8), 134.0, 133.6, 133.4, 133.2 (Cq Arom. Tyr.), 132.3 – 123.9 (Arom.), 122.7, 122.0 
(C5),119.9 (Arom.) 119.1 (CH2 Allyl), 116.1 (CN), 85.9, 85.5 (C1’), 81.7, 81.6, 81.44, 81.36 (C4’), 73.5, 
73.1 (C2’), 70.3, 70.2 (C3’), 67.1, 66.0, 65.9, 65.3 (CH2 Fmoc, CH2 Allyl, CH2 CNEO), 62.9 (C5’), 54.4, 
54.0 (CH α), 47.0, 46.9 (CH Fmoc), 36.6, 36.2 (CH2 β), 33.6, 33.4 (CH iBu), 19.5, 19.4 (CH2 CNEO), 
18.8, 18.7, 18.5 (CH3 iBu). 31P-NMR (161 MHz, CDCl3); δ -6.97, 6.98. IR: 2976, 1738, 1699, 1608, 1583, 
1505, 1456, 1247, 1189, 1155, 1029, 961. LCMS (50 – 90 % B in 15 min), Rt = 10.25. ESI-MS: m/z 
1070.2 [M+H]+. HRMS: [C55H56N7O14P + H]+; 1070.3695 calcd., 1070.3706 found. 
 
2-cyanoethoxy-(Nα-Fmoc-tyrosin-4-yl-allyl ester)-(N2-phenoxyacetyl-2’,3’-di-O-isobutyryl-β-D- 








Nα-Fmoc-tyrosine-allyl ester (0.78 g, 1.77 mmol) was added to amidite 12 (1.0 eq., 1.77 mmol) and the 
two compounds were coevaporated with MeCN and DCE and then dissolved in 1:1 MeCN/DCM (10 mL, 
v/v). Tetrazole (295 mg, 4.2 mmol) was added and the reaction mixture was stirred for 45 minutes until 31P 
NMR showed complete consumption of the phosphoramidite (31P-NMR, 161 MHz: δ 134.18, 134.06). The 
reaction mixture was cooled to 0 oC and m-CPBA was added in portions until 31P NMR showed complete 
oxidation of the phospite (31P-NMR, 161 MHz: δ -6.56, -6.98). The reaction mixture was diluted in 20 mL 
DCM and washed with 5% Na2S2O3 and water. The organic phase was dried (MgSO4) and concentrated. 
The residue was applied to a silica gel using a gradient of EtOAc in PE (50/50 – 70/30) to yield the 
separate epimers at phosphorus as white foams, 233 mg (0.21 mmol, 12 %) (Rt = 0.5, EtOAc) and 476 mg 
(0.47 mmol, 27 %) (Rt = 0.6, EtOAc) of which analytical samples were repurified using silica gel column 
chromatography using a gradient of 2 % MeOH in DCM, and a mix of both epimers (0.43 g, 0.38 mmol, 
24 %) respectively. A total of 1.14 g, 1.0 mmol, 56 %.  
 
epimer A (Rt = 0.6), (93:7 epimeric ration). 1H-NMR (400 MHz, CDCl3); δ 11.74, 10.33 (2 x s, 1H, NH 
H1, NH H2), 7.77 (s, 1H, H8), 7.76 – 7.71 (m, 2H, Arom.), 7.56 – 7.53 (m, 2H, Arom.), 7.37 – 7.33 (m, 
2H, Arom.), 7.31 - 7.24 (m, 4H, Arom.), 7.01 - 6.95 (m, 6H, Arom.), 6.12 - 6.09 (m, 1H, H2’), 5.97 – 5.95 
(m, 2H, H1’), 5.89 - 5.78 (m, 2H, CH Allyl, H3’), 5.26 (m, 2H, CH2 Allyl), 4.60 - 4.52 (m, 7H, CH2 Allyl, 
CH2 Fmoc, H5’, Hα), 4.43 (s, 1 H, H4’), 4.36 - 4.23 (m, 2H, CH2 CNEO), 4.19 – 4.15 (m, 1H, CH Fmoc), 
3.12 - 2.97 (m, 2H, CH2 β), 2.73 - 2.60 (m, 2H, CH2 CNEO), 2.56 - 2.49 (m, 2H, CH iBu), 1.22 – 1.10 (m, 
12H, CH3 iBu). 13C-NMR (100 MHz, CDCl3); δ 175.6, 175.1 (CO iBu), 170.8, 170.1 (CO Pac, CO α), 
156.9, 155.5 (Cq Pac, C6), 155.0 (CO Fmoc), 148.4, 148.3 (Cq Tyr.), 147.4, 146.5 (C4, C2), 143.6, 140.9 
(Cq Fmoc), 134.0 (Cq Tyr), 131.2 (CH Allyl), 130.3 (Arom. Tyr.), 129.4 (Arom. Pac), 127.4, 126.8, 124.9 
(Arom. Fmoc), 122.6, 121.9 (C5), 119.8 , 119.7, 119.6, (Arom. Fmoc, Arom. Tyr.), 118.8 (CH2 Allyl), 
























116.1 (CN), 114.6 (Arom. Pac), 87.0 (C1’), 81.0, 80.9 (C4’), 71.2 (C2’), 70.0 (C3’), 67.0, 66.63, 66.60 
(CH2 Fmoc, CH2 Pac, C5’), 65.8 (CH2 Allyl), 62.8, 62.7 (CH2 CNEO), 54.6 (CH α), 46.8 (CH Fmoc), 36.8 
(CH2 β), 33.5, 33.3 (CH iBu), 19.3, 19.2 (CH2 CNEO), 18.9, 18.6, 18.5, 18.4, 18.3 (CH3 iBu). 31P-NMR 
(161 MHz, CDCl3); δ - 6.94. IR: 2970, 1695, 1610, 1558, 1539, 1497, 1472, 1448, 1188, 1153, 1041. 
LCMS (50 - 90% B in 15 min), Rt = 7.56 ESI-MS: m/z 1116.6 [M+H]+. αD (CHCl3): -17.4. HRMS: 
C56H58N7O16P + H]+ calcd. 1116.3750, found 1116.3765.  
 
epimer B (Rt = 0.5), (96:4 epimer ration). 1H-NMR (400 MHz, CDCl3); δ 11.84, 10.42 (2 x s, 1H, NH α, 
NH H2), 7.75 - 7.73 (m, 3H, Arom.), 7.57 (m, 2H, Arom.), 7.39 - 7.35 (m, 2H, Arom.), 7.29 - 7.25 (m, 4H, 
Arom.), 7.09 - 6.97 (m, 6H, Arom.), 6.01 - 5.95 (m, 2H, H1’, H2’), 5.93 - 5.82 (m, 1H, CH Allyl), 5.79 - 
5.76 (m, 1H, H3’), 5.33 - 5.23 (m, 2H, CH2 Allyl), 4.69 - 4.68 (m, 2H, CH2 Pac), 4.64 - 4.60 (m, 3H, CHα, 
CH2 Allyl), 4.49 – 4.47 (m, 2H, CH2 Fmoc), 4.38 - 4.23 (m, 2H, H4’, H5’), 4.21 - 4.15 (m, 3H, CH Fmoc, 
CH2 CNEO), 3.16 - 3.06 (m, 2H, CH2 β), 2.65 - 2.49 (m, 4H, CH iBu, CH2 CNEO), 1.20 – 1.09 (m, 12H, 
CH3 iBu). 13C-NMR (100 MHz, CDCl3); δ 175.6, 175.1 (CO iBu), 170.7, 170.1 (CO Pac, CO α), 156.9, 
155.5 (Cq Pac, C6), 155.0 (CO Fmoc), 148.4, 148.3 (Cq Tyr.), 147.4, 146.5 (C4, C2), 143.6, 140.9 (Cq 
Fmoc), 134.0 (Cq Tyr),, 131.2, 130.3 (CH Allyl), 129.4, 127.4, 126.8, 124.9 (Arom.), 122.6 (C5), 122.0, 
119.7, 119.6 (Arom.), 118.8 (CH2 Allyl), 116.1, 114.6 (CN), 87.0 (C1’), 81.0, 80.9 (C4’), 71.2 (C2’), 69.9 
(C3’), 67.0, 66.6, 66.4, 65.8, 65.87 (CH2 Allyl, C5’, CH2 Fmoc, CH2 Pac), 62.8, 62.7 (CH2 CNEO), 54.6 
(CH α), 46.8 (CH Fmoc), 36.8 (CH2 β), 33.5, 33.3 (CH iBu), 19.3, 19.2 (CH2 CNEO), 18.9, 18.6, 18.5 18.4 
(CH3 iBu). 31P-NMR (161 MHz, CDCl3); δ -7.3. IR: 2970, 1695, 1610, 1558, 1539, 1497, 1471, 1450, 
1387, 1190, 1153, 1033. LCMS (50 -90% B in 15 min), Rt = 7.61 ESI-MS: m/z 1116.5 [M+H]+. αD 












Compound 13 (0.55 g, 0.53 mmol) was coevaporated with MeCN and dissolved in 1:1 THF/DCM (10 mL, 
v/v). After addition of AcOH (2.6 mmol, 0.15 mL), Bu3SnH (1.05 mmol, 0.32 mL) and Pd(PPh3)4 (0.02 
mmol, 20 mg) the reaction was stirred for 2 hours. The reaction mixture was concentrated and the residue 
was applied to a silica gel column and eluted with a gradient of MeOH in DCM (0/100 – 5/95) to yield the 
title compound as a white foam (0.30 g, 0.29 mmol, 56 %). 1H-NMR (400 MHz, CDCl3); δ 7.92 - 7.87, 
7.75 - 7.73, 7.54 - 7.47, 7.39 - 7.35, 7.29 - 7.25, 7.21 - 7.14 (m, 17H, H6, H5, Arom.), 6.07 (m, 1H, C1’), 
5.72 (m, 1H, NH), 5.46 - 5.42 (m, 2H, C3’, C2’), 4.70 (m, 1H, CH α), 4.48 - 4.43 (m, 2H, CH2 Fmoc), 
4.33 - 4.31 (m, 3H, C4’, C5’), 4.30 - 4.23 (m, 2H, CH2 CNEO), 4.13 (m, 1H, CH Fmoc), 3.18 - 3.11 (m, 
2H, CH2 β), 2.75 - 2.63 (m, 2H, CH2 CNEO), 2.62 - 2.58 (m, 2H, CH iBu), 1.17 – 1.14 (m, 12H, CH3 iBu). 
13C-NMR (100 MHz, CDCl3); δ 175.50, 175.46, 175.4 (CO iBu), 174.3 (CO α), 167.2 (C2), 163.2,163.1 
(CO Bz), 155.6 (CO Fmoc), 154.3 (C4), 148.8, 148.7 (Cq Arom. Tyr.), 145.0 (C6), 143.7, 143.6, 141.0 
(Cq Arom. Fmoc.), 134.0 (Cq Tyr.), 133.0 (Bz), 132.48 (Cq Bz), 131.0 (Arom. Tyr.), 128.50 (Bz), 128.0 
(Arom. Fmoc), 127.5 (Bz), 126.9, 125.0, 124.9 (Arom. Fmoc), 119.8, 119.6 (Arom. Fmoc, Arom. Tyr.), 
116.3 (CN), 97.6 (C5), 89.8, 89.29 (C1’), 80.7, 80.6 (C4’), 73.4 (C2’), 69.4, 69.3 (C3’), 66.95, 66.86, 
66.68 (CH2 Fmoc, C5’), 63.02, 62.97 (CH2 CNEO), 54.6 (Cα), 46.9 (CH Fmoc), 37.0 (Cβ), 33.5(CH iBu), 






















THF/DCM, 2 h, r.t
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1668, 1624, 1558, 1481, 1450, 1249. LCMS (10 – 90 % B in 15 min) Rt = 9.06. ESI-MS: m/z 1006.7 
[M+H]+. HRMS: [C51H52N5O15P + H]+; calcd. 1006.3270, found 1006.3281. 
 
2-cyanoethoxy-(Nα- Fmoc-tyrosin-4-yl)-(N6-benzoyl-2’,3’-di-O-isobutyryl-β-D-adenyl-5’- 










Compound 14 (0.39 g, 0.37 mmol) was coevaporated with MeCN and dissolved in 1:1 THF/DCM (10 mL, 
v/v). After addition of AcOH (1.7 mmol, 0.10 mL), Bu3SnH (0.74 mmol, 0.21 mL) and Pd(PPh3)4 (0.015 
mmol, 18 mg) the reaction was stirred for 2 hours. The reaction mixture was concentrated and the residue 
was applied to a silica gel column and eluted with a gradient of MeOH in DCM (0/100 – 5/95) to yield the 
title compound as a white foam (0.32 g, 0.31 mmol, 85 %). 1H-NMR (400 MHz, CDCl3); δ 8.78 (2x s, 1H, 
H8), 8.12, 7.86 (2x s, 1H, H2), 7.98 - 6.89 (m, 17H), 6.43, 6.38 (2x d, J = 7.2 Hz, 1H, H1’), 5.97, 5.95 (d, 
J = 7.6 Hz, 1H, NH), 5.75 - 5.59 (m, 2H, C3’, C2’), 4.52 - 4.36 (m, 7H, CH2 Fmoc, CH α, C4’, CH2 
CNEO, CH Fmoc), 4.17 - 4.15 (m, 2H, H5’), 3.27 - 3.21 (m, 2H, CH2 β), 2.98 - 2.92 (m, 2H, CH2 CNEO), 
2.72 - 2.48 (2x m, 2H, CH iBu), 1.29 - 1.06 (m, 12H, CH3 iBu). 13C-NMR (100 MHz, CDCl3); δ 175.5, 
175.3 (CO iBu), 174.4, 174.0 (CO α), 165.7 (CO Bz), 155.4 (CO Fmoc), 153.1 (C2), 151.6 (Cq Arom. 
Tyr.), 149.8 (C6), 149.0 (C4), 143.75, 143.68, 143.61, 141.2 (Cq Arom. Fmoc.), 140.4 (C8), 134.0 (Cq 
Tyr.), 133.5 (Cq Bz), 132.7 (Arom. Bz), 131.2, 131.0 (Arom. Tyr.), 128.5, 128.5 (Arom. Bz), 128.2, 128.2 
(Arom. Fmoc), 127.7, 127.6 (Arom. Bz), 127.0, 125.0, 125.0, 124.9, 124.7 (Arom. Fmoc), 122.0, 121.8 
(C5), 119.9, 119.9, 119.7 (Arom. Fmoc, Arom. Tyr.), 116.2, 116.1 (CN), 85.2, 84.8 (C1’), 82.0, 81.9 
(C4’), 73.6, 73.3 (C2’), 70.4, 70.0 (C3’), 67.6, 67.1, 66.6, 66.4 (CH2 Fmoc, CH2 CNEO), 63.0, 63.0, 62.8, 
62.8 (C5’), 55.0, 54.8 (CH α), 47.2 (CH Fmoc), 38.3, 37.9 (CH2 β), 33.79, 33.77, 33.56, 33.53 (CH iBu), 
19.7, 19.6 (CH2 CNEO), 18.9, 18.8, 18.7, 18.6, 18.60, 18.57 (CH3 iBu). 31P-NMR (161 MHz, CDCl3); δ -
6.8, -7.1. IR: 2976, 2360, 1738, 1714, 1700, 1584, 1505, 1455, 1247, 1155, 1032. LCMS (10 – 90 % B in 













A mixture epimers of 15 (0.43 g, 0.38 mmol) was coevaporated with MeCN and dissolved in 1:1 v/v 
THF/DCM (10 mL). After addition of AcOH (2.0 mmol, 0.11 mL), Bu3SnH (0.36 mL, 0.76 mmol) and 
Pd(PPh3)4 (0.02 mmol, 20 mg) the reaction was stirred for 2 hours. The reaction mixture was concentrated 
and the residue was applied to a silica gel column and eluted with a gradient of MeOH in DCM (0/100 – 
















































NMR (400 MHz, CDCl3); δ 7.88 (s, 1H, H8), 7.75 - 6.99 (m, 2H, Arom.), 7.59 - 7.57 (m, 2H, Arom), 7.39 
- 7.35 (m, 2H, Arom), 7.31 - 7.27 (m, 4H, Arom), 7.13 (m, 2H, Arom), 7.04 - 6.99 (m, 5H, Arom), 6.00 – 
5.92 (m, 2H, H1’, H3’), 5.88 - 5.85 (m, 1H, H2’), 4.68 (m, 2H, CH2 Pac), 4.48 - 4.17 (m, 9H, CH α, CH2 
Fmoc, H4’, H5’, CH Fmoc, CH2 CNEO), 3.15 (m, 1H, CH2 β), 2.67 - 2.55 (m, 4H, CH iBu, CH2 CNEO), 
1.27 - 1.10 (m, 12H, CH3 iBu). 13C-NMR (100 MHz, CDCl3); δ 176.2, 175.9, 175.5 (CO iBu), 174.0 (CO 
Pac), 170.3 (CO α), 156.8 (Cq Pac), 155.37, 155.36 (C6, CO Fmoc), 148.9, 148.8, 148.5 (Cq Tyr.), 147.8 
(C4), 146.9 (C8), 143.9, 143.8, 141.3 (Cq Fmoc), 134.2 (Cq Tyr.), 131.2 (Arom. Tyr.), 129.8 (Arom. Pac), 
127.7, 127.1, 125.2 (Arom. Fmoc), 122.6 (C5), 121.6 (Arom. Pac), 119.9, 119.7 (Arom. Fmoc, Arom. 
Tyr.), 116.6 (CN), 114.9 (Arom. Pac), 87.0 (C1’), 80.9, 80.8 (C4’), 72.5 (C2’), 69.8 (C3’), 67.1, 66.9, 66.8 
(C5’, CH2 PAC, CH2 Fmoc), 63.1, 63.03 (CH2 CNEO), 54.9 (CH α), 47.2 (CH Fmoc), 37.1 (CH2 β), 33.8, 
33.7 (CH iBu), 19.5, 19.4 (CH2 CNEO), 18.9, 18.84, 18.81, 18.7 (CH3 iBu).31P-NMR (161 MHz, CDCl3); δ 
-7.0, -7.1. IR: 2951, 1686, 1574, 1560, 1412, 1248, 1209, 1153, 1070. LCMS (10-90% B in 15 min), Rt = 




The crude protected nucleopeptide was cleaved off the resin using TFA/TIS/H2O (95/5/5, v/v/v, 5 mL) by 
shaking for 2.5 hours. After filtration into cold Et2O the precipitate was coevaporated with toluene (2 x 5 
mL) and then treated with 25% aq. ammonia (2.5 mL) in 1,4-dioxane (2.5 mL). After stirring for 4 hours, 
concentration of the reaction mixture afforded the crude title compound. RP-HPLC purification was 
conducted on an automated HPLC system supplied with a semi-preparative C18 column (250 x 10.00 mm, 
5 μM, flow: 4 mL/min). The applied eluent system was; A: H2O, B: MeCN, C: 0,5 % TFA and detection at 
280 nm. Gradient: 10 - 25 % B in 3 CV. The collected fractions were lyophilized, yielding 14.89 mg, 5.6 
μmol (45 % based on original loading of resin) of the nucleopeptide. 31P-NMR (161 MHz, D2O); δ - 4.24. 
LCMS (00 – 90 % B in 15 min.), Rt = 4.18 min. ESI-MS: m/z 2659.2 [M]+, 1330.4 [M]2+, 887.6 [M]3+. 
HRMS: [C114H189N34O37P + H]2+ calcd. 1329.6918, found 1329.6937, [M + H]3+ calcd. 886.7970, found 
886.7981, [M + H]4+ calcd. 665.3495, found 665.3497, [M + H]5+ calcd. 532.4811, found 532.4807. 1H- 
NMR (600 MHz, D2O) δ 7.97 (d, J = 8.0 Hz, 1H), 7.20 (d, J = 8.4 Hz, 2H), 7.10 (d, J = 8.1 Hz, 2H), 6.02 
(d, J = 7.9 Hz, 1H), 5.90 (d, J = 3.9 Hz, 1H), 4.67 (ap. dd, J = 15.2, 7.9 Hz, 1H), 4.61 (ap. dd, J = 12.8, 5.9 
Hz, 1H), 4.57 (ap. dd, J = 8.6, 5.4 Hz, 1H), 4.51 - 4.37 (m, 5H), 4.37 - 4.20 (m, 14H), 4.21 - 4.05 (m, 7H), 
3.97 - 3.77 (m, 8H), 3.70 (ap. dd, J = 16.8, 7.0 Hz, 1H), 3.64 (ap. dd, J = 16.3, 6.8 Hz, 2H), 2.35 (ap. t, J = 
7.6 Hz, 3H), 2.30 - 2.25 (m, 4H), 2.17 - 1.93 (m, 14H), 1.93 - 1.40 (m, 43H), 1.37 (ap. d, J = 7.2 Hz, 7H), 




The crude partially protected nucleopeptide was cleaved of the resin using TFA/TIS/H2O (95/5/5, v/v/v, 5 
mL) by shaking for 4 hours. After filtration into cold Et2O the precipitate was concentrated and RP-HPLC 
purification was conducted on an automated HPLC system supplied with a semi-preparative C18 column 
(250 x 10.00 mm, 5 μ, flow: 4 mL/min). The applied eluent system was; A: 0,5 % TFA in H2O, B: MeCN, 
Gradient: 20- 50 % B in 3 CV and detection at 280 nm. to give partially protected 21. This nucleopeptide 
was then treated with 25% aq. ammonia (1.25 mL) in 1,4-dioxane (1.25 mL). After stirring for 5 hours 
careful concentration of the reaction mixture afforded the crude title compound. RP-HPLC purification 
was conducted on an automated HPLC system supplied with a semi-preparative C18 column (250 x 10.00 
mm, 5 μM, flow: 4 mL/min). The applied eluens system was; A: 0,5 % TFA in H2O, B: MeCN and 
detection at 280 nm. Gradient: 10- 25 % B in 3 CV. The collected fractions were lyophilized, yielding the 
target nucleopeptide 21; 6.1 mg, 2.3 μmol (9% based on initial loading of the resin). 31P-NMR (161 MHz, 
D2O); δ - 4.21. LCMS (00 – 90 % B in 15 min.), Rt = 4.18 min. ESI-MS: m/z 1345.0 [M]2+, 896.6 [M]3+, 
672.7[M]4+. HRMS: [C115H189N36O36P + H]2+ calcd. 1341.6974, found 1341.6949, [M + H]3+ calcd. 
894.8007, found 894.8008, [M + H]4+ calcd. 671.3524, found 671.3532, [M + H]5+ calcd. 537.2833, found 
537.2839. 1H NMR (400 MHz, D2O) δ 8.36 (s, 1H), 8.33 (s, 1H), 6.96 (q, J = 8.8 Hz, 4H), 6.13 (d, J = 5.6 
Hz, 1H), 4.70 - 4.56 (m, 1H), 4.56 - 4.39 (m, 4H), 4.39 - 4.27 (m, 6H), 4.27 - 4.08 (m, 5H), 4.02 - 3.78 (m, 
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5H), 3.78 - 3.71 (m, 1H), 3.67 (ap. d, J = 7.6 Hz, 2H), 3.22 (ap. t, J = 6.9 Hz, 2H), 3.13 - 2.95 (m, 6H), 
2.95 - 2.67 (m, 4H), 2.41 - 2.22 (m, 4H), 2.09 - 2.07 (m, 8H), 1.97 - 1.45 (m, 22H), 1.41 (ap. d, J = 7.1 Hz, 
4H), 1.29 (ap. d, J = 7.2 Hz, 3H), 1.23 (ap. dd, J = 6.3, 3.2 Hz, 5H), 1.19 (ap. d, J = 6.4 Hz, 3H), 1.04 - 




The crude partially protected nucleopeptide was cleaved of the resin using TFA/TIS/H2O (95/5/5, v/v/v, 5 
mL) by shaking for 2.5 hours. After filtration into cold Et2O the precipitate was coevaporated with toluene 
(2 x 5 mL) and then treated with 25% aq. ammonia (1.25 mL) in 1,4-dioxane (1.25 mL). After stirring for 
5 hours careful concentration of the reaction mixture afforded the crude title compound. RP-HPLC 
purification was conducted on an automated HPLC system supplied with a semi-preparative C18 column 
(250 x 10.00 mm, 5 μM, flow: 4 mL/min). The applied eluent system was; A: H2O, B: MeCN, C: 0,5 % 
TFA in H2O, in a gradient of 10- 30 % B (10% C as stationary phase) in 3 CV and detection at 280 nm 
The collected fractions were lyophilized, yielding the target nucleopeptide 22; 9.8 mg, 3.6 μmol (29% 
based on initial loading of the resin).31P-NMR (161 MHz, D2O); δ - 4.21. LCMS (00 – 90% B in 5 min.), 
Rt = 4.21 min., ESI-MS: m/z 2700.2 [M + H]+, 1350.2[M+H]2+, 900.6 [M+H]3+. HRMS: [C115H189N36O37P + 
H]2+ calcd. 1349.6948, found 1349.6952, [M + H]3+ calcd. 900.1323, found 900.1327, [M + H]4+ calcd. 
675.3511, found 675.3508, [M + H]5+ calcd. 540.4823, found 540.4816. 1H-NMR (600 MHz, D2O) δ 7.85 
(s, 1H), 7.08 - 6.84 (m, 4H), 5.86 (d, J = 5.9 Hz, 1H), 4.90 (ap. t, J = 5.6 Hz, 1H), 4.66 (ap. t, J = 7.1 Hz, 
1H), 4.63 - 4.59 (m, 2H), 4.57 (ap. d, J = 11.2 Hz, 1H), 4.50 - 4.37 (m, 9H), 4.37 - 4.26 (m, 13H), 4.26 - 
4.08 (m, 15H), 3.91 (ap. d, J = 13.7 Hz, 3H), 3.89 - 3.79 (m, 5H), 3.77 (ap. d, J = 3.6 Hz, 3H), 3.70 (ap. d, 
J = 7.7 Hz, 2H), 3.64 (s, 4H), 3.19 (ap. t, J = 6.0 Hz, 5H), 3.09 - 2.92 (m, 15H), 2.89 (ap. dd, J = 13.8, 8.9 
Hz, 2H), 2.83 - 2.62 (m, 8H), 2.38 - 2.20 (m, 11H), 2.13 - 1.39 (m, 92H), 1.37 (ap. d, J = 7.2 Hz, 10H), 
1.27 (ap. d, J = 7.2 Hz, 7H), 1.21 - 1.11 (m, 23H), 0.95 (ap. dd, J = 13.3, 6.8 Hz, 23H), 0.90 (ap. dd, J = 
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The synthesis of fragments of nucleoproteins is far more challenging than synthesis of the 
individual nucleic acid or peptide components. Although excellent protocols for (automated) 
synthesis of peptides and nucleic acids are available, the synthesis of nucleopeptides asks for 
the development of a new approach, in which the integrity of the peptide, the nucleic acid and 
the connecting phosphodiester linkage is kept intact. Not all protective groups used in nucleic 
acid and peptide chemistry can be used for nucleopeptide synthesis. Basic conditions 
commonly used in nucleic acid synthesis can cause β-elimination in serine or threonine 
containing nucleopeptides and cleave the crucial phosphodiester linkage between the nucleic 
acid and peptide part.1 Strongly acidic conditions commonly used in peptide chemistry on the 
other hand can give rise to side reactions in the nucleic acid portion of nucleopeptides, such as 
depurination in the case of DNA2 and phosphate migration in RNA.3 Synthetic routes towards 
DNA-nucleopeptides have been extensively explored4, while the more challenging RNA-
nucleopeptides have received less attention. Nucleopeptides, containing a short RNA fragment, 
have been synthetically obtained and have proven to be useful tools in the study, of for instance, 
viral replication pathways.5,6 To gain further insight in the reaction mechanism and structure of 
the proteins involved in these pathways, availability of nucleopeptides carrying longer RNA 
fragments can be very helpful.  
 
Block-coupling strategies in which the final coupling is executed in solution (see Figure 1A) 
have been reported to give access to RNA-nucleopeptides carrying one or two uridylyl 
groups.7,8 In such an approach the phosphoramidite of dinucleotide 2 is coupled to a short resin 
bound peptide 1 and subsequently oxidized to give the desired phosphotriester bond. After 
deprotection and release from the support the nucleopeptide fragment 3 can be condensed with 
another separately prepared peptide fragment 5 to give the desired full length VPgpUpU 
nucleoprotein 6. No successful block-coupling synthesis of nucleopeptides containing 





Another approach involves the synthesis of an oligonucleotide on solid support and the 
subsequent coupling of a separately prepared peptide fragment (see Figure 1B). It has been 
established that coupling of peptidyl phosphoramidite 8 to a RNA fragment anchored on a solid 
support (7) is a viable way to obtain nucleopeptide 9. To date several nucleopeptides have been 
prepared using this methodology.9-12 Peptide sequences having more than 2 amino acids 
attached to a 7-mer RNA fragment have not been reported, due to the limited reactivity of 
peptidyl phosphoramidites.  
An approach in which both peptide and nucleic acid are stepwise elongated on the same solid 
support would be ideal. An example of such an approach starts with the construction of a 
peptide on solid support (11) followed by the construction of the oligonucleotide onto this 
immobilized peptide (12) (see Figure 1C). Final cleavage of the protective groups and release 
from the resin results in the nucleopeptide 13. This approach has been reported to be successful 
for the synthesis of 3’-end linked DNA-nucleopeptide fragments.4 Examples of 5’-end linked 
DNA-nucleopeptides however are scarce13-15 and both 3’-end linked and 5’-end linked RNA-
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Results and Discussion 
The poliovirus VPg protein is a 22 amino acid protein in which tyrosine-3 is linked to the 5’-
end of the viral (+)-strand RNA genome. It has been shown that VPg nucleopeptides containing 
one or two uridylyl moieties act as primers in viral replication pathways. Research on these 
replication processes benefits from well-defined VPg nucleopeptide fragments. Such fragments 
cannot be isolated from natural sources and must be prepared by synthetic procedures. In 
Chapter 5 and Chapter 6 the synthesis of mono-nucleotidylated VPg proteins is described and 
the synthesis of VPg proteins carrying two uridylyl moieties has been reported earlier.8 
However, the assembly of VPg derived peptides carrying longer RNA fragments is not yet 
published. This chapter describes a study toward the synthesis of a dipeptidyl 
nonaribonucleotide 14, a pentapeptidyl tetraribonucleotide 15 and a pentapeptidyl 




In an earlier report the poliovirus derived RNA-nucleopeptide H-Ala-Tyr[5’-pUUAAAAC-3’]-
NH2 has been prepared using the methodology depicted in Figure 1B.9 A similar approach was 
selected to gain access to the VPg nucleoprotein derived H-Ala-Tyr[5’-pUUAAAACAG-3’]-
OH fragment14. In the reported example the RNA fragment was equipped with silyl protective 
groups on the exocyclic amines of the nucleosides, the dipeptide bore a nitrophenylsulfenyl 
(NPS) protective group on the N-terminus, whereas the C-terminus was permanently blocked as 
a carboxamide.10 Altering the protective group strategy on the peptide part of this di-
peptidylribonucleotide fragment to Fmoc and Fm (see compound 20, Scheme 1) would reduce 
the number of deprotection steps, as Fmoc and Fm are readily cleaved under the conditions that 
are used to eliminate cyanoethyl protection on the phosphodiester moieties. In addition this 


















































































Commercially available nucleotide phosphoramidites for RNA synthesis, equipped with acyl 
protective groups on the exocyclic amines were chosen, to avoid the preparation of the 
previously used silyl protected phosphoramidites.  
First peptidylphosphoramidite 20 was prepared in solution (see Scheme 1). Boc protected 
tyrosine 17 was esterified with 9-fluorenylmethanol (FmOH) using EDC·HCl and DMAP to 
give Fm ester 18. Acidolysis of both Boc groups followed by coupling to Fmoc-Ala-OH 
resulted in dipeptide 19, which was phosphitylated to yield the crucial phosphoramidite 20.  
Scheme 1 
 
Conditions and reagents: i. FmOH, EDC·HCl, DMAP, DCM, 16 h, r.t. (62%), ii. DCM, TFA, TIS, 90 min, r.t., iii. 
Fmoc-Ala-OH, DiPEA, EDC·HCl, DCM, 3 h, r.t. (44% over two steps), iv. 2-cyanoethoxy-N,N-
diisopropylaminochlorophosphine, TEA, MeCN/Dioxane, 45 min, 0oC (62%). 
The protected RNA fragment 5’-pUUAAAACAG-3’ was prepared using commercially 
available 5’-O-DMT RNA-phosphoramidites and a standard solid phase synthesis protocol in 
an automated nucleic acid synthesizer (see Scheme 2). In the final coupling cycle the 
immobilized nonribonucleotide was elongated with amidite 20 to give fully protected resin 
bound nucleopeptide 21. Deprotection was accomplished by removing the Fmoc/Fm and CNE 
groups using DBU, cleavage of the acyl functionalities and release from the solid support using 
NH3 in MeOH and final TEA·HF treatment to remove silyl protective groups.  
Analysis of the crude product by LC-MS showed the presence of an additional acetyl group that 
remained on the molecule even after treatment with NH3. The capping step after 
phosphoramidite couplings presumably resulted in acetylation of the mono-acyl protected 
exocyclic amines in the oligonucleotide. One of those acetyl groups might possibly migrate to 







































Conditions and reagents: for each nucleotide the following cycle was used i. 3% DCA in toluene, ii. 5eq. appropriate 
phosphoramidite, 5-benzylmercaptotetrazole, MeCN, iii. I2, pyridine/H2O, iv. N-methylimidazole, Ac2O, lutidine, 
MeCN, v. 2% DBU, DMF, 3x 5 min, vi. NH3/MeOH, 16 h, 50 oC, vii. TEA.HF, DMSO, 16 h, r. t. 
 
The synthesis of nucleopeptides containing longer peptide and RNA fragments (such as 15 and 
16 in Figure 2) however would not be feasible using the above described approach. On the 
basis of a reported, fully sequential solid phase synthesis of partially protected DNA-
nucleopeptide fragments14,15 it seemed appropriate to start with construction of a peptide on 
solid support, followed by RNA synthesis on this immobilized peptide (figure 1C). In this 
approach the oligonucleotide is elongated from the 5’-end towards the 3’-end, in contrast to 
reverse elongation that is usually applied in solid phase nucleic acid synthesis. The use of 5’-
phosphoramidites bearing acyl protective groups on the exocyclic amines and a 3’-O-DMT as 
temporary protective group seemed appropriate for such a synthesis. To assess the viability of 
this approach, the synthesis of nucleopeptides 15 and 16 was undertaken (see Scheme 3). 
Pentapeptidyl tetraribonucleotide 15 and pentapeptidyl nonaribonucleotide 16 are derived from 
the genome bound VPg protein found in picornaviruses and contains the five N-terminal amino 








21 R1 = Fmoc, R2 = CNE, R3 = TBDMS,
R4 = suc-CPG, R5 = Acyl, R6 = Fm
14 R1 = R3 = R4 = R5 = R6 = H, R2 =





















































Conditions and reagents: i. 5eq. phosphoramidite 24 – 27, ii. I2/pyridine/H2O, iii. Ac2O, N-methylimidazole, lutidine, 
MeCN, iv. 3% DCA, toluene, v. 2% DBU, DMF, 3x 5 min, vi. NH3/TFE, 16 h, 50 oC, vii. TEA.HF, DMSO, 16 h, r. t. 
In the first stage immobilized pentapeptide 23 was prepared. The side chain protective groups 
of the amino acid building blocks were chosen to be orthogonal to the DMT group used on the 
phosphoramidites. For this reason TBDMS and Fmoc were selected to protect the threonine 
hydroxyl and N-terminus, respectively. These protective groups are simultaneously cleaved 
with the TBDMS and nucleobase protective groups on the RNA fragment, in the final stage 
towards the target nucleopeptide. Highly cross-linked polysterene (HCP) was chosen as the 
solid support, since oligonucleotide synthesis is known to be optimal using this type of resin. 
The hydroxymethylbenzoic acid (HMBA) linker was applied, allowing simultaneous cleavage 
with the acyl protective groups on the oligonucleotide by NH3 treatment. The first amino acid 
was immobilized by esterification of Fmoc-Gly-OH with the HMBA-HCP resin. Repetitive 
cycles of Fmoc-deprotection and coupling of the appropriate amino acid resulted in formation 
28 R1 = Fmoc, R2 = TBDMS, R3 = HMBA-HCP,
R4 = CNE, R5 = Acyl




























































29 R1 = Fmoc, R2 = TBDMS, R3 = HMBA-HCP,
R4 = H, R5 = CNE, R6 = Acyl
16 R1 = R2 = R3 = R5 = H, R4 =
30 R1 = Ac, R2 = R5 = H, R3 = NH2, R4 =
5








24; NPg = U
25; NPg = ABz
26; NPg = CAc
27; NPg = GiBu
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of pentapeptide 23. Resin 23 was then transferred to an automated oligonucleotide synthesizer. 
The tyrosine hydroxyl in 23 was phosphitylated using the 5’-phosphoramidite of 3’-O-DMT 
protected uridine (24) followed by oxidation, capping and liberation of the 3’-hydroxyl. 
Repetition of this cycle using the appropriate phosphoramidites 24 - 27 resulted in the 
formation of fully protected, resin bound ribonucleopeptides 28 and 29. Resin bound 28 was 
treated with DBU to cleave the Fmoc and cyanoethyl groups and subsequently treated with NH3 
in trifluoroethanol.16 Final treatment with triethylamine hydrofluoride followed by RP-HPLC 
purification and gel filtration gave pentapeptidyl tetraribonucleotide 15. Application of the 
same deprotection protocol to resin bound peptide 29 afforded target pentapeptidyl 
nonaribonucleotide 16 which was found to be accompanied by its N-acetylated form 30.  
 
Conclusion 
In this chapter the synthesis of three RNA-nucleopeptide fragments derived from polio virus 
VPg is demonstrated. In the first approach a dipeptidyl nonaribonucleotide is assembled using a 
methodology were the oligonucleotide is assembled on solid support prior to coupling of a 
dipeptide phosphoramidite, prepared separately in solution. A pentapeptidyl tetraribonucleotide 
and a pentapeptidyl nonaribonucleotide are prepared by an approach in which a solid phase 
peptide synthesis is combined with a solid phase oligonucleotide synthesis in an automated 
nucleic acid synthesizer. First the peptide fragment is assembled on solid support followed by 
stepwise elongation of the RNA using 5’-phosphoramidites starting from the 5’-end towards the 
3’-end. This is the first time that RNA nucleopeptides of this complexity are assembled in a 





















phosporamidite, -O-DMT-2’-O-TBDMS – N4-acetyl –cytidine-5’-(N,N-di-isopropylamino-2-cyanoethoxy) 
phosporamidite and 3’-O-DMT-2’-O-TBDMS – N2-isobutyryl- guanosine -5’-(N,N-di-isopropylamino-2-
cyanoethoxy) phosporamidite were purchased from ChemGenes Corporation, Wilmington, USA and used 
as received. Solvents and reagents for peptide and oligonucleotide synthesis were used as received. 
 
Procedure for solid phase oligonucleotide synthesis: 
The oligo-ribonucleotides were prepared on a 10 μmol scale using an Acta Oligo Pilot (GE) automated 
nucleic acid synthesizer starting from peptidyl-HMBA-HCP resin 8 or commercially available amino-
HCP resin. Couplings were performed using 5 eq. of commercially available amidites at a 0.1 M 
concentration. 5-benzylmercaptotetrazole (BMT, 0.3 M) was used as the activating agent in 15 minute 
coupling cycles. Oxidation was performed by means of standard procedure using I2 (50 mM) in 
pyridine/H2O (90:10, v/v). Capping was performed using a standard protocol employing cap A (40% N-
methylimidazole in MeCN) and cap B (40% Ac2O, 40% lutidine in MeCN) 1:1 (v/v). Cleavage of the 
DMT group was accomplished using 3% DCA in toluene. 
 
HCP-HMBA resin 
Amino HCP resin (1 g, 200 µmol) was treated with 4-hydroxymethylbenzoicacid (HMBA) (92 mg, 600 
µmol), BOP (266 mg, 600 µmol), HOBt (82 mg, 600 µmol) and DiPEA (200 µl, 1.2 mmol) in 10 ml DMF 
for 5 hours at room temperature. The resin was then washed three times with DMF, DCM and air dried. 
 
Fmoc-Gly-Ala-Tyr-Thr-Gly-HMBA-HCP resin 
The resin bound pentapeptide 8 was prepared using a manual coupling protocol starting from HCP-HMBA 
resin (500 mg, 100 μmol). Fmoc-Gly-OH (150 mg, 500 μmol) was coupled using DIC (101 μL, 500 μmol) 
and catalytic DMAP in DCM (5 mL) for 4 hours at room temperature. After washing with DCM the 
unreacted resin was capped using the procedure used for oligonucleotide capping as described above. For 
subsequent peptide couplings of Fmoc-Thr(OTBDMS)-OH, Fmoc-Ala-OH, Fmoc-Tyr-OH and Fmoc-
Gly-OH the following cycle was repeated: 
- Fmoc cleavage using 2% DBU in DMF. 
- Coupling of the appropriate amino acid applying a five-fold excess, activation by 5 eq. HATU in NMP 
(0.22M) and 12.5 eq. DiPEA in NMP (1.25 M) for 1 hour. 
 
Boc-Tyr(OBoc)-OFm (18) 
Boc-Tyr(OBoc)-OH (1.5 mmol, 0.63 g) was dissolved in DCM (20 mL). FmOH (1.47 mmol, 287 mg), 
EDC.HCl (2.25 mmol) and DMAP (0.15 mmol, 24 mg) were added an the reaction mixture was stirred for 
16 hours at room temperature. After washing with 5% citric acid the organic layer was dried using MgSO4 
and concentrated. The crude product was purified using a silica column chromatography cusing a 5% EA 
in PE. The title compound was obtained as a colourless syrup (520 mg, 0.93 mmol, 62 %). 1H-NMR (400 
MHz, CDCl3) δ 7.79 - 7.68 (m, 2H, Arom. Fm), 7.54 (t, J = 7.4 Hz, 2H, Arom. Fm), 7.42 - 7.36 (m, 2H, 
Arom. Fm), 7.30 (t, J = 7.5 Hz, 2H, Arom. Fm), 7.12 - 6.94 (m, 4H, Arom. Tyr.), 4.98 (d, J = 8.2 Hz, 1H, 
NH), 4.61 (dd, J = 13.4, 6.1 Hz, 1H, CH α), 4.50 - 4.36 (m, 2H, CH2 Fm), 4.16 (t, J = 6.7 Hz, 1H, CH 
Fm), 2.99 - 2.95 (m, 2H, CH2 β), 1.53 (s, 9H, tBu), 1.42 (s, 9H, tBu). 13C-NMR (101 MHz, CDCl3) δ 
171.8 (CO α), 155.2 (CO Boc Nα), 151.8 (CO Boc O), 150.2 (Cq Tyr O), 143.54, 143.45, 141.39, 141.35 
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(Cq Fm), 133.6 (Cq Tyr), 130.3, 127.96, 127.93, 127.26, 127.24, 125.04, 125.02, 121.4, 120.1 (Arom. Fm/ 
Tyr.), 83.5, 80.1 (Cq tBu), 67.1 (CH2 Fm), 54.4 (α), 46. 8 (CH Fm), 37.5 (β), 28.4, 27.7 (tBu). 
 
Fmoc-Ala-Tyr(OH)-OFm (19) 
Boc-Tyr(OBoc)-OFm (0.9 mmol) was dissolved in DCM (40 mL) and treated with TFA (6 mL) and TIS 
(0.5 mL) for 90 minutes at room temperature. Toluene was added (20 mL) and the reaction mixture was 
concentrated. The crude product was dissolved in DCM (20 mL) and Fmoc-Ala-OH (0.91 mmol, 283 mg), 
EDC.HCl (0.95 mmol, 120 mg) and DiPEA (1.9 mmol, 315 µL) were added. After stirring for 3 hours at 
room temperature the reaction mixture was extracted using sat. aq. NaH2CO3. The organic layer was dried 
using MgSO4 and concentrated. The crude product was dissolved in a small amount of DCM and 
crystallised from hexane to yield the title compound as a colourless gel (260 mg, 0.4 mmol, 44%).1H-
NMR (400 MHz, DMSO) δ 9.19 (s, 1H, OH), 8.31 (s, 1H, NH), 8.23 (d, J = 7.4 Hz, 1H, NH), 7.96 - 7.83 
(m, 4H, Arom. Fmoc/Fm), 7.76 - 7.55 (m, 4H, Arom. Fmoc/Fm), 7.49 - 7.22 (m, 8H, Arom. Fmoc/Fm), 
6.78 (dd, J = 8.2 Hz, 4H, Arom. Tyr.), 4.50 - 4.29 (m, 4H, CH2 Fmoc, CH2 Fm), 4.16 (m, 6H, CH α Tyr, 
CH α Ala, CH Fmoc, CH Fm), 2.73 (d, J = 7.0 Hz, 2H, CH2 β Tyr), 1.18 (d, J = 7.1 Hz, 3H, CH2 β 
Ala).13C-NMR (101 MHz, CDCl3/MeOD-d4) δ 172.8, 171.3 (CO α Ala, CO α Tyr), 155.6 (CO Fmoc), 
143.1, 143.0, 140.9, 129.9, 127.5, 127.3, 126.8, 126.7, 124.7, 124.6, 119.6, 115.0 (Arom.), 66.8, 66.7 




Fmoc-Ala-Tyr(OH)-OFm (240 mg, 0.37 mmol) was coevaporated with MeCN prior to being dissolved in 
MeCN/dioxane (10 mL, 1:1, v/v) at 0 oC. 2-cyanoethoxy-N,N-diisopropylaminochlorophosphine (90 µL, 
0.4 mmol) and TEA (154 µL, 1.2 mmol) were added and the reaction mixture was stirred for 45 min. The 
reaction mixture was extracted using DCM and sat. aq. NaH2CO3. The organic layer was dried using 
MgSO4 and purified using a pre-neutralized (1 % TEA) silica column using a gradient of EA: PE, 0 → 50. 
The title compound was obtained as a colourless syrup (213 mg, 0.23 mmol, 62%). 1H-NMR (400 MHz, 
CDCl3) δ 7.75 (dd, J = 7.3, 3.3 Hz, 4H, Arom. Fmoc/Fm), 7.62 - 7.44 (m, 4H, Arom. Fmoc/Fm), 7.42 - 
7.22 (m, 8H, Arom. Fmoc/Fm), 7.03 - 6.69 (m, 4H, Arom. Tyr.), 6.54 (d, J = 6.0 Hz, 1H, NH), 5.50 (s, 
1H, NH), 4.85 (dd, J = 13.0, 6.1 Hz, 1H, CH α Ala), 4.63 - 4.32 (m, 4H, CH2 Fmoc, CH2 Fm), 4.26 - 4.04 
(m, 3H, CH α Tyr, CH Fmoc, CH Fm), 3.96 - 3.72 (m, 2H, CH2 CNEO), 3.70 - 3.52 (m, 2H, CH2 β Tyr), 
2.99 (m, 2H, CH iPr), 2.68 - 2.29 (m, 2H, CH2 CNEO), 1.33 (d, J = 6.5 Hz, 3H, CH2 β Ala), 1.15 (dd, J = 
23.3, 6.8 Hz, 12H, CH3 iPr).13C-NMR (101 MHz, CDCl3) δ 172.0, 171.2 (CO α Ala, CO α Tyr), 156.0 
(CO Fmoc), 153.5, 143.9, 143.5, 141.39, 141.35, 130.4, 129.7, 129.6, 128.0, 127.8, 127.3, 127.2, 125.2, 
125.0, 120.3, 120.3, 120.2, 120.1, 117.6 (Arom.), 67.3 (CH2 Fm, CH2 Fmoc), 58.8, 58.6 (CH2 CNEO), 
53.5 (CH α Tyr), 50.5 (CH α Ala), 47.2, 46.7 (CH Fm, CH Fmoc), 43.8, 43.7 (CH iPr), 37.1 (CH2 β Tyr), 
24.7, 24.6, 24.5, 24.4 (CH3 iPr), 20.4, 20.3 (CH2 CNEO), 18.7 (CH2 β Ala). 31P-NMR (161 MHz, CDCl3); 
δ 146.6, 146.4 
 
Ac-Ala-Tyr(pUpUpApApApApCpApG)-OH (22) 
The oligonucleotide was prepared on 10 µmol scale as described above starting from amino-HCP resin. 
The last coupling was performed using amidite 20. The fully protected product was treated with 2% DBU 
in dry MeCN to cleave Fmoc/Fm and cyanoethoxy protective groups (3x 5 min). Subsequent treatment 
with an aqueous solution of concentrated NH4OH/MeNH2 (1 : 1 v/v) overnight at room temperature for 16 
hours cleaved the peptidylated oligo nucleotide of the resin as well as removed all the acyl protective 
groups on the nucleosides. The crude peptidylated oligo nucleotide was concentrated and redissolved in 
DMSO (150 µL) and treated with TEA.HF (850 µL) for 16 hours at room temperature. Precipitation from 




MS (0 - 25 % MeCN in 10 mM NH4OAc in 25 min), Rt = 7.84. ESI-MS m/z: 1602.6 [M + H]2+, 1068.6 
[M + H]3+. 31P-NMR (161 MHz, CDCl3); δ -0.47, -4.16. HRMS [C101H124N39O65P9 + H]+: found 
3202.5111, calc. 3202.5307, [C101H124N39O65P9 + 2H]2+: found 1601.7715, calc. 1601.7690, 
[C101H124N39O65P9 + 3H]3+: found 1068.1828, calc. 1068.1817.  
  
H-Gly-Ala-Tyr(pUpUpApA)-Thr-Gly-NH2 (15) 
The RNA-fragment was assembled on pentapeptide resin 23 using the automated oligonucleotide protocol 
as described above on 10 µmol scale. The fully protected product was treated with 2% DBU in dry MeCN 
to cleave the cyanoethoxy protective groups on the phosphates (3x 5 min.). Subsequent treatment with sat. 
NH3 in trifluoroethanol (750 µL) at room temperature for 16 hours cleaved the peptidylated oligo 
nucleotide of the resin as well as removed all the acyl protective groups on the nucleosides. The resin was 
washed with H2O/EtOH, 1:1, v/v and the filtrate was concentrated. The crude peptidylated oligo 
nucleotide was dissolved in DMSO (150 µL) and treated with TEA.HF (850 µL) for 16 hours at room 
temperature. Precipitation from cold n-BuOH and HPLC purification resulted in the title compound 15 
(1.65 mg, 0.95 µmol, 9.5 %). LC-MS (0 - 20 % MeCN in 10 mM NH4OAc in 15 min), Rt = 6.20. ESI-MS 
m/z: 1737.8 [M + H]+, 869.6 [M + H]2+. 31P-NMR (161 MHz, CDCl3); δ -0.32, -0.39, -0.42, -4.40. HRMS 
[C58H76N20O35P4 + H]+: found 1737.3841, calc. 1737.3850, [C58H76N20O35P4 + Na]+: found 1759.3611, 
calc. 1759.3624 
 
H-Gly-Ala-Tyr(pUpUpApApApApCpApG)-Thr-Gly-NH2 (16) and Ac-Gly-Ala-
Tyr(pUpUpApApApApCpApG)-Thr-Gly-NH2 (30) 
The RNA-fragment was assembled on pentapeptide 23 using the automated oligonucleotide protocol as 
described above on 10 µmol scale. The fully protected product was treated with 2% DBU in dry MeCN to 
cleave the cyanoethoxy protective groups on the phosphates (3x 5 min.). Subsequent treatment with sat. 
NH3 in trifluoroethanol (750 µL) at 50 oC for 16 hours cleaved the peptidylated oligo nucleotide of the 
resin as well as removed all the acyl protective groups on the nucleosides. The resin was washed with 
H2O/EtOH, 1:1, v/v and the filtrate was concentrated. The crude peptidylated oligo nucleotide was 
dissolved in DMSO (150 µL) and treated with TEA.HF (850 µL) for 16 hours at 50 oC. Precipitation from 
cold n-BuOH and HPLC purification resulted in the title compound 16 (0.85 mg, 0.25 µmol, 2.5 %). LC-
MS (0 - 25 % MeCN in 10 mM NH4OAc in 15 min), Rt = 5.70. ESI-MS m/z: 1126.1 [M + H]+. 31P-NMR 
(161 MHz, CDCl3); δ -0.46, -0.51, -0.65, -0.69, -0.85, -4.42. HRMS [C107H136N43O67P9 + H]+: found 
3374.6152, calc. 3374.6267, [C107H136N43O67P9 + 2H]2+: found 1687.8194, calc. 1687.8174, 
[C107H136N43O67P9 + 3H]3+: found 1125.5483, calc. 1125.5471.  
and side-product (30) 
(1.1 mg, 0.32 µmol, 3.2 %). LC-MS (0 - 25 % MeCN in 10 mM NH4OAc in 15 min), Rt = 5.53. ESI-MS 
m/z: 1140.4 [M + H]+. 31P-NMR (161 MHz, CDCl3); δ -0.33, -0.46, -0.54, -0.64, -0.81, -4.42. HRMS 
[C109H138N43O68P9 + H]+: found 3416.6242, calc. 3416.6374, [C109H138N43O68P9 + 2H]2+: found 
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This thesis describes the development of new methodologies directed to the syntheses of 
fragments of naturally occurring hybrid biomolecules composed of a peptide and nucleic acid. 
The two classes of peptide nucleic acid hybrids that are pursued are the class of nucleoproteins, 
which is found to play crucial roles in viral replication pathways and DNA replicating 
machinery in higher organisms, and the class of ADP-ribosylated proteins, which is a result of 
the complicated and non-understood post-translational modification. 
In Chapter 1 an overview is given of known methods to prepare naturally occurring hybrid 
biomolecules, consisting of a peptide fragment and a nucleic acid fragment. Emphasis is placed 
on the way the crucial linkage between the peptide and nucleic acid fragment is constructed. 
In Chapter 2 the scope of a one-pot phosphorylation procedure using a phosphoramidite 
equipped with two acid labile p-methoxybenzyl groups is described. Using this reagent a wide 
variety of phosphoric acid analogues can be synthesized, such as phosphomonoesters, 
phosphorothioates, phosphoramidates, phosphofluoridates, phosphodiesters and 
pyrophosphates. An Arbuzov-like reaction mechanism is proposed to explain the formation of a 
reactive intermediate that allows introduction of several nucleophiles. 
In Chapter 3 a method to introduce a ribosyl moiety on the side chain of glutamine and 
asparagine is reported. Reduction of a ribofuranose carrying an anomeric azide followed by a 
peptide coupling of the formed ribosylamine to the side chain carboxylic acid of the appropriate 
amino acid resulted in the target modified amino acids. Subsequently, these ribosylated amino 
acids were incorporated in small, biological relevant peptides. The methodology described in 
Chapter 2 was used to obtain the required pyrophosphate linkage to adenosine. These first 
examples of synthetically made ADP-ribosylated peptides open the way to more complex 
structures.  
Other sites of ADP-ribosylation have been identified, where the nucleophilic side chains of 
lysine, arginine or cysteine residues form the linkage with the anomeric centre of ADP-ribose. 




subsequent incorporation in ADP-ribosyl peptides can be attained by adaption of the 
methodology from Chapter 3. Hottiger and coworkers have identified lysine residues to be the 
site of ADP-ribosylation in the auto-ADP-ribosylation of the PARP-1 enzyme.1 They have 
proposed a reaction mechanism in which the initial aminoriboside, formed by enzyme catalyzed 
condensation of the lysine ε-amine with NAD+, forms a Schiffs base, which then undergoes an 





The synthesis of ADP-ribosylated peptides containing such a linkage raises the need for a 
different strategy towards a suitably protected lysine-ribosyl ketamine (such as 7, see Scheme 
1). In order to secure the correct stereochemistry in 7, D-lyxose derivative 1 was used to 
synthesize β-hydroxyketone 6. In this approach orthogonal protection of the lyxose 1’ and 5’ 
hydroxyl functions, followed by opening of the furanose ring and oxidation of the liberated 
hydroxyl eventually can give rise to 6.  
Scheme 1 
 
Reagents and conditions: i. DMTCl, pyridine, 72 h, r.t., (80%), ii. NaBH4, EtOH, 16 h, r.t., (68%), iii. TBDPSCl, pyr., 
16 h, r.t., (99 %), iv. DCC, TFA, DCM, 16 h, r.t., (85 %), v. TFA, pyrrole, 15 min, r.t., (68 %). 
Several methods to link a lysine derivative to β-hydroxyketone 6 to obtain 7 can be envisaged 
(see Figure 2). Converting the hydroxyl function in 6 into a good leaving group such as a 
tosylate followed by nucleophilic substitution of the ε-amine of lysine may render 7 (Pathway 
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amination to the ε-amine of lysine is also an option (Pathway B). Alternatively a Mitsunobu 
reaction using ε-nosyl protected lysine and alcohol 6 can be explored (Pathway C). 
Figure 2 
 
Another point of attention is the moderate yield of the introduction of the phosphate mono-
ester on resin bound ribosylated peptides as shown in Chapter 3. Approaches using harsh 
conditions to introduce the phosphate monoester were unsuccessful, and a new approach has to 
be developed. On resin phosphorylation can be circumvented by the design and synthesis of an 
amino acid equipped with a phosphotriester (such as 8 or 9, see Figure 3). Subsequent 
application of phosphorylated amino acid building blocks in a solid phase synthesis followed by 
mild removal of the protective groups is proposed to allow an efficient incorporation of the 
phosphate monoester. Since solid phase peptide synthesis, using the Fmoc-group is projected, 
acid-labile protection for the phosphate group is required. Compound 8 can be prepared using 
phosphoramidite 10, described in Chapter 2. However, the p-methoxybenzyl groups are prone 
to undergo nucleophilic displacement and may therefore be to labile to function as semi-








































Chapter 4 deals with the formation of an α-glycosidic linkage between ribofuranose and 
adenosine. The choice of benzyl ethers as protective groups on the ribofuranose donor not only 
steers the α-selectivity in the glycosylation reaction, but also allows the subsequent introduction 
of orthogonal protective groups on both primary hydroxyls functions in the glycosylation 
product. Such a protective group pattern is a prerequisite for sequential elongation of a poly-
ADP-ribosyl chain using the methods described in Chapter 2 and Chapter 3 to give access to 
poly-ADP-ribosyl peptides (see Figure 4). Reaction of an immobilized peptide anchored to a 
solid support and equipped with 5’-phosphorylribose (I), with the reactive imidazolidate species 
of suitably protected ribosyl-adenosine (II) will give a pyrophosphate linkage (III). After 
removing the DMT protection on the newly introduced ribose group (IV) and phosphorylation 
of the liberated alcohol a new cycle can start. After a number of repetitions of the coupling 
cycle the elongation will be ended (step IV) by using the imidazolidate of adenosine instead of 
ribosyl-adenosine. Finally, removal of the protecting groups and cleavage from the solid 














































In Chapter 5 the synthesis of a protected pre-uridylylated tyrosine building block is described. 
This building block is used in a solid phase peptide synthesis protocol to give several naturally 
occurring nucleoproteins, originating from mammalian pathogens. These compounds are 
presently investigated to gain insight in the replication mechanisms of picornaviruses. 
 
Chapter 6 reports the synthesis of three protected ribonucleotidylated tyrosine building blocks. 
These adenylylated, guanylylated and cytidylylated tyrosine derivatives are incorporated in the 
VPg protein of polio virus using the solid phase synthesis protocol as described in Chapter 5.  
 
Commonly, oligonucleotides and nucleopeptide fragments are prepared by the use of 3’-
phosphoramidite reagents. Chapter 7 reports an approach to create nucleopeptide fragments by 
elongation of the (oligo)nucleotide from the 5’-end towards the 3’-end using 5’-
phosphoramidite RNA building blocks. Immobilized oligopeptides, prepared by solid phase 
peptide synthesis, were extended to give nucleopeptides of unprecedented length with the aid of 
these 5’-phosphoramidites.   
Having established that phosphitylation using 5’-phosphoramidites is a viable entry to 
sequentially synthesize oligo-ribonucleotides on a resin bound peptide, the application of this 
approach to construct an oligoribonucleotide on the full length VPg protein is the next 
challenge. Since standard protective groups on amino acid residues require harsh acidic 
deprotection conditions which are incompatible with the stability of the RNA part of the 















































adapted. For this reason, the lysine residues in the VPg proteins are envisaged to be protected 
with the trifluoroacetyl protective group (see Figure 5), which will be simultaneously cleaved 
with the acyl protective groups on the nucleobases using NH3 treatment. Threonine hydroxyl 
functions are envisaged to be protected using the TBDMS group, which will be cleaved in the 
final TEA·HF treatment of the nucleoprotein. Introduction of aspartic acid β-methylesters may 
lead to formation of the desired asparagine residues in the VPg protein during the NH3 
treatment. Although aspartic esters are notorious for aspartimide formation, this side reaction is 
highly sequence dependent. It has been shown that the -Asp(OX)-Val- and -Asp(OX)-Lys- 
sequences, which are occurring in the polio virus VPg proteins, are not highly susceptible to 




As the results on nucleopeptide synthesis from Chapter 7 indicate that capping during the RNA 
synthesis causes cleavage of Fmoc and subsequent acetylation of the free amine, an alternative 
protective group for the N-terminus is desired. Taking into account that in the polio virus VPg 
an arginine residue is present, and non-acid labile protective groups for this residue are limited, 
a preliminary study was executed using the Alloc protective group both on the N-terminus and 
arginine side chain and the allyl ester as C-terminal protective group. Previous results indicate 
that removal of Alloc/allyl protection is compatible with the integrity of the VPgpUpU 
nucleoprotein.5 In this study, the not routinely used HMBA-HCP resin was selected for the 
construction of fully protected VPg protein 13 (see Figure 5). Deprotection of an aliquot of 13 
to determine the quality of the synthesis was achieved by Pd catalyzed removal of Alloc and 
allyl, subsequent NH3 treatment to remove acyl protection and cleave the peptide from the resin 
and finally fluoride treatment to remove silyl ethers. LCMS analysis revealed that the molecular 
mass of the major product formed corresponds to the fully deprotected polio virus VPg protein. 
Encouraged by these results future RNA oligo-nucleotide synthesis using the 5’-
phosphoramidite approach on protected resin bound VPg protein 13 is a potential approach to 































2,3-O-isopropyl-α/β-D-lyxofuranose (7.4 g, 39 mmol) was dissolved in pyridine (80 mL) and DMTCl 
(15.6 g, 46 mmol) was added. The reaction mixture was stirred for 72 hours at room temperature. 
Concentration of the crude and purification using silica gel column chromatography (EtOAc/PE; 0:100 – 
30:70) afforded the title compound (15.3 g, 31 mmol, 80%). 1H-NMR (400 MHz, CDCl3); δ 7.49 (d, J = 
7.5 Hz, 2H), 7.37 (d, J = 8.7 Hz, 4H), 7.26 (t, J = 7.6 Hz, 3H), 7.17 (dd, J = 8.4, 6.1 Hz, 2H), 6.81 (d, J = 
8.1 Hz, 5H), 5.37 (s, 1H, H1’), 4.95 (d, J = 7.6 Hz, 0.1H, H1’), 4.71 (dd, J = 5.8, 3.8 Hz, 1H, H3’), 4.67 
(dd, J = 6.0, 3.3 Hz, 0.1H, H3’), 4.60 (d, J = 5.9 Hz, 0.1H, H2’), 4.56 (d, J = 5.9 Hz, 1H, H2’), 4.45 (dd, J 
= 6.0, 3.6 Hz, 0.1H, H4’), 4.34 (dd, J = 9.5, 5.7 Hz, 1H, H4’), 3.75 (s, 6H, OMe), 3.40 (d, J = 5.9 Hz, 2H, 
H5’), 3.24 (s, 1H, OH), 1.40 (s, 0.3, iPr), 1.33 (s, 0.3H, iPr), 1.30 (s, 3H, iPr), 1.25 (s, 3H, iPr). 13C-NMR 
(101 MHz, CDCl3); δ 158.4 (Cq DMT) , 145.0 (Cq DMT), 136.3 (Cq DMT), 136.2, 130.28, 130.26, 
128.4, 127.8, 126.73, 113.1, 112.5 (Cq iPr), 101.2 (C1’), 96.8 (C1’A), 86.4 (Cq DMT), 85.5 (C2’), 80.2 
(C3’), 79.80, 79.7 (C4’), 78.7, 75.3, 61.8 (C5’), 61.1 (C5’A), 55.3 (OMe), 26.1 (iPr), 25.9 (iPr), 25.3 (iPr), 
25.1 (iPr).  
 





Compound 2 (6.15 g, 12.5 mmol) was dissolved in EtOH (100 mL) at 0 oC. NaBH4 (1.2 g, 32 mmol) was 
slowly added. The reaction mixture was stirred for 16 hours at room temperature, upon which TLC 
analysis (EtOAc/PE, 70:30) revealed complete consumption of the starting material. The reaction mixture 
was quenched using AcOH until pH = 7.5. The reaction mixture was concentrated and the crude 
redissolved in DCM and washed with aq. NaHCO3. The organic layer was dried (MgSO4) and 
concentrated. Silica gel column chromotography (EtOAc/PE; 0:100 – 50:50) using a pre-neutralized 
column (1% TEA in PE) afforded the title compound (4.2 g, 8.5 mmol, 68%). 1H-NMR (400 MHz, 
CDCl3); δ 7.44 (d, J = 7.9 Hz, 2H), 7.33 (d, J = 8.8 Hz, 4H), 7.26 (t, J = 7.6 Hz, 2H), 7.18 (t, J = 7.2 Hz, 
1H), 6.81 (d, J = 8.9 Hz, 4H), 4.30 (dd, J = 6.9, 2.0 Hz, 1H, H3’), 4.19 (dd, J = 11.6, 4.9 Hz, 1H, H2’), 
3.91 - 3.77 (m, 1H, H4’), 3.80 - 3.65 (m, 8H, H1’, OMe), 3.27 - 3.23 (m, 2H, H5’), 3.17 (s, 2H, OH), 1.46 
(s, 3H, iPr), 1.36 (s, 3H, iPr). 13C-NMR (101 MHz, CDCl3); δ 158.4 (Cq DMT), 144.7 (Cq DMT), 135.9 
(Cq DMT), 135.9, 130.02, 130.00, 128.1, 127.8, 126.8, 113.1, 108.2 (Cq iPr.), 86.3 (Cq DMT), 77.3 
(C2’), 76.2 (C3’), 68.2 (C4’), 65.0 (C5’), 61.2 (C1’), 55.1 (OMe DMT), 27.0, 25.0 (iPr). IR: 3420, 2934, 

































Compound 3 (8.5 mmol) was coevaporated with pyridine and subsequently dissolved in pyridine (50 mL). 
After addition of TBDPSCl (9.3 mmol, 2.4 mL) the reaction mixture was stirred at room temperature for 
16 hours. The reaction mixture was concentrated and purification using silica gel column chromatography 
(EtOAc/PE; 0:100 – 5:95) afforded the title compound (6.2 g, 8.4 mmol, 99%). 1H-NMR (400 MHz, 
CDCl3); δ 7.67 (dd, J = 10.7, 4.1 Hz, 4H), 7.45 (d, J = 7.4 Hz, 2H), 7.41 - 7.33 (m, 9H), 7.26 (t, J = 7.5 
Hz, 2H), 7.22 - 7.13 (m, 2H), 6.80 (d, J = 8.8 Hz, 4H), 4.44 (dd, J = 6.6, 2.4 Hz, 1H, H3’), 4.25 (dd, J = 
11.6, 6.7 Hz, 1H, H2’), 4.10 (dd, J = 6.2, 4.4 Hz, 1H, H4’), 4.00 (dd, J = 10.7, 7.1 Hz, 1H, H1’), 3.82 - 
3.68 (m, 7H, H1’, OMe), 3.40 - 3.17 (m, 2H, H5’), 2.75 (d, J = 6.8 Hz, 1H, OH), 1.42 (s, 3H, iPr), 1.36 (s, 
3H, iPr), 1.05 (s, 9H, tBu). 13C-NMR (101 MHz, CDCl3); δ 158.5 (Cq DMT), 145.0 (Cq DMT), 136.23, 
136.19 (Cq DMT), 135.7 (Arom. TBDPS), 133.1, 133.0 (Cq DMT), 130.19, 130.17, 129.91, 129.89, 128.3 
(Arom. DMT), 127.9 (Arom. TBDPS), 126.8 (Arom. DMT), 113.2 (Arom. DMT), 108.3 (Cq DMT), 86.2 
(Cq DMT), 77.2 (C2’), 76.6 (C3’), 68.2 (C4’), 65.0 (C5’), 63.0 (C1’), 55.3 (OMe), 27.2 (tBu), 27.0, 25.1 
(iPr), 19.3 (Cq tBu). IR: 2933, 1608, 1508, 1248, 1112, 1034, 825. HRMS [C45H52O7Si + Na]+: found 
755.3379, calc. 755.3374. 
 





Compound 4 (1.1 g, 1.5 mmol) was dissolved in DMSO (7 mL) and dicyclohexylcarbodiimide (4.2 mmol, 
870 mg), pyridine (1.4 mmol, 115 µL) and trifluoracetic acid (0.7 mmol, 52 µL) were added. After stirring 
at room temperature for 16 hours the reaction mixture was dilluted in EtOAc (50 mL) and water (10 mL). 
After stirring for 10 min. the organic layer was washed with water five times, dried (MgSO4) and 
concentrated. NMR-spectroscopy revealed circa 50% conversion, so the procedure was repeated once 
more. Final purification using silica gel column chromatography (EtOAc/PE; 0:100 – 5:95) afforded the 
title compound (0.9 g, 1.3 mmol, 85%). 1H-NMR (400 MHz, CDCl3); δ 7.73 - 7.55 (m, 4H), 7.46 - 7.39 
(m, 4H), 7.36 (dd, J = 11.5, 5.0 Hz, 4H), 7.33 - 7.27 (m, 4H), 7.27 - 7.14 (m, 3H), 6.83 - 6.60 (m, 4H), 
4.59 (d, J = 7.6 Hz, 1H, H3’), 4.47 (dt, J = 7.6, 4.7 Hz, 1H, H2’), 4.07 (m, 2H, H5’), 3.85 - 3.69 (m, 7H, 
1H’, OMe), 3.61 (dd, J = 11.2, 4.8 Hz, 1H, H1’), 1.38 (s, 3H, iPr), 1.27 (s, 3H, iPr), 0.97 (s, 9H, tBu). 13C-
NMR (101 MHz, CDCl3); δ 204.6 (CO), 158.7 (Cq DMT), 144.4 (Cq DMT), 135.77, 135.76 (Arom. 
TBDPS), 135.61, 135.59 (Cq DMT), 133.2 (Cq), 130.13, 130.11, 129.79, 129.75, 128.2, 128.1, 127.79, 
127.76, 127.1 (Arom. DMT/TBDPS), 113.4 (Arom. DMT), 109.7 (Cq iPr), 87.2 (Cq DMT), 79.8 (C3’), 
78.5 (C2’), 69.3 (C5’), 62.3 (C1’), 55.3 (OMe), 26.9 (tBu), 26.8, 24.9 (iPr), 19.3 (Cq tBu). IR: 2932, 2857, 
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Compound 5 (1.1 mmol) was dissoled in DCM (15 mL) at 0 OC and treated with pyrrole (700 µL) and 
dichloroacetic acid (300 µL). After 15 minutes the reaction mixture was washed with sat. aq. NaHCO3, 
dried (MgSO4) and concentrated. Purification using silica gel column chromatography (EtOAc/PE; 0:100 
– 10:90) afforded the title compound (0.3 g, 0.8 mmol, 68%). 1H-NMR (400 MHz, CDCl3); δ 7.85 - 7.68 
(m, 2H), 7.64 (dd, J = 7.6, 1.6 Hz, 2H), 7.50 - 7.33 (m, 6H), 4.67 (d, J = 8.3 Hz, 1H, H3’), 4.56 (m, 2H, 
H5’), 4.44 (dd, J = 8.2, 3.5 Hz, 1H, H2’), 3.76 (m, 2H, H1’), 2.98 (s, 1H, OH), 1.59 (s, 3H, iPr), 1.36 (s, 
3H, iPr), 1.02 (s, 9H, tBu). 13C-NMR (101 MHz, CDCl3); δ 209.7 (CO), 135.84, 135.75, 135.65 (Arom. 
TBDPS), 133.0, 132.8 (Cq TBDPS), 129.92, 129.89, 127.9, 127.8 (Arom. TBDPS), 110.1 (Cq iPr), 79.5 
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Dit proefschrift beschrijft de ontwikkeling van nieuwe methoden voor de synthese van hybride 
biomoleculen die samengesteld zijn uit een peptide- en een nucleïnezuurfragment. Zulke 
hybride moleculen komen in de natuur voor en hebben belangrijke functies. In dit proefschrift 
wordt aandacht besteed aan twee klassen van hybride biopolymeren; de klasse van 
nucleoproteinen, die een belangrijke rol speelt in virale replicatie processen en de klasse van 
ADP-geribosyleerde eiwitten, die het resultaat zijn van een post-translationeel modificatie 
proces. 
In Hoofdstuk 1 wordt een overzicht gegeven van bestaande synthetische methoden, die 
toegang geven tot natuurlijk voorkomende nucleïnezuur bevattende peptiden. Speciale aandacht 
wordt besteed aan de methoden waarmee de cruciale en labiele binding tussen het nucleïnezuur-
fragment en het peptide kan worden geïntroduceerd. 
In Hoofdstuk 2 worden de mogelijkheden beschreven van een eenpots fosforyleringsprocedure, 
die gebaseerd is op het gebruik van een fosforamidiet voorzien van twee zuur-labiele p-
methoxybenzyl groepen. Met behulp van dit fosforamidiet is het mogelijk gebleken een aantal 
fosforzuur analoga te maken, zoals fosfaten, fosforothioaten, fosforamidaten, 
fosforofluoridaten, fosfodiesters en pyrofosfaten. Er wordt een mechanisme voor de vorming 
van een reactief intermediair gepostuleerd dat de introductie van verschillende nucleofielen 
mogelijk maakt en de vorming van fosforzuur analoga verklaard. 
In Hoofdstuk 3 wordt een methode beschreven om een ribosyl groep aan te brengen op de 
zijketen van de aminozuren glutamine en asparagine. Een azide, aangebracht op de anomere 
positie van de ribofuranose, werd gereduceerd en vervolgens werd een peptide koppeling 
uitgevoerd tussen het gevormde amine en de zuurgroep in de zijketen van glutaminezuur of 
asparaginezuur. De verkregen gemodificeerde aminozuren werden ingebouwd in verschillende 
biologisch relevante peptiden met behulp van vaste drager chemie. De geribosyleerde peptiden 
konden worden verlengd met een pyrofosfaat binding naar adenosine door toepassing van de 
fosforyleringsmethode uit Hoofdstuk 2. De aldus ontwikkelde methodologie naar ge-ADP-
ribosyleerde peptiden opent de weg naar meer complexe structuren. 
Hoofdstuk 4 omvat een studie naar het introduceren van een α-glycosidische binding tussen het 
anomere centrum van ribofuranose en de 2’-hydroxyl van adenosine. Geribosyleerd adenosine 
is de repeterende eenheid die wordt gevonden in ge-poly-ADP-ribosyleerde eiwitten. De keuze 
van benzylethers als beschermgroep op de ribofuranose donor bepaalde niet alleen de α-
selectiviteit van de glycosyleringsreactie maar maakte ook de introductie van orthogonale 
beschermgroepen op de beide primaire hydroxylgroepen in het reactieproduct mogelijk. De 
aldus vervaardigde bouwsteen kan in de toekomst gebruik gaan worden voor de synthese van 
ge-poly-ADP-ribosyleerde peptiden. 
Hoofdstuk 5 behandelt de synthese van een geuridylyleerde tyrosine bouwsteen. Deze 




genoomeiwitten van de zoogdier-pathogenen; poliovirus type 1, coxsackievirus type A, 
coxsackievirus type B en humaan enterovirus type 71. Deze gemodificeerde eiwitten zijn 
mogelijk belangrijk gereedschap voor de biologie om inzicht te verkrijgen in de 
replicatiemechanismen van picornavirussen. 
In Hoofdstuk 6 wordt de synthese beschreven van de overige drie ribonucleotide derivaten van 
tyrosine. Deze geadenylyleerde, geguanylyleerde en gecytidylyleerde tyrosine bouwstenen 
werden vervolgens via een vaste drager synthese ingebouwd in het genoomeiwit VPg van polio 
virus door gebruik te maken van de methodes die in Hoofdstuk 5 wordt beschreven. De zure 
condities nodig om de beschermgroepen te verwijderen en het eiwit van de vaste drager af te 
splitsen bleken in het geval van adenosine ook depurinering te veroorzaken en daarmee voor 
een lagere opbrengst te zorgen. 
 
Hoofdstuk 7 behandelt de synthese van nucleïnezuur bevattende peptide fragmenten op de 
vaste drager met behulp van 5’-fosforamidieten. De RNA fragmenten die met deze amiditen 
kunnen worden bereid, worden in de ongebruikelijke 5’ naar 3’-richting verlengd. 
Geïmmobiliseerde peptiden, gesynthetiseerd door middel van een vaste drager synthese, werden 
met behulp van de 5’-fosforamidieten voorzien van een RNA-fragment. Op deze manier 
werden een pentapeptidyl tetranucleotide en een pentapeptidyl nonanucleotide vervaardigd. 
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